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Resumen  
 
Evaluación y mejora de la calidad de la prescripción al alta hospitalaria de 
pacientes pediátricos diagnosticados de Fibrosis Quística que ingresan 
para tratamiento intravenoso de antibióticos en un hospital inglés. 
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1. Antecedentes. 
La Fibrosis Quística (FQ) es una enfermedad conocida desde la edad 
media, aunque durante esa época no estaba descrita como tal sino más 
bien como un hechizo maligno.  En 1943, Farber propuso el término 
mucoviscidosis y este término se sigue utilizando en la actualidad.  
La FQ es la enfermedad hereditaria autosómica recesiva grave más 
frecuente en la población blanca, con una incidencia en Europa que oscila 
entre 1:1.353 en Irlanda y entre 1:25.000 en Finlandia, y una frecuencia 
de portadores de 1 por cada 2527. Es una enfermedad de las células 
epiteliales exocrinas, que se caracteriza por la producción de un moco 
espeso y viscoso que obstruye los conductos del órgano donde se localiza. 
Aunque puede afectar a la mayoría de los órganos, los más dañados son 
el páncreas y el pulmón, siendo la enfermedad pancreática o pulmonar la 
mayor causa de morbilidad y mortalidad en estos pacientes.  
El gen de la FQ ha sido el primer gen humano aislado sin conocer la 
proteína para la que codificaba, ni disponer de claves citogénicas que 
permitiesen un avance rápido en su identificación.   
La FQ está causada por las mutaciones en el gen CFTR1,2, AMPc /PKA-
dependiente, que codifica para una proteína conocida como CFTR (Cystic 
Fibrosis Transmembrane Conductance Regulator), que actúa como canal 
principal del cloro de la membrana e influye en otros iones (calcio, sodio, 
etc.) y suele localizarse en la membrana apical del epitelio secretor de las 
glándulas mucosas de vías aéreas, digestivas y reproductoras, y en las 
serosas del sudor y saliva.  
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La alteración del transporte de electrolitos, principalmente del transporte 
de cloruro, es la anomalía principal de la FQ, conllevando a secreciones 
en diversos órganos excesivamente espesas y deshidratadas, provocando 
la obstrucción de los conductos del páncreas, glándulas salivares, 
epidídimo, intestino, bronquios y bronquiolos principalmente. La 
formación de esas secreciones anormalmente espesas es el resultado 
final de un flujo alterado de iones de cloruro y de sodio, además del agua 
que les acompaña3.  
Cada persona hereda un gen CFTR del padre y otro de la madre, siendo 
una enfermedad recesiva que solo se desarrolla cuando existen 
mutaciones perjudiciales en los dos genes CFTR. Se han descrito casi dos 
mil mutaciones del gen CFTR en la base de datos de mutaciones de CFTR 
a disposición pública (https://www.cftr2.org/) y más de 1550 son 
causantes de enfermedad. Desgraciadamente, el conocimiento actual es 
incompleto ya que se siguen descubriendo nuevas mutaciones del gen 
CFTR.  
Gracias a los avances de la ciencia realizados durante el siglo XX (que han 
permitido mejorar el conocimiento de la fisiopatología de la FQ) y al 
cuidado multidisciplinar que reciben los enfermos, la supervivencia de los 
pacientes con FQ en la actualidad supera los 40 años de edad, cuando a 
mediados del siglo pasado, la edad media de supervivencia no superaba 
el año de vida. 
Los pilares del tratamiento de la FQ se basan en la nutrición, fisioterapia 
respiratoria, ejercicio físico, y utilización de medicamentos destinados a 
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paliar la sintomatología y a tratar deficiencias, como las de vitaminas y 
enzimas pancreáticas, a mejorar el aclaramiento de la vía aérea, o a actuar 
de forma profiláctica en las infecciones pulmonares como ocurre con el 
uso de antibióticos.  
Los tratamientos farmacoterapéuticos que reciben los niños con FQ en 
Inglaterra se basan en: 
 mucolíticos nebulizados para mejorar el aclaramiento de la vía 
aérea y oral en el tratamiento y prevención del síndrome de 
obstrucción intestinal distal; 
 antiinfecciosos nebulizados, por vía intravenosa y oral;  
 nutritivos de enzimas pancreáticos, principalmente vitaminas 
liposolubles y suplementos de iones como sodio y calcio;  
 agonistas de los receptores beta (broncodilatadores);  
 insulinas cuando se desarrolla diabetes causada por FQ y por el 
uso de fármacos antiinflamatorios; 
 gastrointestinales para acelerar la motilidad intestinal en el 
reflujo, evitar exceso de mucosidad en el aparato digestivo y para 
prevenir el síndrome de obstrucción intestinal distal; 
 moduladores de la proteína CFTR (solo en determinados 
pacientes y a partir de una cierta edad).  
En Inglaterra existe amplia experiencia en la integración del farmacéutico 
clínico como parte del equipo multidisciplinar que atiende a los pacientes. 
El farmacéutico pediátrico es, en efecto, una figura clave en el equipo de 
pase de visita a los enfermos ingresados en planta y participa en las 
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decisiones clínicas encaminadas a optimizar el tratamiento 
farmacoterapéutico que recibe al paciente y a mejorar el grado de 
conocimiento que este tiene de su tratamiento y de su enfermedad, lo 
que contribuye por una parte a que los pacientes aumenten el grado de 
adherencia del tratamiento farmacoterapéutico que reciben y por otra a 
que se facilite, de forma temprana, la identificación  de problemas 
relacionados con la medicación, tanto reales como potenciales. 
En los niños con FQ, además de la propia complejidad inherente al 
paciente pediátrico, se suman otros factores que aumentan todavía más 
la complejidad de la farmacoterapia, tales como las múltiples potenciales 
interacciones farmacocinéticas o la limitada disponibilidad de formas 
farmacéuticas adecuadas para su administración en niños, lo que 
requiere el uso frecuente en este grupo de pacientes de fármacos no 
aprobados para su uso, con el consiguiente riesgo de errores en el 
proceso de prescripción. Todo lo anterior justifica la participación activa 
del farmacéutico clínico en el equipo interdisciplinar, trabajando de 
forma descentralizada en las áreas clínicas e interactuando diariamente 
con los pacientes y familiares, con el personal médico y de enfermería, y 
cuando se requiere, con fisioterapeutas, psicólogos y dietistas. 
El objetivo de la atención farmacéutica proporcionada por el 
farmacéutico clínico integrado en el equipo multidisciplinar es contribuir 
a alcanzar resultados terapéuticos predefinidos que mejoren la calidad de 
vida del paciente y minimizando los riesgos inherentes al uso de los 
medicamentos4. Con la publicación en 1999 del informe del Institute of 
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Medicine (IOM), To ERR is Human: Building a safer Health System129, se 
despertó en las instituciones sanitarias el ánimo de proteger al paciente 
y desde ese momento las publicaciones científicas relacionadas con la 
seguridad clínica del paciente, entre ellas, las que evalúan los errores de 
medicación, incrementó considerablemente. En este sentido, el estudio 
desarrollado en España sobre los efectos adversos vinculados con la 
hospitalización (ENEAS) concluye que la incidencia de efectos adversos 
durante el periodo del estudio fue de un 8.4%, siendo los medicamentos 
responsables del 37% de los casos y en la mitad de ellos estos eran 
prevenibles86. Una cultura de seguridad es indispensable en un ambiente 
hospitalario, en donde se debe compartir el conocimiento de errores, 
reales o potenciales, con el fin de evitar que alcancen al paciente. El 
National Patient Safety Agency (NPSA) presenta los pasos necesarios para 
conseguir una organización más segura donde el paciente es el centro de 
atención de seguridad83. Estos pasos están dirigidos a crear una cultura 
de compartir y comunicar abiertamente los errores con el fin de aprender 
de ellos, integrando sistemas de gestión de riesgos, de análisis de las 
causas y factores contribuyentes al error de medicación, con el fin de 
proponer las soluciones que se estimen necesarias para mitigar el riesgo 
de que el mismo error vuelva a ocurrir.   
En la práctica clínica, un error es un fallo que causa o que podría causar 
daño a los pacientes tanto por práctica clínica realizada incorrectamente 
o por práctica clínica omitida. Según la FDA, el error de medicación es 
aquel evento prevenible que podría causar o que genera un uso 
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inapropiado del medicamento, mientras la medicación está en manos del 
profesional sanitario, del paciente o del consumidor. La prescripción y la 
administración de medicamentos son dos procesos integrados en la 
cadena farmacoterapéutica que tienen implícito un riesgo de error de 
medicación elevado. Varias organizaciones han adoptado el concepto de 
los 5 parámetros que deberían cumplirse en una prescripción médica (5 
rights) para considerarla de calidad: Right patient, Right drug, Right dose, 
Right route, Right time5. Desde la experiencia clínica diaria en plantas de 
hospitalización de pediatría es importante añadir un parámetro adicional, 
la forma farmacéutica, y adoptar en los estudios de medicación realizados 
en pacientes pediátricos la necesidad de que las prescripciones reflejen 
de forma correcta los seis parámetros arriba indicados. 
Con el fin de conocer y entender cómo ocurren y cómo se pueden 
prevenir los errores, se requiere disponer de una clasificación clara de los 
mismos. La tipificación de los errores de medicación realizada en esta 
Memoria se basa en dos tipos: cometidos (cuando se comete un error) u 
omitidos (cuando se omite cualquier parámetro imprescindible para 
considerar una prescripción de calidad). Y a su vez, estos se subdividen 
atendiendo al parámetro evaluado: fármaco, dosis, vía de administración, 
frecuencia, duración del tratamiento y forma farmacéutica.  
Las causas de los errores definidas en los 7 pasos de la NPSA se pueden 
aplicar en cualquier disciplina. Así pues, las causas de los errores de 
medicación pueden clasificarse como educacionales, comunicativas, 
tecnológicas, organizativas o humanas. De esta manera, conociendo las 
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causas de los errores y haciendo el esfuerzo de crear una cultura de 
seguridad se podría alcanzar el objetivo de prevenirlos.  Los 7 pasos para 
la seguridad del paciente se resumen en los siguientes:  
1. Paso 1: crear una cultura de seguridad. 
2. Paso 2: liderar y dar soporte al personal. 
3. Paso 3: integrar la actividad en un manejo de riesgo con el fin de 
asesorar lo que ha fallado. 
4. Paso 4: promocionar la comunicación de los errores. 
5. Paso 5: involucrar al paciente y al público, siendo abiertos y 
honestos respecto al error. 
6. Paso 6: aprender y compartir/difundir las lecciones de seguridad, 
hacienda análisis en modo de fallo. 
7. Paso 7: implementar soluciones para prevenir daño.  
Respecto a la calidad y seguridad de la prescripción en niños con FQ, es 
necesario tener en cuenta que la prescripción es el primer paso 
documentado de una serie de procesos que ocurren hasta que el 
medicamento se administra al paciente. En el sistema de salud inglés se 
dispone de múltiples fuentes de prescripción. Además, la documentación 
que se maneja en cada una de ellas es compleja en sentido logístico, pues 
los niños, y una gran mayoría de enfermos crónicos, no asumen el gasto 
de la medicación o de los tratamientos que reciben. Así pues, quienes 
financian los tratamientos crean sus propias redes para controlar el gasto 
y optimizar los tratamientos de la mejor manera posible. En 
consecuencia, la medicación que disponen los pacientes de FQ puede 
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provenir de una oficina de farmacia dispensada en atención primaria, o 
de una farmacia externa anexa a pacientes externos en el hospital 
(secundaria), de un servicio a domicilio o desde el hospital mientras el 
paciente está ingresado. De esta manera la conciliación de la medicación 
que reciben estos pacientes, afectados de patologías crónicas, siempre 
polimedicados y de alto coste para el sistema de salud, en el ingreso 
hospitalario, es un reto.  
Cuando un paciente requiere una asistencia que conlleva un cambio de 
nivel asistencial (por ejemplo: el paciente requiere un ingreso 
hospitalario, o el paciente ingresado cambia de planta médica, entre 
otros) está más expuesto a errores de medicación. Si a este hecho se 
añade el factor pediátrico (dosis ajustada por peso/edad, distintas formas 
farmacéuticas con distinta biodisponibilidad, etc.) y una enfermedad 
crónica, que tiene patologías asociadas tratadas todas ellas con diferentes 
fármacos, la probabilidad de errores de medicación se incrementa y 
puede alcanzar un alto valor cuando la frecuencia de ingresos 
hospitalarios de los pacientes para recibir tratamiento por vía intravenosa 
es elevada. Estas circunstancias ponen de relieve la importancia de 
disponer para este grupo de pacientes de una prescripción médica al alta 
hospitalaria de elevada calidad, ya que este documento debería ser el de 
referencia para el paciente además de garantizarle una farmacoterapia 
segura y de calidad. 
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2. Objetivos.    
Objetivo general: 
Mejorar la calidad de la prescripción al alta hospitalaria en el paciente 
pediátrico diagnosticado de fibrosis quística que ingresa para tratamiento 
intravenoso mediante la utilización de indicadores de seguridad. 
Para ello el estudio se ha realizado en dos periodos, uno retrospectivo y 
otro prospectivo, teniendo en cada uno de los periodos los siguientes 
Objetivos específicos 
Fase retrospectiva: 
 Evaluar de forma cualitativa y cuantitativa los errores de 
medicación en las prescripciones al alta hospitalaria validadas por 
el farmacéutico. 
 Evaluar de forma cualitativa y cuantitativa los errores de 
medicación en los informes médicos emitidos en el alta 
hospitalaria. 
 Identificar, tipificar y analizar las causas de los errores de 
medicación detectados con mayor frecuencia. 
 Proponer recomendaciones de mejora a los profesionales 
implicados y diseñar estrategias para implementar dichas 
recomendaciones en la práctica asistencial. 
Fase prospectiva: 
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 Evaluar de forma cualitativa y cuantitativa los errores de 
medicación en el ingreso hospitalario de los pacientes. 
 Evaluar de forma cualitativa y cuantitativa los errores de 
medicación en las prescripciones al alta hospitalaria tras 
validación por el farmacéutico. 
 Evaluar el impacto de las recomendaciones de mejora realizadas. 
 
3. Material y Métodos  
3.1. Pacientes, criterios de inclusión y ámbito del estudio. 
Pacientes pediátricos diagnosticados de FQ que ingresan en la planta de 
respiratorio del hospital Royal London para recibir antibioticoterapia 
intravenosa. El hospital de estudio es uno de los Hospitales del Sistema 
de Salud Publico del grupo Barts Health NHS. 
La propuesta de estudio se valoró y autorizó por la unidad de efectividad 
clínica de Barts Health NHS Trust (el número de identificación del estudio 
otorgado fue: 7080). 
3.2. Fases del estudio.   
Una primera fase retrospectiva de dos años de duración, desde Enero de 
2013 a Diciembre de 2014. 
Una fase de presentación de resultados al Departamento de Neumología 
infantil del Royal London Hospital destinada a definir y acordar 
estrategias de mejora (3 meses de duración). 
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Una fase prospectiva realizada desde mayo a diciembre de 2016 (8 
meses). 
3.3. Fuentes de información. 
A continuación se resumen las siete fuentes de información utilizadas 
para realizar el estudio: 
1. EPR, referente a “electronic patient’s records”, donde se 
encuentra la prescripción electrónica utilizada al alta hospitalaria 
durante los años 2013 y 2014. 
2. Informe médico de alta, documento de texto donde se explican 
los acontecimientos ocurridos durante la estancia del paciente en 
el hospital (motivo de ingreso, tratamiento recibido, gérmenes 
identificados, espirometría, etc.) y el listado de medicamentos al 
alta. El informe de alta se refiere a las siglas DL, correspondientes 
a “discharge letter”. 
3. CRS, las siglas se refieren a “clinical record system”, donde se 
encuentra la prescripción electrónica utilizada al alta hospitalaria 
durante el periodo del estudio prospectivo. 
4. SCR, se refiere a “summary care records”, es la prescripción 
electrónica de Atención Primaria que realiza el médico de 
cabecera. 
5. PODs, siglas utilizadas para “patient’s own drugs”, la medicación 
del paciente, que en Inglaterra por ley debe de tener una etiqueta 
con la información de lo que se ha prescrito, a quién, cuando, por 
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quién, dónde e instrucciones de cómo y cuándo preparar, 
administrar o tomar la medicación.  
6. Hoja de tratamiento hospitalario, donde se prescribe la 
medicación que el paciente debe de recibir mientras está 
ingresado (referente a drug chart). 
7. Prescripciones del servicio a domicilio, que es un servicio 
contratado por el hospital con el fin de reducir el coste de los 
fármacos utilizados en FQ más caros, generalmente antibióticos 
nebulizados. 
3.4. Variables estudiadas.  
Se estudiaron un total de 30 variables, algunas comunes en ambas fases 
del estudio y otras exclusivas de una fase u otra. La tabla siguiente resume 
las variables estudiadas.  
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Tabla 1. Variables estudiadas: denominación y fase en la que se estudian. 
Variables 
relacionadas con 
Numeración y denominación de la variable Fase análisis de la variable: 
Retrospectiva (R) Prospectiva (P) 
El paciente 0- Número hospitalario R,P 
1- Edad R,P 
2- Género R,P 
3- Número de patologías asociadas R,P 
4- Tipo de patologías asociadas  R,P 
5- Si la lengua materna de los padres es inglés P 
6- Si el niño vive con ambos padres P 
La estancia 
hospitalaria 
7- Motivo de ingreso R,P 
8- Número de días de estancia hospitalaria R,P 
9- Día de la semana del ingreso P 
10- Día de la semana del alta R,P 
La farmacote-
rapia 
11- Documentación de peso R,P 
12- Documentación de alergias R,P 
13- Coincidencia de alergias documentadas en Atención Primaria   P 
14- Tipo de fármacos R,P 
15- Medico prescriptor R,P 
16- Farmacéutico que valida la prescripción R,P 
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17- Cargo o experiencia del farmacéutico R,P 
18- Existencia del informe de alta R 
19- Fecha del día de alta  R 
20- Número de discrepancias en el informe de alta respecto a EPR R 
21- Número de fármacos prescritos R,P 
22- Número de fármacos prescritos con nombre comercial R 
23- Prescripción desde Atención Primaria de tratamientos 
nebulizados de alto coste  
P 
Las estrategias de 
mejora. 
24- Número fuentes de información para reconciliar medicación   P 
25- Número de tarjetas recordatorias para prescripción al alta P 
26- Número de intervenciones farmacéuticas y tipo P 
27- Número de intervenciones farmacéuticas aceptadas P 
28- Número de altas previamente listadas por el técnico de farmacia P 
29- Necesidad de comunicarse con Atención Primaria  P 
30- Comunicación realizada P 
EPR: Electronic prescription used in the retrospective fase. 
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3.5. Oportunidades de mejora. 
Las oportunidades de mejora (OM) (I.O, para las siglas de “improvement 
opportunities”) se definieron como cualquier circunstancia que causa o 
que podría causar un error de medicación alcanzando o dañando al 
paciente debido a información incorrecta o a la falta de información que 
se produce durante el proceso de prescripción.  
Las I.O se analizaron en ambas fases del estudio en la prescripción 
electrónica al alta. Además, en la fase retrospectiva se analizaron en el 
informe médico de alta hospitalaria (DL) y en la etapa prospectiva en la 
conciliación de tratamientos realizada al ingreso. 
La clasificación de las OM se realizó según si se trataba de errores 
relacionados con el procedimiento de prescripción (omisión del peso, las 
alergias o la firma del prescriptor); o si se trataba de errores de 
medicación, por información incorrecta u omitida en alguno de los seis 
parámetros considerados imprescindibles en una prescripción segura y 
de calidad. 
3.6. Errores de medicación. 
Los errores de medicación (ME) se definieron como cualquier incidente 
que podría causar o que causó daño al paciente por el uso inapropiado de 
fármacos debido a una prescripción incorrecta o incompleta, durante la 
estancia hospitalaria o al alta a domicilio.  
La tipificación de los ME se resume en el capítulo de antecedentes y se 
describe en la siguiente Tabla 2.  
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Tabla 2. Descripción de tipos y subtipos de errores de medicación. 
 Cometidos: información incorrecta en la prescripción Omitidos: omisión de la información 
Fá
rm
ac
o
 
 Incorrecto.  
 Continúa el tratamiento cuando se debería de haber 
parado. 
 Interacciones o problemas de absorción entre dos o 
más fármacos prescritos conjuntamente, que 
afectan la eficacia o pudiendo causar problemas de 
medicación (por ejemplo itraconazol junto con 
inhibidores de la bomba de protones,). 
 El nombre del fármaco prescrito en EPR no aparecía 
en la carta del informe de alta (DL) o viceversa.  
 La farmacoterapia regular del paciente no estaba 
prescrita (antibióticos nebulizados, insulinas, etc). 
 Evidencia en la que el paciente debería de tener 
terapia de rescate prescrita en primaria.  
D
o
si
s 
 Dosis se prescribía en volumen o con unidades 
erróneas (se excluyo en estos casos: AquADEKs®, 
Sytron® y Lactulosa). 
 Cuando la dosis por edad/peso prescrita era un 20% 
mayor o menor del que correspondía.  
 Dosis o unidades omitidas en la prescripción.  
 Dosis que indicaran “Tómelo como lo he indicado”. 
Se excluyo las pancreatininas enzimáticas y 
pomadas o medicación que no tenía que ver con FQ 
o alguna de las patologías asociadas del niño/a. 
Fr
ec
u
en
-
ci
a
  Cualquier frecuencia mayor o menor del 20% de lo 
que se esperaría para la edad/peso.  
 Frecuencia omitida o indicado “cuando lo necesite” 
pero sin indicar la posología máxima diaria que se 
puede administrar. 
D
u
ra
ci
ó
n
  La duración prescrita era incorrecta. 
 Antibióticos orales o nebulizados o cortisona 
estaban prescritos sin indicar el tiempo de 
tratamiento. 
 Nueva medicación prescrita sin indicar una fecha de 
revisión del fármaco.  
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Fo
rm
a 
fa
rm
ac
é
u
ti
ca
  Forma farmaceútica incorrecta.  
 Formulación no accesible para el paciente. 
 Existían preparaciones más económicas que el 
paciente podría tomar. 
 Formulaciones inconsistentes para un mismo niño. 
 Prescripción de pastillas en niño en el que se conoce 
que no las puede tragar 
 
 No se indicaba la presentación farmacéutica y 
existen varias comercializadas (referente a 
soluciones orales). 
 Ausencia de prescripción de tratamiento 
nebulizado, inhalador o insulina.  
 
V
ía
 a
d
m
i-
n
is
tr
ac
io
n
  Si era incorrecto. 
 Si era inconsitente con otros fármacos prescritos que 
normalmente utilizarían la misma vía. 
 Cuando se había omitido. 
EPR: Electronic prescription used in the retrospective fase; DL: Discharge letter 
 
  
 
3.6.1. Causas y gravedad de los errores 
Las causas de los errores se dividieron en 5 categorías: 
 Tecnológicas. 
 Oganizativas (del Sistema de salud). 
 Comunicativas. 
 Educativas (al personal sanitario o al paciente y/o cuidador). 
 Humanas.  
La gravedad de los errores se clasificó según la escala de gravedad 
definida en el método de atención farmacéutica IASER©. Este método 
utiliza una escala tipo Likert en la que se otorgan cinco valores de escala 
ordenados de menor, cuando la gravedad del error no causaba daño de 
signos vitales pero se requirió monitorización (1), a mayor gravedad (5) 
en el que el error causa la muerte del paciente. 
3.7. Conciliación de tratamientos  
Se evaluó en el ingreso hospitalario durante la etapa prospectiva del 
estudio y al alta hospitalaria en ambas fases del estudio. 
Se analizó la existencia o no de discrepancias (al ingreso y al alta) y en 
caso de que las hubiera se investigó si estaban justificadas o no. Cuando 
las discrepancias no estaban justificadas se consideraron errores de 
medicación (también llamados errores de conciliación). 
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3.8. Estrategias de mejora y acciones de seguridad. 
Los resultados obtenidos en la fase retrospectiva del estudio se 
presentaron al Departamento de Neumología infantil del Royal London 
Hospital y con el objetivo de mejorar la calidad de la prescripción al alta 
de los pacientes de estudio se definieron y acordaron las siguientes 
estrategias: 
1. Elaborar el informe médico de alta hospitalaria a partir de la 
prescripción electrónica al alta realizada por el médico y validada por el 
farmacéutico. 
2.  Diseñar una tarjeta destinada a añadirse a la hoja de tratamiento 
en la que se incluyeran los errores detectados con mayor frecuencia en la 
fase retrospectiva del estudio. 
3.  Realizar la conciliación de medicamentos en el ingreso 
hospitalario de los pacientes utilizando un mínimo de tres fuentes de 
información. 
4. Monitorizar las intervenciones realizadas por el farmacéutico 
durante la estancia hospitalaria de los pacientes que estaban 
documetadas en la hoja de tratamiento (drug chart). 
5.  Incorporar personal de refuerzo (técnico de farmacia) en el 
proceso de la validación técnica de la prescripción médica al alta 
hospitalaria. 
6.  Comunicar al equipo multidisciplinar de Atención Primaria los 
cambios requeridos en el tratamiento farmacoterapéutico de los 
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pacientes durante la estancia hospitalaria que implicaran una 
modificación de la prescripcion de primaria. 
3.9. Indicadores de calidad. 
Los indicadores de calidad se diseñaron para evaluar la calidad de la 
prescripción al alta (fases retrospectiva y prospectiva) así como para 
evaluar el impacto de las acciones de mejora implantadas en la fase 
prospectiva del estudio. 
Estos indicadores se crearon considerando la medicación necesaria, para 
que los órganos afectados con mayor frecuencia en los pacientes con FQ 
estuvieran tratados correctamente de acuerdo a su situación clínica, con 
dosis individualizadas óptimas según edad/peso. 
Se definieron 19 indicadores de calidad: unos característicos de la 
prescripción al alta hospitalaria que se evaluaron y compararon en ambas 
etapas del estudio (1-11) y otros exclusivos de la fase retrospectiva: los 
relacionados con aspectos administrativos de la DL (12-13) o los de la fase 
prospectiva: los relacionados con las acciones de mejora (14-18). El 
indicador 19 es un indicador de calidad global de la prescripción que se 
fundamenta en los 5 parámetros que debería reunir una prescripción 
para considerarla de una calidad óptima, además de un sexto que se ha 
considerado muy importante en la población pediátrica, la forma 
farmaceutica (6-11). 
La nomenclatura utilizada para los indicadores de calidad, los valores 
considerados como estándar en este estudio y las fases del estudio en las 
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que se han evaluado se resumen en la siguiente Tabla 3 (ver también las 
Tablas 3.6-3.9). 
Tabla 3. Descripción de los indicadores de calidad con su valor estándar y fase del estudio 
se aplicaron. 
Indicador calidad; Qi (descripción) Valor 
Standard (%) 
Retrospectivo (R) 
Prospectivo (P) 
Qi 1 (identidad) 100 R, P 
Qi 2 (peso registrado) 80 R, P 
Qi 3 (alergias registradas) 80 R, P 
Qi 4 (vitaminas prescritas) 80 R, P 
Qi 5 (enzimas pancreáticos prescritos) 80 R, P 
Qi 6 (fármaco) 90 R, P 
Qi 7 (dosis) 90 R, P 
Qi 8 (frecuencia) 90 R, P 
Qi 9 (forma farmacéutica) 90 R, P 
Qi 10 (vía de administración) 90 R, P 
Qi 11 (duración) 90 R, P 
Qi 12 (informe de alta) 80 R 
Qi 13 (fecha/retraso informe de alta) 80 R 
Qi14 (reconciliación al ingreso, variable 24) 80 P 
Qi 15 (cartilla recordatoria, variable 25) 80 P 
Qi 16 (intervenciones aceptadas, variable 27) 80 P 
Qi 17 (técnico farmacia, variable 28) 60 P 
Qi 18 (comunicación con primaria, variable 30) 80 P 
 
 𝑄𝑖19
𝐸𝑃𝑅 𝑜𝑟 𝐶𝑅𝑆
  (calidad y seguridad global) 
 
 
50 
 
R, P 
EPR, CRS: prescripción electrónica en la fase retro y prospectiva respectivamente. 
 
3.10. Análisis estadístico 
En el proceso de recogida y análisis de datos se ha utilizado el programa 
Excel 2013®. Para comparar las proporciones se han utilizado las pruebas 
estadísticas Chi cuadrado y para conocer la magnitud de la diferencia se 
calculó el Odds ratio o el riesgo relativo. Las variables continuas se 
compararon con las pruebas estadísticas t student o ANOVA.  
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Se ha considerado significación estadística cuando p<0.05. 
4. Resultados 
La población incluida en ambas fases del estudio no presentó diferencias 
estadísticamente significativas en género, edad, tiempo de estancia 
hospitalaria, número de fármacos prescritos al alta, días de la semana de 
alta y la mayoría de patologías asociadas. Se encontraron diferencias 
estadísticamente significativas en la enfermedad hepática como 
patología asociada (p=0.0255) y en el motivo de ingreso de los pacientes 
incluidos en las dos fases del estudio, donde el ingreso por exacerbación 
fue del 45.00% en la fase retrospectiva y del 63.63% en la fase prospectiva 
(p=0.027).  
Se encontraron más niñas ingresadas para recibir tratamiento con 
antibióticos por vía intravenosa, siendo esta proporción niño/niña 
significativa en ambas fases del estudio (p<0.001 en la retrospectiva y  
p=0.030 en la prospectiva). 
En la fase retrospectiva se comparó el sistema electrónico de prescripción 
al alta (EPR) y uno de texto libre (informe de alta). La detección de 
oportunidades de mejora de prescripción fue significativamente mayor 
en el sistema de texto libre al valorar el porcentaje del número de 
episodios de alta (p<0.001). 
Al comparar las OM en ambas fases del estudio se detectaron de forma 
significativa menor porcentaje de pacientes y de altas con OM en la fase 
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prospectiva. Sin embargo, el porcentaje de fármacos prescritos con OM 
fue significativamente mayor en la fase prospectiva.  
Al analizar las tasas de OM por paciente y por alta no se encontraron 
diferencias significativas entre los dos periodos aunque la tasa de OM 
analizada en base a cien fármacos prescritos, sí fue significativamente 
mayor en la fase prospectiva (p<0.001). 
El porcentaje de altas validadas por el farmacéutico tuvo menos OM en el 
estudio prospectivo (81.18% en la fase retrospectiva y 52.00% en la fase 
prospectiva, p<0.001). 
En la fase retrospectiva el porcentaje global (cometidos y omitidos) de 
errores de medicación detectados en la prescripción electrónica al alta 
hospitalaria (EPR), fué similar (47% omitidos y 53% cometidos), 
destacando el subtipo de errores cometidos mas frecuentes los de dosis 
(43.59%) y errores omitidos de fármaco (40%). Mientras que los errores 
de medicación encontrados en el informe de alta fueron 
mayoritariamente por omisión (84% omitidos vs 17% cometidos), 
sobresaliendo los errores de dosis como errores cometidos en un 47.27% 
y errores de omisión de forma farmacéutica en un 35.97%. 
Al comparar los errores encontrados en la prescripción electrónica al alta 
de la fase prospectiva con la del periodo retrospectivo (EPR), se 
encontraron menos errores de fármaco, dosis, duración/clarificación de 
tratamiento en la fase prospectiva (p<0.001). Asímismo, los errores de 
forma farmacéutica fueron ligeramente menores en la fase prospectiva 
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del estudio. Sin embargo, la frecuencia de error de vía de administracion 
fue menor en la fase retrospectiva (p<0.001).  
Respecto al subtipo de errores comparando ambas fases de estudio, los 
errores cometidos fueron más frecuentes en la fase retrospectiva 
(p<0.05), pero los de omisión lo fueron en la prospectiva (p<0.05), 
principalmente por omisión de la vía de administración. 
La causa más probable de error en la fase retrospectiva del estudio  podría 
atribuirse a la organización del Sistema, mientras que en la fase 
prospectiva la causa más probable de error puede tener origen 
tecnológico. 
Los errores de medicación detectados en la fase prospectiva al ingreso 
fueron principalmente por omisión de fármacos y dosis incorrecta. 
Respecto a las estrategias de mejora y de seguridad implantadas en la 
fase prospectiva previas a la prescripción de alta: 
 Todas las hojas de tratamiento tuvieron incorporadas la cartilla 
recordatoria (prompt card). 
 Se encontraron oportunidades de mejora al ingreso hospitalario 
en la hoja de tratamiento en un 65.45% de los casos y en un 
70.91% en la prescripción de atención primaria. 
 Se observaron un total de 134 intervenciones documentadas en 
las hoja de tratamiento, mayoritariamente de tipo correctivo de 
modificación de dosis, aceptandose un 98.53% de ellas. 
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El valor de los indicadores de calidad global de la prescripción al alta 
durante la fase retrospectiva del estudio fue 22% para la prescripción 
electrónica (EPR) y 9.21% para el informe de alta (DL). Este indicador 
alcanzó el valor de 41.82% en la fase prospectiva (CRS) (p=0.010). No se 
alcanzó en ninguna de las fases del estudio el valor predefinido como 
estándar de calidad de la prescripción (50%).  
Los indicadores de calidad de la prescripción que mejoraron 
significativamente en la fase prospectiva fueron los de fármaco (Qi 6), 
dosis (Qi 7), frecuencia (Qi 8), vía de administración (Qi 10) y duración de 
tratamiento (Qi 11), (p<0.05).  
A continuación, en la siguiente figura se resumen los valores de los 
indicadores de calidad obtenidos en ambas fases del estudio. 
 
 Figura 1. Valores de los indicadores de calidad. 
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5. Discusión 
El programa de calidad descrito se podría considerar un programa de 
monitorización de errores de medicación y de otras oportunidades de 
mejora de la prescripción de medicamentos al alta hospitalaria, así como 
un estudio de seguimiento del impacto en la seguridad del paciente 
derivado de una mayor integración del farmacéutico en el cuidado del 
paciente pediátrico con FQ. El estudio permitió evaluar la calidad global 
de la prescripción al alta hospitalaria en ambas fases del estudio de 
investigación realizado, retrospectiva y prospectiva, permitiendo evaluar 
el impacto de las diferentes estrategias de mejora y acciones de seguridad 
implantadas.  
Sin embargo, se detectan más errores de la prescripción en la fase 
prospectiva, a expensas de un mayor número de errores por omisión de 
vía de administración, cuya causa se encuentra en las particularidades del 
sistema informático implantado durante esta fase del estudio.  
La literatura disponible relacionada en estudios similares al realizado es 
escasa y en algunos casos los resultados de esta Tesis contradicen los 
obtenidos en otras investigaciones6 en las que se concluye que la 
utilización de sistemas informatizados de prescripción reducen los 
errores de medicación. Sin embargo, en este estudio el sistema 
informático utilizado en la fase prospectiva parece ser la principal causa 
de las omisiones de la forma farmacéutica y de la vía de administración 
detectadas en la prescripción, ya que la aplicación informática carece de 
un campo exclusivo para realizar el registro de estos parámetros de tal 
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forma que alerte al prescriptor en caso de que no se haya completado. 
No obstante, a pesar de esta limitación del sistema informático, el 
número total de errores de medicación cometidos (no omitidos) durante 
la fase prospectiva fue menor. Este resultado puede interpretarse como 
una mejora de la calidad de la prescripción durante la fase prospectiva del 
estudio que puede atribuirse, al menos en parte, al impacto de las 
estrategias de mejora de la calidad y de seguridad definidas tras el análisis 
de los resultados de la fase retrospectiva del estudio e implantadas 
durante la fase prospectiva del mismo. Sin embargo, la mejora de la 
calidad observada en la fase prospectiva no puede atribuirse únicamente 
a las estrategias de mejora implementadas, ya que otros aspectos que 
subyacen en el cuidado del paciente pediátrico diagnosticado con FQ y 
otros factores no cuantificados en este estudio, entre ellos los 
relacionados con el grado de experiencia del farmacéutico integrado en 
la planta de respiratorio en esta fase, no pueden deslindarse del resultado 
final. 
6. Conclusiones. 
1. Los indicadores utilizados para evaluar la calidad de la prescripción al 
alta hospitalaria de los pacientes pediátricos diagnosticados de fibrosis 
quística durante la fase retrospectiva del estudio no alcanzan el estándar 
de calidad definido (50%), siendo mayor la calidad de la prescripción 
electrónica (22%) que la calidad del informe médico del alta hospitalaria 
(9.21%). Esta diferencia de valores realza la importancia de utilizar un 
sistema de prescripción que integre campos diseñados para registrar la 
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información específica de los seis parámetros fundamentales de la 
prescripción (fármaco, dosis, frecuencia, duración de tratamiento, forma 
farmacéutica y vía de administración). 
2.  En la fase retrospectiva del estudio el porcentaje de errores de 
medicación, cometidos y omitidos, detectados en la prescripción 
electrónica al alta hospitalaria, fué similar. Sin embargo, en los informes 
médicos de alta hospitalaria los errores de medicación omitidos se 
realizaron en mayor proporción. Los tipos de errores de medicación más 
frecuentes en la prescripción electrónica fueron de forma farmacéutica 
seguidos de fármaco y dosis, mientras que en el informe médico al alta 
hospitalaria fueron tambien por forma farmacéutica aunque seguidos de 
dosis y de vía de administración.  
3. Los factores contribuyentes a los errores de medicación registrados en 
la fase retrospectiva del estudio a partir de la prescripción electrónica y 
del informe médico al alta hospitalaria pueden asociarse a factores 
relacionados con la organización del sistema.  
4. Las estrategias de mejora implantadas tras el análisis de errores de 
medicación detectados en el estudio retrospectivo estuvieron dirigidas a 
mejorar la organización del proceso de prescripción, mejorando la 
conciliación del tratamiento al ingreso y al alta hospitalaria, así como la 
integración del farmacéutico en el equipo multidisciplinar que atiende al 
paciente pediátrico diagnosticado de FQ.  
5.  En la fase prospectiva del estudio los errores de medicación detectados 
con mayor frecuencia en el ingreso hospitalario del paciente fueron por 
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fármacos omitidos, seguido de dosis incorrecta. Sin embargo, en el alta 
hospitalaria los errores de medicación más frecuentes fueron por omisión 
de la vía de administración seguidos de incorrecta frecuencia. En esta 
fase, las principales causas contribuyentes a cometer los errores de 
medicación fueron de naturaleza tecnológica.  
6. En la fase prospectiva del estudio, realizada tras la implantación de las 
recomendaciones de mejora diseñadas, el porcentaje de altas con 
oportunidades de mejora detectadas en el proceso de validación 
farmacéutica de las prescripciones refleja un incremento significativo en 
la calidad  tras observarse una reducción del 29.18% en el porcentaje de 
oportunidades de mejora detectadas en el proceso de validación 
farmacéutica de las prescripciones tras el alta hospitalaria (81.18% de OM 
en el periodo retrospectivo, 52% de OM en la fase prospectiva). 
7. La formación de equipos multidisciplinares que integren profesionales 
expertos clínicos (médicos y enfermeros) y expertos en el uso de los 
medicamentos (farmacéuticos y técnicos en farmacia) facilita la toma de 
decisiones clínicas que aumentan el estándar de calidad en el cuidado del 
paciente pediátrico diagnosticado de FQ. Estas mejoras repercuten en la 
optimización de la farmacoterapia, en el grado de aceptación de las 
actuaciones farmacéuticas durante la estancia hospitalaria de los 
pacientes y podrían contribuir a mejorar la adherencia al tratamiento 
farmacoterapéutico por parte del paciente. 
8. Los indicadores utilizados para evaluar la calidad de la prescripción 
médica de pacientes pediátricos diagnosticados de fibrosis quística 
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indican que la implantación de las medidas correctoras diseñadas en este 
estudio ha contribuido a una mejora del proceso (22% en la fase 
retrospectiva vs 41.82% en la fase prospectiva). No obstante, a pesar de 
la mejora cuantificada el valor del indicador de calidad utilizado no 
alcanza el estándar definido (50%). Este hecho pone de relieve la 
necesidad de potenciar, mantener y mejorar las estrategias de seguridad 
iniciadas para alcanzar las cotas de calidad deseadas.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
1. Introduction 
  
Evaluation and improvement of the quality of discharge prescriptions in CF children. 
 
 
 
 
1.1. Sixty five roses 
The term "65 Roses" is synonymous with the history of cystic fibrosis (CF).  
In the 1960s, Ricky Weiss, a four-year old with cystic fibrosis, overheard 
his mother, Mary, talking on the phone.  As a mother of three sons with 
CF, Mary was making phone calls to gather support for CF research. Ricky, 
confronted his mother and told her that he knew about her calls. His 
mother was surprised, because she had kept any knowledge of the 
condition hidden from her sons. Confused, mum asked Ricky what he 
thought the phone calls were about, to which he answered "You are 
working for 65 Roses".   
Needless to say, his mother was incredibly moved by his innocent 
mispronunciation of cystic fibrosis, as have many since who hear the 
story.  Since then, the term "65 Roses" has been used by to help children 
put a name to their condition.  
 
1.2. Background  
Only a few decades ago having a conversation about cystic fibrosis was 
rare. The gigantic steps that we have seen in the lasts decades in medicine 
and pharmacology show how far we have come with what was a disease 
that initially never reached the adult stage.  
Although a true documented history of CF did not exist until well into the 
1930s there were observations found in a German manuscript from the 
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15th century (Codex Latinus Monacensis 849) warning “Woe is the child 
who tastes salty from a kiss on the brow, for he is cursed, and soon must 
die”.  
A few other references have been found in medical texts as early as 1595 
that linked salty skin and damage to the pancreas with death in childhood 
of infants who were “hexed” or “bewitched”7. The German folklore code 
with the blessing against the enchanted children “Wilder elbe” suggested 
licking the child’s nose (supposedly enchanted) to find out if there was a 
salty flavour or not “so sint es dy elbe”.  
These are the first known documentations that relate the salty flavour 
and a disease, now known as Cystic Fibrosis (CF).   
In 1606 a Professor in Medicine in a Spanish University, Dr Juan Alonso y 
de los Ruyzes, wrote in his book “Diex privilegios para mugeres prenadas” 
(Ten privilieges for pregnant ladies) that witched people were found after 
scratching the front brow then noticing a salty flavour in the fingers”. This 
is another reference to the salt and curse. 
Most likely the first macroscopic anatomopathological description of CF 
was done by Peter Paaw in 1595 in Leiden, after an autopsy of an 11 years 
old girl. He described “the girl was supposedly cursed; she had strange 
symptoms for 8 years and was skinny and was exhausted due to 
prolongued fever”. “Pancreas was swollen, cirrotic and was bright white”. 
“The cause of dead was the pancreas”, concluded Paaw.  
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Nils Rosen von Rosenstein (1706-1773), a Swedish paediatrician in his 
book about children disease described a symptom called “fluxux 
coeliasus” characterised of diarrhoea, distrophia, weakness, lack of 
thriving despite good appetite. He described dilated hands and feet and 
distended abdomen and hard pancreas. These were likely his CF patients. 
Carl Von Rokitansky described in 1838 the results of a 7 months old foetus 
autopsy, with a thin intestine perforated and meconium flow in the 
peritoneal cavity with an inflammatory reaction. Possibly this was what 
we now know as a meconium ileum. 
In 1850 Alois Bednar in Viena described a similar case in a newborn that 
died after six days of life. Around the same time there were similar 
descriptions in England. 
The earliest paper written about CF was produced in 1934 Dr Fanconi, a 
Swiss pediatrician. According to the webpage AboutCysticFibrosis.com, in 
a thesis written under his direction, Dr. Fanconi referred to CF as “celiac 
syndrome”, based on how celiac syndrome starts as a digestive disorder 
that interferes with the absorption of nutrients.  
There was much written about medical findings in the 1930s, that in 
hindsight can be assumed to have been factors of CF in patients. 
However, the first person to give this disease the name of cystic fibrosis 
was Dr. Dorothy Andersen, a pathologist at Babies’ Hospital at the 
Columbia-Presbyterian Medical Center in New York. While conducting an 
autopsy on a child who showed the clinical picture of celiac disease, Dr. 
Anderson noted a lesion in the pancreas. Subsequently, she performed 
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an extensive search of the autopsy records and related medical literature, 
and discovered a clear, though previously unrecognised, disease pattern, 
which she referred to as “cystic fibrosis”, as stated on the National Library 
of Medicine website. 
Based on her findings, Dr. Anderson wrote a paper in 1938 entitled “Cystic 
fibrosis of the pancreas and its relation to celiac disease”, which stated 
that out of 49 patients she studied, “in 45 of the cases, the pancreas 
presented a microscopic picture which is described by the term cystic 
fibrosis,” as noted at CFMedicine.com. This writing also described 
intestinal obstruction in newborns, as well as intestinal and respiratory 
complications.  
In the 1950s, pathologist Martin Bodian wrote of Dr. Anderson’s paper 
“such a clear account of the symptoms, that it enabled many cases to be 
recognized that had hitherto been missed”. For first time this author 
described the focal biliar cyrrosis, a patognomonic lesion of CF in the 
liver8. 
Around the same time Di’ Sant Agnese, confirmed the abnormal 
elimination of the Chloride via sweat, which was the base of the sweat 
test9.  
In 1956 Bishop & Koop’s ileostomy technique10 allowed saving lifes of new 
borns with meconium ileum. 
Soon in 1959 the chloride technique was modified by Gibson & Cook with 
pilocarpine11, which so far it is one of the diagnostic techniques currently 
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used. Furthermore, Schwachman was the first investigator who published 
that not all patients had a pancreatic insufficiency and established a 
gravity clinical evaluation system12 that is in current use. 
Later in 1965 Noblett used Gastrografin® in non-complicated meconium 
ileum permitting a cure in babies without surgical intervention13.  
Other pharmacological progress like penicillin and pancreatin enzymes, 
for instance were a positive contribution to push the disease to longer 
age survival.  
The key in the investigation of CF was in 1983 when Quinton discovered 
that the specific defect of the CF was a defect of chloride in the epithelial 
glans14.  
Nowadays, with the advanced technology identifying genes, medicine 
evidence base and the different type of treatments available the way the 
experts look at the disease is totally different than few years ago. And of 
course the approach taken today by professionals without any doubt is 
more optimistic than before.  
Significant improvement in the survival of patients with CF has been 
achieved in the last decades. 
Obviously, this is only possible when there is a good understanding of the 
disease and its infections as well as prompt diagnosis with neonatal 
screening, timely and aggressive nutritional support, physiotherapy, 
pharmacotherapy initiation and its adherence amongst others factors.  
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Treatment at a specialized CF center by a multidisciplinary (MDT) 
dedicated team, including frequent visits, and periodic routine tests are 
essential to detect and treat early changes. Adherence to these therapies 
is challenging and it should be discussed with the patients at every clinic 
visit15. 
Due to the complex pharmacology to which CF children are daily exposed 
and the importance of medicines optimisation it is crucial to have 
accurate up to date information of the pharmacological treatment a child 
is on.  
Furthermore, as children grow the drugs doses must be individualised 
with most updated weight/age. Nevertheless paediatric pharmacokinetic 
is not the only challenge in CF but pharmaceutical forms, adherence, as 
well as clarity of prescriptions and parents also play a big part of it. 
Current experience in the wards and clinics suggests that there is area for 
improvement in the way of prescribing. 
 
1.3. Cystic Fibrosis- Disease and epidemiology. 
CF is an autosomal recessive genetic disease affecting upper and lower 
airway, lungs, exocrine pancreas, small and large intestines, hepatobiliary 
system, salivary and sweat glands, and vas deferens16,17. It is also known 
as muscoviscidosis disease or fibrocystic disease of the pancreas. 
CF is the most common inherited, autosomal recessive disorder in 
Caucasians, with a prevalence of approximately 1 in 2500 live births18. The 
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underlying abnormality lies in the chloride ion channel encoded by the 
cystic fibrosis transmembrane conductance (CFTR) gene19. CFTR is a large 
glycoprotein and a member of the adenosine triphosphate (ATP)-binding 
cassette superfamily of proteins. CFTR is expressed in many cell types, 
with phenotypic alterations primarily identified in epithelial cells of 
airways, sinuses, the gastrointestinal tract (including the pancreas and 
biliary system), the sweat glands, and the genitourinary system. 
Dysfunction of CFTR leads to a wide and variable array of presenting 
manifestations and complications20. 
Although technically a rare disease, CF is ranked as one of the most 
widespread life-shortening genetic diseases.  
In 1997, about 1 in 3,300 Caucasian children in the United States was born 
with cystic fibrosis. In contrast, only 1 in 15,000 African American children 
suffered from cystic fibrosis, and in Asian Americans the rate was even 
lower at 1 in 32,00021. At present over 100,000 people suffer from this 
disease worldwide22. 
It is most common among nations in the Western world. Approximately 1 
in 25 people of European descent, and one in 30 of Caucasian Americans23 
is a carrier of a cystic fibrosis mutation. Although CF is less common in 
these groups, approximately 1 in 46 Hispanics, 1 in 65 Africans and 1 in 
90 Asians carry at least one abnormal CFTR gene24,25. An exception in 
Europe is Finland, where only one in 80 people carry a CF mutation26. 
During the past two decades, care for European patients with CF has been 
increasingly organized in specialized centres and diagnoses generally 
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reported to regional or national registries. This facilitates determination 
of the prevalence of CF for most European countries.   
A recent study tried to find the EU prevalence and the results still vary 
depending of countries. Table 1.1 shows the prevalence in most of the 27 
EU members. In this study, the calculated prevalence value is 1.37 per 
10,000 in the UK and in Spain 0.5 per 10,00027, which is well below the 
requirement of less than 5 per 10,000 for orphan designation in the EU28. 
Most recent data in the UK shows that around 10,500 people in the UK 
have CF, one in every 2,500 babies born29. More than half of the cystic 
fibrosis population in the UK will live past 41, and improved care and 
treatments mean that a baby born today is expected to live even longer.  
The prognosis of cystic fibrosis has improved substantially so that now 
more than half of the patient population is in the adult age range30. 
Whilst previously, CF was a disease for paediatrics only, north American 
data from Cystic Fibrosis Foundation Patient Registry Annual Data Report 
inform that the median predicted survival age for patients has increased 
from 25 years in 1985 to 37 years in 2008 and 39.3 in 2014 (this means 
that 50 percent of individuals with CF in the Registry in 2014 are expected 
to live to 39.3 years of age)31. Although research might seem controversial 
to American data, UK research showed that patients born today are 
expected to have a median survival into their sixth decade32, the real fact 
is that the age survival is in crescendo.  According to United Kingdom CF 
Registry 2010 the median survival for patients with cystic fibrosis is 
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currently 41.4 years. However, the median age at death is currently 27 
years. Most people with CF who die each year are young adults.   
Severely ill patients may need lung, heart or heart/lung transplants. 
Annual expenditure on standard care (excluding transplantation) for 
cystic fibrosis in England is around £100m33. 
Children with CF born after year 2000 can be expected to survive well into 
their 50’s34. The usual cause of death is respiratory failure. The increased 
life expectancy of CF patients is a challenge to paediatric teams unused 
to managing medical problems unique to adolescents and young adults35.  
Table 1.1. Population and prevalence of patients with CF in EU countries27 
Country CF prevalence (per 10000) Estimated CF incidence 
Austria 0.839 1:3500 
Belgium 1.03 1:2850 
Bulgaria 0.226 1:2500 
Cyprus 0.335 1:7914 
Czech Republic 0.55 1:2833 
Denmark 0.761 1:4700 
Estonia 0.618 1:4500 
Finland 0.123 1:25000 
France 0.750 1:4700 
Germany 0.829 1:3300 
Greece 0.521 1:3500 
Ireland 2.98 1:1353 
Italy 0.872 1:4238 
Netherlands 0.781 1:4750 
Poland 0.256 1:5000 
Portugal 0.271 1:6000 
Romania 0.106 1:2056 
Slovakia 0.627 1:1800 
Slovenia 0.328 1:3000 
Spain 0.546 1:3750 
Sweden 0.403 1:5600 
United Kingdom 1.37 1:2381 
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1.4. Cystic Fibrosis- Diagnostic 
Since October 2007, newborn screening for CF has been in place 
throughout the UK; the majority of new diagnoses are via it. Conventional 
methods of diagnosis are still used however to either confirm the 
screening results or for the children born before the introduction of 
neonatal screening tests and patients coming from abroad.  
1.4.1.  Newborn screening in the United Kingdom. 
The first test is the heel prick test. Immunoreactive trypsinogen (IRT) is 
measured on a dried blood spot obtained on the Guthrie card during the 
first 7 days of life. Samples with abnormally raised IRT levels will undergo 
CFTR mutation screening as per the chart in Figure 1.1.  
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Figure 1.1. National standard screening process for newborn screening for CF (2014)36 
If the screening result comes back positive, further tests are needed37. A 
Clinical CF Nurse Specialist (CNS) will contact the family normally within 
the first week of the positive result. A mandatory sweat test to confirm a 
positive result of the genetic test must be performed. It is a very stressful 
time for parents and the CF Team in the UK works within a group of 
experts to provide the most instructive information in a delicate way. 
It is hard for parents to accept this diagnose as CF babies are normally 
well and treatment does not commence at this time, except of pancreatic 
enzyme supplements if symptoms show possible pancreatic insufficiency. 
Before this is actioned, a stool sample to identify elastase is performed.  
Introduction. 
49 
  
The child’s primary care doctor is informed and an appointment in CF 
outpatients’ clinic is arranged for the parents within a week after the 
diagnosis and then they meet each member of the multidisciplinary team: 
consultant, CNS, dietician, physiotherapist, pharmacist and clinical 
psychologist. Home visits are organised with an aim to educate parents in 
their understanding of CF disease. The CNS specialist has a crucial role in 
being the parents’ point of contact for any CF related problems. If proven 
that the baby is pancreatic insufficient, medication with pancreatinin 
enzymes is started straight away and depending on the parents and how 
ready they feel they can commence a new treatment, then fat soluble 
vitamins or/and prophylactic antibiotics are commenced. 
1.4.2. Sweat test. 
Sweat test measures the amount of Chloride in the sweat and its testing 
will reliably make the diagnosis in 98% of patients38. Despite the 
availability of genotyping (and because of its limitations) the majority of 
children in whom CF needs to be excluded will undergo sweat testing. This 
group will include the following:  
A. Child with suggestive history / symptoms/ examination.  
B. Sibling of a known case (even if asymptomatic).  
C. More distant relative of known case if clinical suspicion.  
Results must be interpreted in the clinical context39 
 Normal range          Cl- <30 mmol/l. 
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 Boarderline        Cl-  30 to 60 mmol/l.  
 CF confirmed           Cl- >60 mmol/l.  
Chloride is the primary ion measured; sodium should not be measured 
alone. The diagnosis of CF should be made on the basis of two sweat test 
results, not one, to confirm that no false negative or positive results have 
occurred. 
False negative results. Cases are increasingly recognised where the 
clinical picture of CF is supported by genotyping excluding the diagnosis 
on the basis of a normal sweat test alone. It is then recommended to 
perform a genetic test. 
False positive results. Those which may be encountered include 
malnutrition or skin disorders such as severe dermatitis/eczema. 
Transient increases in sweat electrolytes have also been reported in 
young patients with immunodeficiency states38. 
1.4.3. Clinical presentation symptoms. 
Thanks to the newborn screening, the clinical presentation of one or two 
decades ago has become rarer. As mentioned in point 1.4, the exceptions 
are children born before the screening technique was available as these 
children may present late with clinical features, and also children born in 
countries with no neonatal screening. Lack of experience of clinical staff 
may lead to further delays in diagnosis in such groups of children. The 
history and/or examination will usually raise suspicions of the CF 
diagnosis. Common features are:  
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 recurrent respiratory infections, 
 failure to thrive with steatorrhoea, 
 finger clubbing and/or 
 nasal polyps. 
Other features in a baby that mean CF must be excluded include:  
 meconium ileus,  
 rectal prolapse,  
 salty tasting skin,  
 prolonged obstructive jaundice,  
 electrolyte disturbance suggestive of Pseudo-Bartter’s syndrome 
and unexplained haemolytic anaemia,  
 hypoalbuminaemia and/or 
 oedema.  
1.4.4. Genetic analysis. 
There are nearly two thousand identified mutations in the CFTR gene, 
although not all of them are definitely associated with the clinical 
presentation of CF. There is a special genetic mutation nomenclature. The 
most common mutation in the Caucasian population is a class II mutation, 
F508del = new nomenclature (protein): p.Phe508del = new nomenclature 
(nucleotide) c.1521_1523delCTT40.   
Any child diagnosed with CF will have a genetic test in order to facilitate 
screening for other family members. Mothers giving birth to a CF child are 
also genetically tested to allow prenatal diagnosis of future pregnancies.  
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Genetic therapy is currently in study. Hence all CF patients are genotyped. 
Also, in newborn siblings of affected children, cord blood should be taken 
at the time of birth.  
Pancreatic status should be confirmed with a faecal elastase in all cases.  
1.4.5. Other tests. 
To support the diagnosis of CF, the following tests can also be performed:  
Stool elastase38: low in CF with pancreatic insufficiency (usually 
<15 mcg/g). Normal levels (are expected by day 3 in term infants 
and by 2 weeks of age in those born less than 28 weeks gestation, 
so tests should not be performed before this time.   
 Normal                                                     > 200     mcg/g stool 
 Moderate pancreatic insufficiency    100-200 mcg/g stool 
 Severe pancreatic insufficiency           < 100     mcg/g stool 
Nasal potential difference (PD)38: it is recommended to do it once 
all other CF investigations are done only if there is still doubt of 
the diagnosis as it is a difficult investigation. It is also difficult in 
small children as requires co-operation, but may be useful in older 
indeterminate cases (over 8-10 years). If a child is going to have a 
procedure under general anaesthetic, then this is the best time to 
perform it. Doctors rarely obtain useful readings in the presence 
of nasal polyps or if there has been previous nasal surgery and the 
technic should be postponed if the child has had a recent cold. 
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1.5. Cystic Fibrosis-Pharmacological treatments. 
Despite great advances in supportive care and in our understanding of its 
pathophysiology, there is still no cure for the disease but many 
treatments are available to manage it, including physiotherapy, nutrition 
and obviously pharmacotherapy41. Some reviews highlight salient insights 
into pathophysiology and candidate molecules suitable for CFTR 
pharmacotherapy. But no reviews have been found to analyse the quality 
of prescribing in CF patients. 
Pharmacotherapy is key to help patients keep the disease controlled. 
However, due to associate pathologies of CF, the number of medicines CF 
patients take is expected to be rather large. Table 1.2 summarises the 
main therapeutic groups of drugs used in CF. 
The pharmacological management of patients with cystic fibrosis largely 
focuses on maintaining lung function; however, other aspects of care, 
such as managing pancreatic insufficiency, are also important42, especially 
in young children whose growth is affected due to poor absorption of 
nutrients and having a negative effect on the progression of the disease. 
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Table 1.2. Main pharmacological therapeutic groups of drugs used in CF. 
Main treatment by body-system Sub therapeutic group 
 Anti-infectives   Anti bacterials, antifungals 
 Endocrine system   CF related Diabetes 
 Gastro-intestinal  Antacids, proton pump inhibitors, 
prokinetics, laxatives 
 Nutrition and metabolic 
disorders 
 Electrolytes, metabolic disorders, 
vitamins 
 Respiratory   Glucocorticoids, Ivacaftor, mucolytics, 
bronchodilators 
 
Managing the respiratory symptoms and complications of CF forms the 
backbone of treatment. Nebulised, oral and intravenous antibiotics are 
used to prevent bacterial colonisation and treat infection. Other 
treatments include antifungals, mucolytics and 
physiotherapy42.  Treatments for the non-respiratory manifestations of 
CF include enzyme supplements; anti-reflux or prokinetic medication; 
proton pump inhibitors; insulin for pancreatic insufficiency; 
ursodeoxycholic acid for liver dysfunction; laxatives for constipation as 
well as systemic acetylcysteine to avoid bowel obstruction often named 
DIOS (Distal Intestinal Obstruction System).  
Vitamins and supplements like calcium for the bones or sodium to replace 
the loss of salt in the body are also part of key medication that is likely to 
be life long or at least modified during seasons or countries where CF 
patients live. 
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1.5.1. Respiratory system. 
Respiratory care is extremely important in CF children.  Lung function can 
deteriorate fast, with challenges to reverse to previous spirometry.  
A. Mucolytics 
Most common mucolytics used in CF are delivered by nebulisation 
with the aim of clearing mucociliary in the lungs.  
 Hypertonic Saline 
Hypertonic saline (HTS) nebules help by breaking the mucus and are 
used from an early age in the childhood of a CF child. Hypertonic 
saline can be used in the short term to induce sputum as well. They 
can cause bronchoconstriction43 so the first dose should always be 
given with spirometry before and afterwards.  
HTS is administered immediately before physiotherapy or in some 
cases it is combined with physiotherapy. There are different 
preparations in the market, the most common one is the 7% HTS but 
if patients are not tolerating this strengths, 3%-6% concentrations can 
be worked out by mixing the 7% HTS with water for injections when 
other strengths are not available in formularies. 
Sometimes other mucolytic agents need to be introduced: 
recombinant DNase (Dornase alfa) or NAC (N-Acetyl cysteine) is also 
used for our kids in the UK as unlicensed when their mucolytic output 
is compromised. 
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 Dornase alfa (DNase) 
DNase is a synthetic enzyme that cleaves neutrophil derived DNA in 
sputum to reduce viscosity and thus in theory to aid sputum removal 
by breaking it easier.  
In the UK, it is licenseg for use from five years of age44 and the 
Consultant decides when to start treatment with DNase although a 
European report initially recommended starting it in all patients that 
are 6 years old or older, independently of the lung function45.   
DNase dose is 2.5mg in the afternoon 1 hour before physiotherapy by 
appropriate compressor and nebuliser i.e., standard or faster E-flow 
or I-Neb (if using the I-Neb 1ml DNase is nebulised and the rest is 
discarded).  
DNase is considered a safe drug as adverse events are rare and mild.  
From a finance prescribing point of view, DNase is a high cost 
nebuliser (over £500 per patient/month when used once a day) and 
medicines optimisation is required. Advice is given to children and 
careers as the mucolytics need to be nebulised before physiotherapy 
at least once a day in the evening. 
 N-Acetylcysteine (NAC) 
There is no nebulised NAC preparation licensed in the UK and the IV 
preparation is the only alternative to be used nebulised (normally 
diluted with WFI) due to its mucolytic action in CF children that either 
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do not fully respond to Dornase alpha or require further mucolytic 
effect with HTS or even whilst being on DNAse too.  
B. CFTR Modulator: Ivacaftor. 
Ivacaftor is a small molecule which binds at the cell surface and leads 
the chloride channel to open (this is termed ‘potentiation’). It has 
mostly been administered twice daily at 150mg in tablet form. It is 
crucial that it is taken with or very shortly after a high-fat meal or 
snack, as otherwise absorption is poor. Tablets must not be chewed. 
Recently EMA approved a license for a form of granules that can be 
mixed with food. 
In December 2012, Ivacaftor was approved by NHS England for clinical 
use in CF patients of 6 years of age and above with at least one copy 
of the G551D mutation. Few studies show the safety of Ivacaftor in 
children over 2 years old and CF organisations have requested the 
National Institute of Clinical Evidence (NICE) to review the licensed 
age from 2 years old instead of from 6 years old. The Scottish health 
system has approved its use in children from 2 years old with the 
G551D mutation.  
The cost of one patient being on Ivacaftor is £14000 per 56 tablet 
pack, equivalent to one month’s treatment (price from BNFc 2016).  
Due to the very high cost of the drug, the British Commissioners in 
England have mandated monitoring and have imposed stopping 
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criteria46 and there is no need to say that this treatment needs 
optimisation as well, from a pharmacoeconomic perspective. 
In December 2016 NHS-England approved its commissioning for all 
children aged 2-5 years old with CF and at least one of nine gene 
mutations, after providing evidence of cost effectiveness in children 
aged 2-5 years old with CF with specific mutations and being this 
prescribed by specialist centres.47 
Side effects like rashes or rising liver function tests were observed in 
some patients. If this occurs monitoring and dose reduction for 
patients with significant hepatic or renal impairment is 
recommended. 
Ivacaftor presents some significant interactions, most importantly: 
Azole antibiotics: (itraconazole, voriconazole) lead to inhibition of the 
breakdown pathways of ivacaftor and accumulation of the drug. If co-
administration is necessary the dose of ivacaftor should be reduced; 
manufacturers suggest to twice weekly although this comes from 
modelled data, not human PK studies, and anecdotally, this may lead 
to loss of efficacy. Consultant advice should be sought in this event. 
Ivacaftor levels are not currently available, but sweat Cl- could provide 
a useful surrogate for bioavailability.   
Clarithromycin: also leads to accumulation of the drug so suggested 
take ivacaftor three times a week. There is no interaction with 
azithromycin.  
Introduction. 
59 
  
Rifampicin: will significantly reduce ivacaftor levels; co-
administration not recommended.  
High dose corticosteroids: may significantly decrease serum levels of 
ivacaftor and reduce efficacy. 
C. Treatment of infection, prophylaxis and use of antibiotics 
(oral, intravenous, nebulised). 
Table 1.3 describes most common chest exacerbation indicators38. 
The threshold of antibiotics prescribing in CF is lower than other 
pathologies; hence if any of the indicators show symptomatology of 
chest exacerbation, antibiotics are started. 
Furthermore, longer courses and higher doses of antibiotics are used 
in the CF population than would be prescribed for other patients 
because CF patients have altered pharmacokinetics, with increased 
clearance and volume of distribution. They also require high plasma 
concentrations of drugs to be achieved, to penetrate viscous mucus48.  
Table 1.3. Chest exacerbation indicators. 
Main chest exacerbation indicators of infection 
 Increased cough, and in particular a new or increased ‘wet’ cough 
should always be taken seriously.  
 Adverse changes in sputum production (volume, colour, consistency).  
 Haemoptysis.  
 Increased dyspnoea.  
 Chest pain or tightness.  
 Malaise, fatigue and lethargy.  
 Fever > 38ºC. Although most CF chest exacerbations are not 
accompanied by fever.  
 Loss of appetite or weight loss.  
 Drop in FEV1 or FVC >10% from previous recording.  
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity.  
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When a patient presents with an exacerbation, antibiotics are initially 
given orally and CNS monitors the clinical status of the child whilst 
feeding back to the consultants. If there is poor response after oral 
intake of antibiotics, IV treatment is essential.  
At least two intravenous antibiotics should be prescribed to reduce 
the risk of antibiotic resistance which has been associated with 
monotherapy49. 
A combination of betalactam antibiotics with aminoglycosides has 
been shown to be synergistic. Ceftazidime and Tobramycin are in the 
United Kingdom’ the first line treatment in most CF referral centres. 
The doses given are higher than other respiratory conditions and as 
per protocol, the monitoring for Tobramycin levels is performed in 
the hospital regularly. There is a monitoring form designed by 
pharmacy and used by nursing staff for aminoglycosides, this form 
needs to be followed and filled in prior to administering the drugs in 
order to comply with safety aspects of the drugs. This way it is 
ensured that the dose of the aminoglycoside, pharmacokinetic levels 
and other aspects are double checked and the risk of an 
administration error is mitigated. 
Persistent infection and resultant colonisation produces thick mucus 
and causes chronic inflammation, leading to irreversible 
bronchiectasis (abnormal and permanent dilation of bronchus). The 
most common pathogens in CF are summarised in Table 1.450. 
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CF children are taught at an early age to routinely give sputum 
samples, which are then cultured and the sensitivities tested. This 
gives a recent microbiological profile against which antibiotics can be 
selected. Sputum induction is sometimes necessary in non-producers 
who are clinically deteriorating on blind therapy and this can be 
achieved by nebulising a hypertonic saline solution in a controlled 
environment. In small children and ones that cannot expectorate the 
usual sample used is a cough swab. 
In order to prevent infections caused by Staphylococcus aureus 
(mainly in infancy), Haemophilus influenzae and Pseudomonas 
aeruginosa being the major pathogen in older children and adults51, 
antibiotic prophylaxis can be started. Nebulised antibiotics are 
prescribed for patients who are chronically colonised with 
Pseudomonas aeruginosa. There are not many nebulised antibiotics 
in the market. However those that are, have shown to reduce the rate 
of respiratory function deterioration and to reduce the number of 
courses of intravenous antibiotics needed to treat exacerbations52.  
Antibiotics most commonly administered by nebulisation are colistin 
and aminoglycosides (normally tobramycin or gentamicin, but 
amikacin is also used, depending on sensitivities). In the UK, colistin is 
generally used first line and tobramycin is reserved for patients who 
cannot tolerate it or continue to decline despite its use. As there is no 
nebulised licensed preparation of any other aminoglycosides other 
than Tobramycin nebules, intravenous preparations must be used as 
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nebulised, a clear unlicensed use. As IV preservatives might cause 
bronchospasm, it is imperative that pharmacists screening these 
types of prescriptions are aware that preservative free formulation 
should be dispensed53.  
Table 1.4. Most common pathogens isolated in CF. 
Pathogen General Comments 
Staphylococcus 
aureus 
(S aureus) 
 
In the UK, flucloxacillin is recommended for long-term prophylaxis 
in infants under the age of two years54. Shown to reduce the 
incidence of S. aureus infection, clinical symptoms and the need 
for additional antibiotics55, but its benefits are controversial as 
some countries recommend flucloxacillin in their guidelines 
against in others56.  
If prophylaxis is given, review after the child is 3 years old.  
Haemophilus 
influenza  
(H influenza) 
If the child keeps isolating influenza, UK Consultants will discuss 
the possibility to start long term prophylactic antibiotics. 
Azithromycin is the third generation macrolide in the market. The 
pharmacology of Azithromycin is not only antimicrobial but also 
has an anti-inflammatory effect that is of benefit in respiratory 
patients57. It is a well-tolerated drug amongst most CF patients 
despite medics using it in caution in liver function abnormalities. 
If this is started in patients that already are on prophylactic 
flucloxacillin, it should be recommended flucloxacillin to stop.  
 
Pseudomonas 
aeruginosa  
(P. aeruginosa)  
 
Chronic colonisation with the organism is associated with a more 
rapid decline in lung function and deterioration in chest X–rays58. 
When patients are colonised, nebulised antibiotics are prescribed. 
If the child’s lung function deteriorates a routine admission to 
hospital every 3-4 months for IV antibiotics is programmed and 
the focus of this study is in hospitalised patients.  
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Aspergillus 
fumigatus and 
allergic 
bronchopulmonar
y aspergillosis 
(ABPA)  
 
The mainstay of treatment for ABPA is antifungal drugs and oral 
corticosteroids in order to attenuate inflammatory and 
immunological responses59. Prednisolone is used for one to two 
weeks then taper based on clinical response. The non-enteric 
coated preparation prednisolone should be used in patients with 
CF since there are case reports of treatment failure with the 
enteric coated preparation60. A possible reason for this is that 
enteric coated prednisolone, is released at a pH of 6.8 and it may 
not be absorbed in the jejunum of CF patients where the pH is 
often lower than 5 for prolonged periods61. 
 
Since April 2015 in the United Kingdom high cost nebulisers (HCN) are 
considered specialised treatment for CF patients and are also 
commissioned by NHS-England62, hence reference centres in 
secondary care have been forced to repatriate each CF patient’s 
prescribing on HCN and their monitoring63. This is for some 
parents/carers difficult to understand and creates confusion with 
primary care doctors who might not be aware of the commissioning, 
creating potential extra costing and treatment delay. One of the 
quality indicators that will be observed in this study is whether 
primary care still keeps high cost nebulisers as part of the patient’s 
repeat prescription. If this is the case, there is a risk of misuse and 
uncontrolled expenditure.  
Nebulised antibiotics should be administered after chest 
physiotherapy and bronchodilators to maximise deposition in the 
lung. The importance of good labelling, dispensing and counselling is 
a key factor for adherence, as well as the time to nebulise these 
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antibiotics. The patient’s daily routine is frequently discussed to best 
fit the regime with the child’s day. 
D. Pharmacology of antifungals used in CF with ABPA. 
The criteria for diagnosing ABPA is challenging and the clinical 
diagnosis needs to be done by investigations as the clinical 
presentations are not specific. 
Although most of the time steroids are used, antifungal therapy is also 
needed. Internet and media might create confusion on the use of 
steroids and patients are likely not to adhere to treatment even if 
good counselling has been provided. It is very important that the 
counselling the pharmacist provides is in concordance with the 
treatment the medics have chosen, length of steroids, and options to 
treat ABPA as part of optimisation and enforcement to patient’s 
adherence as often parents have other questions and consistency 
should be provided.  
Interactions with the co-medication have to be considered when 
treating ABPA. A small number of antifungal pharmacokinetic studies 
indicate a high inter-subject variability for itraconazole, voriconazole 
and posaconazole, and therefore therapeutic drug monitoring is 
recommended64. 
Due to the need of antifungal drugs and their pharmacology 
individualisation of therapy is required in paediatric population with 
ABPA.  
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After efforts from doctors deciding best treatment for the child, the 
prescription is the next step to confirm that treatment will be 
administered and the labelling precedent should be clear. 
Table 1.5 covers some pharmacological aspects of main antifungals 
used in CF with a focus on azoles systemic therapy. Liposomal 
amphotericin can also be used with a local effect at the site of the 
infection nebulised. In summary, the treatment’s options in ABPA are 
limited and bring several discussions to the multidisciplinary team.  
  
Table 1.5. Pharmacological aspects of main antifungals used in CF patients with ABPA. 
Drugs in 
ABPA 
Main pharmacokinetics 
Steroids IV Methylprednisolone is used as pulse therapy every 2-4 
weeks to help adherence. 
Oral prednisolone’s absorption is pH-dependent and can be 
optimised using non-enteric coated preparation. See Table 1.4. 
Itraconazole Antifungal and anti-inflammatory effect, allowing lower doses 
of steroids to be used65,66.  
Highly lipophilic and only ionised at low pH. The absolute 
availability of capsules in healthy volunteers under fasting 
conditions is about 55% and is increased after a meal67. 
Absorption is pH-dependent and can be optimised by dividing 
the daily dose in two and administering the treatment only 
before food with an acidic drink such as cola or orange juice68. 
99.8% bound to human plasma proteins and its apparent 
volume of distribution is about 11 L/kg. Half-life of itraconazole 
is about 24 hours. Dose-dependent pharmacokinetic 
behaviour67 
No routinely PK levels done. Some hospitals eg The Royal 
Brompton Hospital are doing trough sample levels on day 14 
(in 1ml of serum into clotted blood vacutainers) with aimed 
level of 1 - 4mg/l. 
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Current hospital practice at Barts Health NHS suggests that CF 
patients do not achieve therapeutic levels and this might be 
due to impaired absorption.  
Voriconazole Treat refractory Aspergillus spp infections and like Itraconazole 
reaching therapeutic levels might be a challenge too69. 
However voriconazole may have an advantage over 
itraconazole because it has a 96 per cent oral bioavailability70 
and is less protein bind to albumin (around 58%). Due to photo 
sensibility of voriconazole, albumin levels can be considered in 
countries/seasons where sun exposure is frequent. 
Linear non-saturable dose-exposure pharmacokinetic profile 
has been described for children71 
In order to obtain efficacious blood levels, daily doses of up to 
14 mg/kg are needed in the paediatric setting (compared with 
6 to 8 mg/kg for adults). However, blood concentration 
variability and sub-therapeutic values in the paediatric 
population have also been reported72.  
Little literature is available in regards sample PK levels, 
however The Royal Brompton Hospital take trough sample 
levels on day 3 (in a 1ml of serum into clotted blood 
vacutainers) with aim levels of 1.3 - 5.7mg/L, and this can be 
used as a reference guide. 
Posaconazole This is the most recently approved triazole antifungal73 and has 
a long elimination half-life (>24 h).  
A number of factors have been demonstrated to impact upon 
posaconazole absorption including food (and fat specifically), 
gastric pH (and the use of proton pump inhibitors), mucosal 
health, and frequency of administration (due to saturable 
absorption)74. Clinical pharmacokinetic studies in non-CF 
patients have shown that the co-administration of 
posaconazole with a nutritional supplement containing 14g of 
fat increases the AUC by more than 200%75.  
Limited clinical pharmacokinetic and pharmacodynamic data 
are available. 
It is highly protein bound (> 98 %)76 and there is limited date in 
children77 
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Allergies  
Repeated courses of high-dose antibiotics put patients at risk of 
developing allergies to antibiotics at any time during a course of 
antibiotics. The reactions can manifest as bronchoconstriction or rash and 
further exposure could escalate to anaphylaxis. All allergies and their 
nature should be carefully documented in patients’ notes. This will help 
to identify patients who may be suitable for desensitising (administering 
increasing concentrations of an antibiotic by infusion to a patient until the 
therapeutic dose is achieved), should this be necessary due to multiple 
resistance problems.  
1.5.2. Gastrointestinal system and nutritional care.  
The incidence of gastro-oesophageal reflux disease (GORD) is increased 
in CF patients and this is possibly due to hyper-acidity of gastric 
secretions, constipation and increased abdominal pressure secondary to 
coughing. Uncontrolled GORD aggravates CF disease78.  
Motility stimulants are frequently used, being the most common 
domperidone and erythromycin. Doctors have to evaluate individually if 
the risk of cardiac effects outweighs the beneficial use of domperidone79.  
H2-antagonists or proton pump inhibitors (PPIs) are prescribed to reduce 
the acidity of secretions. These may also improve the effects of pancreatic 
enzyme supplements in preventing fat malabsorption. 
The licensed Ranitidine liquid is formulated with ethanol and the tablets 
present as effervescent or normal tablets. When, for religious reasons 
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primary care prescribe unlicensed Ranitidine liquid (so no alcohol is 
added), the strength varies depending on the manufacturer. This poses a 
risk of misdosage for the patient as some parents remember the dose 
primarily by volume. 
Omeprazole and Lansoprazole are the most common PPIs used and the 
presentations also vary, hence the importance of having this written in 
the prescription. 
Pancreatic insufficiency is another concomitant disease to CF, is prevalent 
in young infants with CF and has a significant impact on growth and 
nutrition80. Some infants may initially be pancreatic sufficient however 
they may become insufficient over time, this must be considered should 
they present with symptoms of fat malabsorption or poor weight gain. 
Pancreas failure and inability to secrete digestive enzymes leads to 
malabsorption of fats and fat-soluble vitamins as well as some proteins 
and carbohydrates. In these patients, it is essential to supplement meals 
and snacks containing fat with pancreatic enzymes. The amount of 
enzyme required is determined on an individual basis based on the fat 
content of food consumed.  
There are several enzymes available on prescription but the most 
commonly used brand in CF is called Creon®. Creon® contains three 
digestive enzymes - lipase, protease and amylase, helping digest the 
different component of foods: fat, protein and carbohydrates 
respectively. The enzymes come in various strengths including enteric-
coated microspheres (Creon® Micro), and capsule forms.  
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Enzyme capsules should be swallowed whole and are generally taken at 
the start of a meal, however enzymes can be taken at the beginning, 
during, or at the end of a meal. 
The enzymes are most effective for 20-30 minutes so ideally meals should 
be finished within this time. This might not be practical for all children so 
additional enzymes may be given towards the end of a meal or between 
the main course and the pudding.  
It is important to have quick and easy access to enzymes to aid adherence. 
Between the ages of 2-5 years old children should be encouraged to learn 
to swallow capsules whole. Capsules can still be opened out and taken 
with fruit puree or yoghurt but this may compromise their effectiveness, 
and can be less convenient, especially as a child gets older. 
Pancreatic enzymes should be taken with all meals, snacks and drinks 
containing fat. Education on the amount of Creon® taken with different 
foods is provided by the dietitian.  
Dietitians play an important role in educating patients and parents of 
children to tailor enzyme use to the needs of the individual. Over-use of 
enzymes can present with the same symptoms as malabsorption.  
Each patient has a preference pancreatic medication and we must respect 
this in order to help adherence, hence a CF pharmacist would expect a 
pancreatinin prescription to be prescribed branded. 
Another common gastrointestinal presentation in CF children is 
constipation with a complication known as distal intestinal obstructive 
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syndrome (DIOS) and this occurs most frequently in pancreatic-
insufficient patients as a result of accumulating of partially digested food. 
It is important good pharmaceutical care as well as outstanding 
prescribing practice, so children and carers use the medication in the best 
possible way. 
Furthermore, salt depletion in CF patients tends to occur during hot 
weather because of increased sodium and chloride loss in sweat. During 
summer months, some patients may require sodium supplements, such 
as slow sodium 600mg tablets or unlicensed sodium capsules or oral 
solutions. Dioralyte® sachets are also used as they are more palatable to 
younger children. 
Another gastrointestinal system that must be mentioned here in CF 
patients is the liver disease which causes hepatomegaly with significantly 
elevated liver function tests, abnormal clotting or evidence of cirrhotic 
changes on liver ultrasound scan (USS). 
These children with CF liver related pathologies are treated with vitamin 
K supplement but as the impaired liver will create biliary stasis, patients 
will also be treated with ursodeoxycholic acid to promote bile flow and 
also displace toxic endogenous bile acids which accumulate in cirrhotic 
livers. A review from the Cochrane Library concluded that there was 
insufficient evidence to support the routine use of ursodeoxycholic acid 
in CF81. However there is some evidence supporting its use to improve 
cholestasis in patients with liver abnormalities82. 
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Aspirin and NSAIDs in those with documented cirrhosis should be avoided 
and drugs to be used in caution with liver disease include: fusidic acid, 
minocycline, rifampicin, and azithromycin, itraconazole and voriconazole. 
1.5.3. CF-related Diabetes  
CF-related diabetes (CFRD) rarely occurs in patients under 10 years old 
although up to a third of this age group will already have impaired glucose 
tolerance and it is mainly managed with insulin. 
All CF individuals with exocrine pancreatic insufficiency have insulin 
deficiency, which worsens with increasing age. Insulin secretion is 
reduced even in individuals with normal glucose tolerance. There is an 
increase in the prevalence of impaired glucose tolerance and diabetes 
with age. The reported prevalence of CFRD depends on the diagnostic 
criteria used and screening methods, but approximately 50% of CF 
patients will have CFRD by age 30. CFRD is distinct from either type 1 or 
type II diabetes mellitus and there are different approaches to diagnosis 
and management. 
Current CF trust recommend screening for abnormal glucose tolerance 
and diabetes in all CF patients over 12 years.  
The primary cause of the abnormal glucose tolerance in CF patients is 
insulin deficiency so the treatment for this is insulin. Insulin has been 
shown to improve lung function and nutritional status in CF patients. Oral 
hypoglycaemic agents are not used in CF patients.  
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Treatment starts in every patient with a diagnostic of diabetes or with 
symptomatic hyperglycaemia. CF trust has diagnostic criteria for CF 
related diabetes.  Some patients are considered for treatment without 
clear diagnosis of diabetes if they have a declining lung function or 
nutritional status with no other cause found or nutritional concerns, for 
example on overnight feeds or supplements and not gaining weight. 
The endocrine department is heavily involved and they decide the type of 
insulin to prescribe. Paediatric endocrinology teams in University 
hospitals have a comprehensive guideline on insulin types, starting doses 
and the use of higher doses in children already receiving high doses of 
steroids. 
The safer insulin prescribing guidance published in January 2017 by 
National Institute for Health and Clinical Excellence (NICE) recommends 
that all health care professionals prescribing, screening or administering 
insulin should have had training in the safe use of insulin. The reason for 
this is that there are many clinical incidents in the UK each year related to 
incorrect insulin prescription and administration. Common incidents 
include giving the wrong insulin, lack of clarity in prescriptions, and 
drawing up or giving insulin with the wrong type of syringe. 
Safe insulin prescriptions38,83 
 Get the correct insulin name (there are some insulins with similar 
names) but also the presentation, e.g. cartridges, disposable pen.  
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 State when the insulin is to be given. For short acting insulin this 
will be before a meal and not at a particular time of day.  
 If the dose is variable (for example short acting insulin for meals) 
you must make it clear how the dose will be decided.  
 For paper prescriptions the word “units” must be written in full 
and never “u” or ”iu”. A badly written “u” can be mistaken as a 
zero.  
 
1.6.  Hospital Pharmacists in the UK. 
The United Kingdom’s hospital pharmacists (HPs) are seen as the experts 
of the drugs: pharmacokinetics and pharmacodynamics conversations 
with other healthcare professionals occur as part of daily routine work 
during ward visits. HPs are required to be a great source of advice for 
patients and work closely with medical and nursing staff on the wards to 
ensure that the most appropriate treatment is being prescribed safely.  
Hospital pharmacist inform patients on all aspects of their medicines, 
including recommending choices, as well as administration routes and 
dosages, which are all very dependent on the individual's needs.  
Medics rely on HPs to recommend safe combinations of medicines or 
solutions to specific patient problems. HPs also inform them of any 
potential side effects and check that medicines are compatible with 
existing medication as well as monitor the effects of treatments 
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prescribed to ensure that they are providing effective, safe and 
appropriate treatment to the patient.  
Nursing staff also rely on HP to provide a clinical screen, counsel on 
administration and supply the right pharmaceutical form for each patient. 
A HP undertakes series of training in order to develop to a specialization. 
Table 1.6 shows mains tasks of HPs according to their seniority. The 
complexity of each task varies depending on the seniority of the HP. 
Grades are set up from band 5 for pre-registration pharmacists (in the UK 
last year students that choose to do their placement in a hospital, follow 
structured interviews to mark them). The students that passed these 
competitive interviews for hospital pharmacy are offered a year student 
place (remunerated) in order to taste what a hospital pharmacy career is 
like as well as helping prepare them for the final exam.  
At the end of the pre-registration year, the student sits the final exams of 
their degree and once passed they can register in the General 
Pharmaceutical Council, which is mandatory for work as a pharmacist 
(community, industry, prison, hospital).  
Once registered, the pharmacist can apply for band 6 jobs through highly 
selective and competitive interviews.  
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Table 1.6 Main tasks delivered by HP depending on seniority. 
Band Ward cover Ward rounds Financial Organizational Educational 
6 ✓     
7 ✓ ✓   ✓ 
8a ✓ ✓  ✓ ✓ ✓ 
8b  ✓ (clinics) ✓ ✓ ✓ 
8c   ✓ ✓  
9 Chief pharmacist 
 
1.6.1. Band 6 pharmacist: Rotational Pharmacist. 
Successful pharmacists will start their careers with a rotational plan 
together with an extensive educational programme. This programme is 
followed by the junior pharmacist (also known as foundation pharmacist) 
and looked after by his/her designated Educational Supervisor, normally 
a highly specialist pharmacist (from band 8a upwards).  
The programme for a band 6 pharmacist is supported by the Clinical 
Diploma training, which focusses on at two sets of 18 months each. Each 
set is also divided into three six months programmes with a clear focus 
on different areas, from clinical, governance, audit, finance, 
manufacturing, purchasing, dispensing, etc.  
During the six month period of each learning programme the foundation 
pharmacist will have regular meetings with their Educational Supervisor 
to ensure they are developing in the required way within clinical 
pharmacy.  At the end of 18 months set, the Diploma student will meet 
with a panel of expert pharmacists to assess student’s level of knowledge 
Introduction. 
76 
  
and they will decide if the student should repeat the same learning set or 
whether the pharmacist can carry on to the next step of her/his Diploma. 
After the end of the Diploma the pharmacist will be ready to start 
focussing on specific clinical areas they would like to join in, and often 
either they apply for band 7 jobs or stay as band 6 for a certain time.  
Generally speaking, band 6 pharmacist stay in this rotational post 
between 3 to 6 years; senior pharmacist encourage them to make sure 
what speciality they want to focus on. 
One of the minimum requirements to apply for band 7 jobs or to be 
selected to Band 7 interviews at Barts Health NHS is the possession of the 
Clinical Diploma but a Band 7 pharmacist also needs to show in the 
interview good level of clinical knowledge for the area they apply. 
1.6.2. Band 7 pharmacist: Specialist Clinical Pharmacist. 
This section focusses on Women and Children Specialist but Band 7 
pharmacists can be rotational and are also part of departments such as 
renal, hepatology, neurology, surgical, intensive care, production, 
oncology, commissioning, gastroenterology, respiratory, care of elderly, 
cardiology and infection disease. 
A women and children specialist clinical pharmacist (band 7) at Barts 
Health hospital will also follow a rotation of each speciality (depending on 
the type of hospital these may vary): neonatal intensive care, respiratory, 
trauma and surgery, neurology, gastroenterology, paediatric intensive 
care, obstetrics in high dependency unit, gynaecology. Being part of each 
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rotation is key in order to be able to understand the pharmacokinetics 
difference in infants, children, adolescent or obstetrics.  
Band 7 pharmacists undertake higher responsibility for their area. They 
need to liaise with consultants, clinicians, managers, nursing staff, other 
clinical pharmacists, pharmacy operational managers and trust medicines 
effectiveness pharmacist. They must also deal with parenteral nutrition 
issues, supply problems, etc.  
They will participate in developing clinical pharmacy services to the 
women and children’s wards and organise the training of band 6 
pharmacists, junior doctors and nursing staff too. 
Band 7 pharmacists must demonstrate excellent pharmaceutical 
knowledge of the drugs in their area, from pharmacology, to supply in 
hospital or even community environment and when supply problems 
arise, with the aid of a senior, the band 7 pharmacist will decide the most 
appropriate alternatives after balancing clinical/cost benefit versus the 
drug that needs to be substituted. 
Regulations to allow pharmacists to prescribe independently came into 
effect in 2006. An independent prescriber pharmacist may prescribe 
autonomously for any condition within their clinical competence. An 
intense training followed in the area to prescribe is undertaken and at our 
trust a senior band 7 can start this training when funding is approved. 
It is expected that a band 7 pharmacist will monitor medicines use within 
the ward area and this includes recording of significant clinical 
Introduction. 
78 
  
interventions and risk management like participating in investigating 
clinical incidents; recording significant clinical incidents/near misses as 
well as ensuring compliance with medicines legislation and local policies. 
As a specialist pharmacist the band 7 HPs might be requested to 
participate in ward rounds, clinical meetings or out-patient clinics in order 
to provide pharmaceutical advice to prescribers and other health care 
professionals. It is not unusual to deal with primary care enquiries as 
more often HP get phone calls from doctors in general practitioners’ 
surgeries. 
Other roles undertaken at a band 7 level are participating in ward-based 
clinical audits and the development and implementation of treatment 
protocols and guidelines for use of medicines within the clinical area. 
A band 7 pharmacist as well as a senior band 6 is asked to act as a role 
model and mentor for clinical pharmacy.  
The above are daily tasks required for a band 7 pharmacists but they also 
undertake other roles that are not less important.  
Generally speaking the culture of UK senior HPs aim to keep staff happy 
and motivated as this is essential to support learning and achieve best 
results for the department. Monthly communication meetings occur 
within the women and children department and weekly meetings for 
general development too. In the UK it is also common to organise team 
building exercises to enhance best communication within the team.  
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A band 7 pharmacist within the women’s and children’s department will 
have a speciality preference and might work towards a higher 
specialisation in the area in order to achieve the next opportunity as a 
band 8a, the next recognised step for a band 7 hospital pharmacist. 
1.6.3. Band 8a and above. 
The responsibilities and tasks are greater as high as the pharmacist 
progresses hierarchy. Monthly finance reports are pulled out and 
addressed properly to each medical budget holder and commissioning 
groups.  
Highly specialist pharmacist or band 8a role are normally attached to a 
clinical area or need (for instance risk specialist) but also manage a team 
and report closely to 8b pharmacists who are often the budget holders 
for the Department.   
The role referring from now on is CF highly specialist pharmacist, which is 
a band 8a and therefore has an in depth knowledge of tasks taken by band 
7 and 6 pharmacists.  Being a senior role, the CF pharmacist is expected 
to multitask hundreds of jobs and participates in the recruitment of junior 
and band 7 pharmacists, as well as support the team and the juniors. The 
CF pharmacist has excellent knowledge of the consensus document 
outlining pharmacy standards in CF care published by the CF trust in 
November 2011.  
A highly specialist pharmacist provides a comprehensive medicines 
management service to children on long term conditions that relate to CF. 
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They work with multidisciplinary teams to enhance optimal prescribing 
and provide training and education for children, parents and other 
members of the multidisciplinary team. 
The provision of professional advice is required and support to other 
health and social care professionals within the community health services 
on the safe prescribing, handling and administration of medicines is part 
of daily routine. 
 Band 8a pharmacists in CF will lead on the medicines aspects of patient 
care to optimise medicines as well as reduce medicine related risks and 
improve adherence to taking medicines. This also includes co-ordinating 
and leading on interventions to reduce medicine related problems by 
developing care plans in agreement with clinicians, patients and other 
health and social care professionals as well as facilitate collaborative 
working between multidisciplinary teams/agencies.  
The developing of best practice guidelines and medicines processes fall 
under band 8a pharmacist responsibilities. These must be efficient, 
consistent, practical and sustainable within the constraints of the existing 
systems and take into account the values of patients and their careers.  
In CF, a daily identification of areas of risk relating to medicine use in 
primary care is a routine task as pharmacists facilitate compliance with 
medicines legislation to ensure delivery of safe standards in the 
prescribing and handling of medicines in the community across health 
and social care, including schools. 
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Working with the CF team as well as Clinical Commissioning Groups (CCG, 
these are a group of prescribing experts and they hold the budget for 
primary care) medicines management teams and community pharmacy 
leads develop and implement strategies to improve medicine adherence 
in paediatric CF population.  
Furthermore band 8a pharmacists are expected to deputise for the 
operational lead of the department during their absence (8b 
pharmacists), a big role for a pharmacist in the UK. 
The input of the band 8a pharmacist in CF is of great importance because 
of multiple disease states and the use of polypharmacy. As the complexity 
of the pharmacology in CF is enormous, the pharmacist delivers better 
care within CF children amongst other factors. Having a CF pharmacist in 
the department will result in increasing the quality of the prescribing as 
this is expected to be at a great standard.  
CF patients come into hospital and some of their regular medication is 
stopped during their stay. The re initiation or any possible changes done 
during the weeks the patients have been having IV therapy must be 
managed appropriately. Furthermore CF treatment also has a high-cost 
area of drug therapy and the pharmacist can have a significant input in 
medicines optimisation. 
It is accepted that a child with CF might take a number of medicines that 
would rarely decrease whilst they grow and reach adult phase.  A CF 
pharmacy special interest group held its first meeting in February 2000 
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and there it was acknowledged that treatment for CF must be 
individualised to fit in with a patient's lifestyle.  
Also, the volume of drug therapy and other treatments, such as 
physiotherapy can be felt as very time consuming. Therefore planning 
treatments around individual patient's requirements and modifying 
treatment ideals are necessary in order to achieve best medicines 
optimisation and improve patient adherence. 
1.6.4. Ward visit and drug chart. 
Medicines reconciliation is an essential part during admission process of 
a patient. New medication prescribed might interact or have an effect 
with the regular medicines and is important to gain the most up to date 
information and the actual way the patient takes the medicines. 
In the UK, the HP or a senior technician will list the name of the medicines 
that patients take if they have not yet been written up in the drug chart. 
However if the regular medication has been completed in the drug chart, 
the pharmacist will give a number and will link this to the front page of 
the drug chart with comments if needed. The comments will be used for 
discharge, to review the previous posology and the new one and 
communicate with primary care as well as with the patient, reinforcing 
adherence. The next serial of figures 1.2 to 1.7 are some examples of the 
drug chart.  
The drug chart is the tool used in UK hospitals to record the medication 
prescribed and administered to each patient. The drug chart is an A4 
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booklet with different pages in it and each pages covers the following 
information: 
Page 1: Used for medicines reconciliation, allergies, demographic 
information and relevant information for pharmacy.  
Page 2: Once a day, loading dosing drugs prescription and administration 
and drug blood levels record. 
Page 3-6: Regular medication to be taken during hospital admission and 
administration records. And page 6 also has space to record the 
prescribing and requirement of oxygen/patient’ saturations. 
Page 7: Medication to be prescribed as when required. 
Page 8 (last page): Drugs not administered code and intravenous flushes.  
Evaluation and improvement of the quality of discharge prescriptions in CF children. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Front page of drug chart: medicines reconciliation. 
The allergy and demographic part is an A4 size and will be seen 
after each turn of page in the drug chart. 
Figure 1.3. Second page of drug chart: once only medicines and 
loading doses prescription section with therapeutic drug 
monitoring. The top page saying drugs not administered belongs to 
the last page of the drug chart that is A4 size. 
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Figure 1.4 and 1.5. Part of the drug chart to prescribe regular medication. Each administration will have a date, time, dose, route recorded 
by the administering staff. Each change of dose or frequency is noted in the second left column. The pharmacist validates the prescription by 
writing in green in the pharmacy section (top right). 
At the bottom of the page there are numbers coded to represent reason for not giving a drug and this code is linked with the last page of the 
drug chart. 
  
 
The drug chart is manually manipulated and is attached to the patient’s 
notes together with other clinical information relevant to the patient. 
Each drug chart has been designed for 14 days duration. Patients staying 
longer will need a reboard with a new chart. 
The fields to complete in a prescription are manually filled in and 
omissions are likely to happen. The drug charts are in continuous design 
with feedback from prescribers, governance team and pharmacist to 
make sure the risk of error is mitigated. 
Next page’s flow chart (Figure 1.8) summarises the main daily tasks of a 
hospital pharmacist in a ward visit/ward round in the UK.  
The pharmacist has access to the handover list of the patients admitted 
to the ward. This helps identify which speciality the patient is under and 
clinical situations that require more or less pharmacological input. The 
handover list is also helpful to pharmacist as aids prioritising new 
patients. Patients admitted days before will also be seen by pharmacist 
to ensure that if new medicines have been added to the prescription that 
they are clinically screened.  
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Figure 1.8.  
 
 
  
 
 
 
 
 
 
 
 
 
Day handover list – 
patient’s identification 
Prioritise: New 
admissions, Discharges, 
clinical needs, complex 
pharmacotherapy (PT) 
 Drug history 
 Patient/Parent 
 Primary care (SCR) 
 Patient’s own drugs PODs 
 Last admission/Clinic visit 
 Community pharmacy 
Discharge New admission 
Drug chart 
 Clinical screening: Drug, dose, frequency, pharm 
form, route, administration information; 
guidelines; formulary; legalities; … 
 Confirmation of any changes during hospital stay 
from previous posology – are they reflected in 
Prescription? 
 Communicate with doctors and GP to follow up 
 Adherence and Educations 
 Screen the current prescription: 
drugs, dose, frequency, pharm 
form, route, guidelines 
administration, cost, etc. 
 Inform of discrepancies 
 Note relevant info for discharge 
1- New patients 2- From day 2 
onwards  
New drugs 
Save monitoring 
Follow guidelines 
Complex PT treatment 
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1.7. Quality of the pharmacotherapy and patient 
safety. 
The Department of Health publication ‘An organisation with a memory’ 
mobilised the patient safety movement in the British National Health 
System (NHS)84. The report reviewed the growing body of international 
evidence on patient safety. It drew attention to the scale and pattern of 
potentially avoidable patient safety incidents (any unintended or 
unexpected incident that could have or did lead to harm for one or more 
patients receiving NHS-funded healthcare) and the devastating 
consequences these can have on patients, their families and the 
healthcare staff involved. The report also acknowledged that, as in many 
other countries, there has been little systematic learning from these 
patient safety incidents and service failure in the NHS.  
It is difficult to accurately estimate the extent of unintended harm to 
patients across the NHS from the current studies. There is likely to be 
significant under-reporting and inadequate documentation of patient 
safety incidents within medical records (the usual source of information 
on unintended harm for most studies). 
On the best available data in England, extrapolating from a small study in 
two acute care trusts based in London, it is estimated that around 10% of 
patients (900,000 using admission rates for 2002/3) admitted to NHS 
hospitals have experienced a patient safety incident, and that up to half 
of these incidents could have been prevented85. This study also estimated 
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that 72,000 of these incidents may contribute to the death of patients, 
although it is unclear what proportion of this number would die as a direct 
result of the incident.  
In the ENEAS study, the most recent Spanish national study about adverse 
events in hospitalised patients, the incidence of adverse events was 8.4%, 
being medicines responsible of 37% of the effects but also the half of 
them were preventable86. Studies in the United States have found that 
between 44,000 and 98,000 incidents are estimated to contribute to 
patient deaths87,88. This is viewed by many commentators as under-
estimating the extent of the problem. Studies in Australia89, New Zealand 
and Denmark90 have suggested similar findings.  
Adverse events are an emerging problem in medication’s field. 
Consequences of harm caused by drugs affect directly patients and 
services with an increase in costs91. Hence professionals and 
commissioners are keen on offer a safe, efficient and effective patient’s 
care and patient’ safety has become a key factor in quality of health 
systems.  
The Audit Commission report in the UK, A Spoonful of Sugar, emphasised 
in 2001 that NHS trust boards should recognise that medicines 
management was a significant part of clinical governance responsibilities. 
In this report it was acknowledge that medication errors occur too often 
and their effect on patients and NHS costs can be profound; additionally 
many patients do not take their medicines as recommended once they 
leave hospital92. Ten years after another finance and safety concern 
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looked at homecare medication in the UK, The Hackett report (2011), 
which made a list of recommendations to improve the financial and 
clinical governance arrangements for patients receiving medicines in the 
UK via the homecare route93. 
The Carter report (2015) acknowledged the need of the hospital 
pharmacist to spend greater time in clinical services as part of the 
optimisation resources of the NHS94 and a hospital model was published 
in October 201695. 
In general, all of the above reports intend to build a safer health care 
system at minimal possible cost utilising best resources available.  
In fact, research around patient safety has highlighted that the majority 
of staff try to create a safe environment, preventing things from going 
wrong. Despite some high profile cases the overwhelming majority of 
incidents are not caused by malicious intent or even lack of competence 
on the part of the individual delivering the care96, the best people can 
make the worst mistakes97. 
Having a safety culture encourages a working environment where many 
components are taken into account and recognised as contributing to an 
incident or to the events leading up to it. This moves the investigator 
away from focusing blame on individuals and looks at what was wrong 
with the system in which the individuals were working. This is called the 
systems approach98.  
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Therefore the previous National Patient Safety Agency (NPSA) now 
known as the National Reporting and Learning Service (NRLS), presented 
an overview of the 7 key steps required to achieve a safer organisation. 
The first 3 steps introduce the concepts, methods, research and practical 
tools in relation to developing a safety culture (step 1), establishing a 
strong focus on patient safety throughout the organisation (step 2) and 
integrating risk management systems (step 3). The following steps 
describe national and local reporting requirements (steps 4), patient and 
public involvement in safety (step 5), the root cause analysis approach to 
incident investigation (step 6) and transferring lessons to solutions (step 
7). Every day more than a million people are treated safely and 
successfully in the NHS. However the advances in technology and 
knowledge in recent decades have created an immensely multifaceted 
healthcare system. Patient safety is such an important concept that it is 
vital that healthcare staff can progress towards delivering this safety 
agenda. The 7 steps provide a guide to help them achieve this99. 
Nonetheless it is widely acknowledged that the term ‘error’, when 
investigating an incident and attributed to humans, implies blame and 
responsibility. Adopting a positive culture of learning from mistakes might 
lead to reporting open and sharing what can be learnt. Figure 1.9 shows 
the circle of safety in 7 steps.  
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Figure 1.9. Circle of safety modified from NRLS seven steps.  
 
1.7.1. Medication errors. Causes and consequences. 
In healthcare practice, an error is a mistake act that causes or could cause 
harm to patients due to commission or omission in the clinical practice of 
the healthcare professionals. This mistake might contribute to an adverse 
incident100,101.  
According to the FDA a medication error is "any preventable event that 
may cause or lead to inappropriate medication use or patient harm while 
the medication is in the control of the health care professional, patient, or 
consumer.  Such events may be related to professional practice, health 
care products, procedures, and systems, including prescribing; order 
communication; product labelling, packaging, and nomenclature; 
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compounding; dispensing; distribution; administration; education; 
monitoring; and use." 
Medication errors are one of the most common types of medical error102. 
It has been estimated that 1–2% of patients admitted to US hospitals are 
harmed as a result of medication errors, the majority of which are errors 
in prescribing103,104. In a study about medication errors carried out in a 
Valencian Hospital (Spain), the global percentage of potential medication 
errors was 7.2% and 4.4 % of them reached the patient105.  The safe 
administration of medicines is an important part of ensuring patient care. 
Nurses are the professionals most likely to administer medication and the 
Nursing & Midwifery Council (NMC) recognises that it is not a mechanistic 
task to be performed in strict compliance with the instructions of the 
prescriber, but requires thought and the exercise of professional 
judgment106. 
The administration of medicines has been identified as a source of risk to 
patients. The National Reporting and Learning System highlights that the 
most frequently reported source of medication errors are wrong dose, 
omitted or delayed medication and administration of the wrong 
medicine107. This has prompted many organisations to adopt the ‘5 rights’ 
approach to medication administration: Right patient, Right drug, Right 
dose, Right route, Right time (Jones 2009). Some types of errors, such as 
maladministration of insulin, are now classed by the Department of 
Health (DH) as ‘never events’ which are considered to be unacceptable 
and eminently preventable. Of the 14 current ‘never events’ (previously 
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25), 5 relate to medication issues108. Therefore we can say that the rights 
of medication administration are the foundation for medication safety, 
however we must take into account that priot administering a medicine, 
we need a prescription. Once the right prescription has been written, the 
nurse following the original five rights of medication administration will 
give (1) the right patient the (2) right drug (3) with the right dose via (4) 
the right route at the (5) right time.  
Medicines reconciliation is defined as ‘being the process of identifying the 
most accurate list of a patient’s current medicines –including the name, 
dosage, frequency and route – and comparing them to the current list in 
use, recognizing any discrepancies, and documenting any changes, thus 
resulting in a complete list of medications, accurately communicated109. 
Reliable reconciliation of medicines at admission and discharge from 
hospital is key to reducing unintentional prescribing discrepancies at 
transitions of healthcare110. Therefore multiple transitions of the patient 
are critical factors for conciliation errors, being a subtype of medication 
errors produced by these transition. 
Prescribing errors are considered a type of medical errors but prescribing 
faults, a subset of medication errors, should be distinguished from 
prescription errors. A prescribing fault is a failure in the prescribing 
(decision-making) process that leads to, or has the potential to lead to, 
harm to the patient. The converse of this, balanced prescribing is the use 
of a medicine that is appropriate to the patient's condition and, within the 
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limits created by the uncertainty that attends therapeutic decisions, in a 
dosage regimen that optimizes the balance of benefit to harm.111  
A prescription error is a failure in the prescription writing process that 
results in a wrong instruction about one or more of the normal features 
of a prescription. The normal features include the identity of the 
recipient, the identity of the drug, the formulation, dose, route, timing, 
frequency, and duration of administration111. 
In fact prescribing errors are a well-recognised cause of adverse incidents 
and have a direct effect on patients112. This impacts on the doctor-family 
relationship and results in breakdown of trust and communication113.  
In one study in a UK hospital, pharmacists identified and rectified a 
prescribing error in 1.5% of all medication orders written, of which about 
one quarter were potentially serious and likely to result in patient 
harm114. 
In another more recent study also in the UK, the incidence of prescribing 
errors was 8.4% and most of them occurred at hospital discharge115.  
Other recent reports of prescribing errors vary widely, from 5% to 81% of 
prescriptions116,117. A significant proportion of errors are believed to be 
caused not by system design features or software glitches, but by human 
factors, such as fatigue, selecting the wrong option, or entering the wrong 
patient information into an often cumbersome system. And although 
most prescribing errors are detected and resolved by pharmacists in both 
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the inpatient and community settings118,119,120, some still slip through the 
entire medication use chain, making it all the way to the patient. 
In 2000, the UK Department of Health report recommended that serious 
errors in the use of prescribed drugs should be reduced by 40% by 
2005121.  A report from the UK Audit Commission122 emphasised the 
problem of medication errors in UK hospitals and highlighted the 
importance of hospital pharmacists in preventing them.  
 
Typification of medical errors. 
The best way to understand how medication errors happen and how to 
prevent them is to consider their classification, which can be contextual, 
modal, or psychological111. Generally speaking contextual classification 
deals with the specific time, place, medicines, and people involved; modal 
classification examines the ways in which errors occur (e.g. by omission, 
repetition, or substitution) and psychological theory123 explains events 
rather than merely describing them.  
Modal classification seems to be the best way to analyse the cause of 
medication errors. They are classified in two types: 
 Committed errors (or real): where there was an actual mistake in 
the prescription due to lapse, lack of knowledge, lack of 
procedures of checking, training need, etc. 
 Omitted errors or missing errors caused by information omitted. 
 And both of them have the 5 rights as subtype:  
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1. drug 
2. dose  
3. frequency  
4. pharmaceutical form  
5. route of administration.  
Any evitable occurrence relating to the inappropriate use of drugs whilst 
they are controlled under an environment with healthcare professionals 
is considered a medication error. Adverse effects are excluded from the 
concept of medication error however adverse events can be a 
consequence of a medication error. The possibility of committing 
medication errors are multiple and they have been analysed in different 
studies124,125,126,127.  
Effective error management requires an understanding of the varieties of 
human error and the conditions likely to promote them. If human error 
factors (such as administering the wrong dose of a prescribed drug) are 
identified, organisations can start to find solutions that predict or prevent 
it and make changes that maximise performance rather than set people 
up to fail. In addition the causes of any patient safety incident extend far 
beyond the actions of the individual healthcare staff directly involved, and 
are often out of their control. And while human error might immediately 
precede an incident, in a technically and socially complex system like 
healthcare, there are usually entrenched systemic factors at work.128 
Errors occur in health care as well as in every other very complex system 
that involve human beings. The message in To Err is Human is that 
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preventing death and injury from medical errors requires dramatic, 
system wide changes129. Among three important strategies—preventing, 
recognizing, and mitigating harm from error—the first strategy 
(recognizing and implementing actions to prevent error) has the greatest 
potential effect, just as in preventive public health efforts. This report To 
err is human, was published by The institute of Medicine of USA in 1999 
and was reviewed 7 and 10 years after, always with the same message in 
medication as an area that needs constant surveillance and improvement. 
Medication errors are a multidisciplinary problem and a multidisciplinary 
approach is required in order to reduce their incidence130. And although 
medication errors can occasionally be serious, they are not commonly so 
and are often trivial. However, it is important to detect them, since 
system failures that result in minor errors can later lead to serious errors. 
Reporting of errors should be encouraged by creating a blame-free, non-
punitive environment. Avoiding medication errors is important in 
balanced prescribing, which is the use of a medicine that is appropriate 
to the patient's condition and, within the limits created by the uncertainty 
that attends therapeutic decisions, in a dosage regimen that optimizes 
the balance of benefit to harm. In balanced prescribing the mechanism of 
action of the drug should be married to the pathophysiology of the 
disease131. 
Causes and consequences of errors. 
The National Reporting and Learning Service (NRLS) analysed the 7 steps 
published in order to prevent mistakes to happen.  
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The seven steps to patient safety causal factors are classified into the 
following groups132: 
 Active failures: these are actions or omissions that are sometimes 
called ‘unsafe acts’. They are actions by frontline healthcare staff 
who are in direct contact with patients, and include slips, lapses, 
mistakes or violations of a procedure, guideline or policy. Usually 
short lived and often unpredictable, they are influenced by latent 
system conditions and contributory factors (see below) such as 
stress, inadequate training and assessment, poor supervision or 
high workload. An examples of active failures could be an infusion 
bag with added potassium is incorrectly stored on the first shelf 
(for saline only) rather than the normal place on the second shelf. 
In an emergency a staff member picks up the bag from the first 
shelf assuming it is saline and gives the patient the wrong bag; 
 Latent system conditions: These are the underlying rather than 
immediate factors that can lead to patient safety incidents. They 
relate to aspects of the system in which people work. They are 
usually actions or decisions taken at the higher levels of an 
organisation, which seem well thought out and appropriate at the 
time but can create potential problems within the system. These 
factors can lie dormant and unrecognised for some time. 
Alternatively they may be recognised but changing them is not a 
priority. The latent conditions combined with local conditions 
(active failures and contributory factors) create the potential for 
Introduction. 
100 
 
incidents to happen. Examples of latent system factors include 
decisions on:  
–Planning: fixed staffing levels may be adequate until 
extreme situations occur, such as more than the usual 
numbers of staff are on sick leave, or there are more than 
the usual number of critically ill patients; 
–Designing: designing a new clinic, practice, ward or 
diagnostic centre without considering vulnerable groups, 
such as children or mental health patients, and leaving 
dangerous equipment within their reach;  
–Policy-making: having a strict take-home policy for 
drugs, which doesn’t take into account difficult times to 
get to a pharmacy (holidays such as Christmas) or 
unlicensed medication that may not be local stock items; 
–Communicating: having only a limited reporting 
structure for patient safety incidents, which means vital 
lessons are not learned across the organisation. 
 Violations: these are when individuals or groups deliberately do 
not follow a known procedure or choose not to follow a 
procedure for a number of reasons, including: 
– they may not be aware of the procedure; 
– the situation dictates a deviation; 
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– it has become habit; 
– the procedure has been found not to work; 
– the procedure has been surpassed by a new one but it 
has yet to be rewritten. 
 Contributory factors: these can contribute to an incident in 
relation to: 
–Patients: unique to the patient involved in the incident, 
such as the complexity of their condition or factors such 
as their age or language; 
–Individuals: unique to the individual involved in the 
incident. They include psychological factors, home 
factors, and work relationships; 
– Tasks: these include aids that support the delivery of 
patient care, such as policies, guidelines and procedural 
documents. They need to be up to date, available, 
understandable, useable, relevant and correct; 
–Communication: these include communication in all 
forms: written, verbal and non-verbal. Communication 
can contribute to an incident if it is inadequate, 
ineffective, confusing, or if it is too late. These factors are 
relevant between individuals, within and between teams, 
and within and between organisations;  
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–Team and social factors: these can adversely affect the 
cohesiveness of a team. They involve communication 
within a team, management style, traditional hierarchical 
structures, lack of respect for less senior members of the 
team and perception of roles;  
– Education and training: the availability and quality of 
training programmes for staff can directly affect their 
ability to perform their job or to respond to difficult or 
emergency circumstances. The effectiveness of training as 
a method of safety improvement is influenced by content, 
delivery style, understanding and assessment of skill 
acquisition, monitoring and updates; 
–Equipment and resources: equipment factors include 
whether the equipment is fit for purpose, whether staff 
know how to use the equipment, where it is stored and 
how often it is maintained. Resource factors include the 
capacity to deliver the care required, budget allocation, 
staffing allocation and skill mix; 
–Working conditions and environmental factors: these 
affect ability to function at optimum levels in the 
workplace, and include distractions, interruptions, 
uncomfortable heat, poor lighting, noise and lack of or 
inappropriate use of space.  
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The seven steps causes of errors can be applied to any discipline and in 
grosso modo medical causes are: 
 1. Educational- due to lack of knowledge 
 2. Communication- due to failure in communicating properly 
 3. Technological- due to aspects of the electronic components allied 
to the health care system 
 4. Organizative- due to a decline of the workload organisation 
 5. Human- due to lapse, tiredness. 
However and from a pharmacy perspective the most common cause of 
errors are the ones described in Table 1.7. 
Table 1.7 Most common specific errors from a pharmacy perspective. 
 Unawareness of medication history of the patient and clinical history  
 Use of an inappropriate drug 
 Wrong drug due to similar name or package 
 Wrong dose  
 Wrong frequency 
 Unawareness of drug interactions 
 Wrong calculation in obese, paediatrics, elderly or renal patients 
 Dotted numbers misplaced 
 Wrong pharmaceutical form 
 Wrong route of administration 
 Use of non standard abbreviations 
 Insufficient communication between healthcare professionals. 
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Regardless of the cause or the type of the incident there might be some 
mitigating factors, whether actions or inaction such as chance or luck, 
may have mitigated or minimised a more serious outcome. When 
investigating these factors it is important that these are drawn out so that 
the lessons can be used to support and promote good safety practice. 
Figure 1.5 represents how human errors can reach the patient if the steps 
to follow the process of medication prescribing are missed. 
The consequences of a medical error define the impact an incident can 
have, ranging from no harm to the patient to various levels of severity of 
harm: low, moderate, severe and death96.  Studies classify consequences 
of errors in severity values/scales. Regardless of the scale a consequence 
of medical error is that health care providers at all training levels 
experience feelings of guilt, disappointment, fear and sense of 
inadequacy of varying degree.133,134 After all, the effects of harming a 
patient can be widespread and there can be devastating emotional and 
physical consequences for patients and their families. 
As per the 7 steps and current practice within the NHS Hospitals 
consequences should be shared to learn in the best possible ways and 
causes need investigation to prevent similar incidents to occur again.  
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Figure 1.5. Incident analysis framework, adapted from Reason J’ model of accident 
causation135.  
1.7.2. Safety actions and improvement strategies. 
The seven steps to patient safety’s document overview the National 
Reporting and Learning Service (NRLS)’s detailed guide to good practice, 
which covers building a safer culture and managing, reporting and 
learning from patient safety incidents. It sets out the seven steps that 
NHS organisations should take to improve patient safety. These are 
summarised in Table 1.8. 
Identifying safety actions and implementing strategies is an essential part 
in the safety of the patient. But most importantly is that staff actively 
engage in with a safety plan and have a clear understanding of patient 
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safety improvement and the role they play in achieving this.  Engagement 
is essential in order to create synergy and integrated working. 
Table 1.8. The Seven steps to patient safety and each one’s aim. 
Step 1 Build a safety culture Create a culture that is open and fair  
 
Step 2 Lead and support your 
staff 
 
Establish a clear and strong focus on patient 
safety throughout your organisation 
 
Step 3 Integrate your risk 
management activity 
 
Develop systems and processes to manage 
your risks and identify and assess things that 
could go wrong 
 
Step 4 Promote reporting 
 
Ensure staff can easily report incidents locally 
and nationally 
 
Step 5 Involve and 
communicate with patients 
and the public 
 
Develop ways to communicate openly with and 
listen to patients 
 
Step 6 Learn and share safety 
lessons 
Encourage staff to use root cause analysis to 
learn how and why incidents happen 
 
Step 7 Implement solutions 
to prevent harm 
 
Embed lessons through changes to practice, 
processes or systems 
 
 
A safety plan sets out the key patient safety aims, goals or prioritised 
areas of improvement work that need to be reliably implemented and 
spread in order to achieve the high level strategic aims and patient safety 
outcomes. Normally these plans start with a focus on identified pilot 
areas, taking a multidisciplinary team based approach and where possible 
informed by current local data that identifies the size and scale of the 
problem and therefore informs us of where best to focus improvement 
effort to maximise impact.  
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The Table 1.9 summarises some of the requirements to successfully 
implement safety plans.   
In the UK, NHS organisations have a Governance team monitoring closely 
incident reports. The use of medicines is a complex system and patients 
are at the end of the chain, therefore pharmacists adopt a crucial role in 
improving drug usage and preventing prescribing errors ensuring safety 
of the patient. The use of medicines’ system includes different episodes 
of risks of errors as well as quality defects that can be a cause of harm in 
the health of the patient. This situation requires the establishment of a 
quality system to assess risks and prevent errors that may occur in 
patient’s pharmacotherapy but also preventing errors in each phase of 
the pharmacotherapy process (prescription, screening, labelling, 
preparation, dispensing, administering the medicine).  
Table 1.9. Main requirements for a successful implementation plan. 
 Strong, clear and visible clinical leadership attention to patient safety.  
 Multidisciplinary team approach to priority areas. 
 Infrastructure and dedicated resources to establish a patient safety 
improvement team. 
 Capability of key staff groups in patient safety and quality improvement 
to support implementation.  
 Engagement, ownership and involvement of all staff. 
 Organisational commitment and learning about medical errors 
encouraging. 
 Dedicated budget for Patient Safety. 
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 Supportive, learning environment and culture to assist with the sharing 
of knowledge, skills and experience to effect behavioural changes 
 Recognition and reporting of errors and near misses as well as 
identification of risks to patient safety without judgment or placement of 
blame. 
 Proactive involvement of patients, relatives and carers in decisions about 
their health care promoting open communication about own experience. 
Feedback request. 
 A dedicated patient safety communication plan, web resource and media 
support.  
 An infrastructure, technological resource and dedicated data team to 
make collection, analysis of data and meaningful measurement for safety 
improvement from ward to board. 
Furthermore and in a global way The Care Quality Commission (CQC) is 
the independent regulator of health and adult social care services in 
England. Their aim is to make sure health and social care services provide 
people with safe, effective, compassionate, high-quality care, and with 
regular inspections they encourage care services to improve. CQC 
monitors, inspects and regulate services to make sure they meet 
fundamental standards of quality and safety and their findings are 
published with information on the rating of the performance. It is obvious 
that CQC visits are taken seriously by healthcare professionals working in 
the NHS as their rating will be publised. After a CQC visit, they propose 
actions and targets consistent with the 7 steps of patient safety and NHS 
organisations to health care professionals are encouraged to pursue 
these objectives. 
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Safety actions are the aftereffect of a plan after the incidents have been 
analysed. Often root cause analysis (RCA) are needed in safety 
investigations. A RCA is a structured method used to analyse serious 
incidents; as an individual RCA is essentially a case study of a specific error 
(unexpected event), analysis of multiple RCAs performed at different 
institutions may help identify patterns of error and point the way toward 
solutions. There are different ways to implement strategies to improve 
such as daily prompt emails, posters with relevant information, checklist 
of most common risk areas to assess, regular meetings, etc. In order to 
help the investigating process in a RCA, it is important to understand the 
tools needed for the investigators: 
 gather and map information; 
 identify care and service delivery problems;  
 analysing to identify contributory factors and root causes;  
 generate solutions; 
 log, audit and learn from investigation reports 
There may be more than one causal factor in any incident. Therefore a 
root cause analysis is a fundamental component of which is to understand 
and identify the causal factors that influence risk and safety. The Table 
1.10 is an example of action plan template suggested by NPSA, and 
recommends pointing the names of the persons to action certain tasks 
with deadlines to implement.  
RCA is one of the tools that helps establishing a safety culture. It is 
necessary workers report incidents as well as learning/sharing from 
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errors. However from a constructive perspective sharing from positive 
actions that staff carry out is another category that can help learning 
patient safety but this vision has not been implemented widely. 
Table 1.10. Example of Action plan template suggested by NPSA136 
 Action 1 Action 2 More 
Root cause     
Effect on patient    
Recommendation    
Action to address root cause    
Level for action  (Org, Directorate, Team)    
Implementation by:    
Target date for implementation    
Additional resources required  (time, 
money, other) 
   
Evidence of progress and completion    
Monitoring & evaluation arrangements     
Sign off - action completed date:    
Sign off by:    
Barts Health NHS use Datix© system to report incidents. The governance 
body for each speciality meets monthly to analyse each incident and they 
make sure reports are reviewed and actions are taken to prevent/reduce 
incidents. The UK has a culture of share the learning with relevant staff 
and design ways to implement safety environtment. The is a risk registrar 
too that is under the Governance body, in there the risk assessments that 
score a certain number are analysed to help preventing serious incidents 
or never events. 
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1.7.3. Quality and safety in the prescribing process in children with 
Cystic Fibrosis. 
Safe administration of medication is a national priority. It is an essential 
standard of the Care Quality Commission137 and NHS Litigation 
authority138 in England, and a key outcome of the Scottish Patient Safety 
Programme139 and 1000 lives plus safety programme in Wales140. 
Therefore it is important that all NHS Professionals’ flexible workers are 
aware of their responsibilities with regards to medication administration. 
Not only nursing staff. 
The complexity of CF disease and its pharmacology is also transfered to 
the different type of prescriptions that the medicines have to be 
prescribed in the UK. Despite doctors deciding best pharmacological 
treatment for the child, the prescription must be clear since it is the next 
step to confirm that best treatment will be administered. The prescription 
is the labelling precedent, hence the quality of this prescription should be 
considered to reach best and consistent information to patient, with a 
review of concomitant drugs too and the possibility of discontinuation of 
certain treatments. Considering some patients might take medication at 
school time, the community nurse administering the medication to CF 
children should also be advised of possible other drug therapies being 
discontinued, hence communication with primary care is also a very 
important factor. 
The quality of the CF prescriptions for children that are frequently 
admitted to hospital should focus in the following aspects: 
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 The presence of the weight of the child in the prescription 
 The presence of any of medicines that concord with associated 
pathologies in the discharge prescriptions as well as correct 
optimised dose/frequency. 
 Pharmacokinetic aspects like drug interactions that might affect 
the pH of the stomach, concomitant medication that is liver 
metabolised (looking in to dose adjustment), dosing, and 
information on length of treatment.  
 The clarity of the prescription that relates to antibiotics, either 
nebulised, oral or IV- when to stop and to restart. 
 Duration of treatment, when the drug is newly started to ensure 
review of symptoms and effectiveness. 
 Pharmaceutical forms, especially if there are particular drugs that 
the patient prefers, to help adherence. 
 Any allergy information documented. 
Table 1.11 summarises the main aspects that should be reviewed to 
achieve quality of the prescription for each drug/group of drugs. 
Table 1.11. Main aspects to take into consideration to provide quality of CF prescriptions 
regarding main associated pathologies and group of drugs.  
 Indication/ 
Omission 
Pharmaceutical 
form 
PK 
interactions 
Duration 
Pancreatinin 
enzymes 
✔    
Fat soluble 
vitamins 
✔ ✔   
Gastro-
intestinal drugs 
✔ ✔   
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ABPA treatment 
with antifungals 
✔ ✔ ✔ ✔ 
Nebulised 
antibiotic 
✔ ✔  ✔ 
 
Patient- related risk factors. 
Paediatric patients have significant need for research and development 
into paediatric medicines. Only a small fraction of the drugs marketed and 
utilized as therapeutic agents in children have been clinically evaluated. 
The majority of marketed drugs are either not labelled, or inadequately 
labelled, for use in paediatric patients. The absence of suitable medicines 
or critical safety and efficacy information poses significant risks to a 
particularly vulnerable patient population. However, there are many 
challenges when developing medicines for the paediatric population and 
thia is reflected with the limited paediatric formulations in the market. 
The paediatric population is made up of a wide range of individuals of 
substantially varied physical size, weight and stage of physiological 
development141.  
A recent study in a London hospital aimed to quantitatively assess the 
level of medication error for paediatric inpatients on admission and 
discharge and to ascertain whether discharge summary information is 
sent to the GP in a timely manner but none of the standards set up were 
met, emphasising the need to develop better medicines reconciliation 
practice142.  
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Previous research has acknowledged that paediatric patients are at risk 
of encountering medication errors including prescribing errors143. 
However there are not many studies in the UK that calculate the incidence 
of prescribing errors in the paediatric population.  
A general definition of a prescribing error was developed for 
paediatrics144 and the following factors were considered prescribing 
errors: 
 Failure to communicate essential information 
 transcription errors and the use of drugs 
 formulations  
 inappropriate doses 
However, no studies have been found for quality prescribing in CF 
children, when polytherapy is a daily fact. Studies of pharmacists’ 
interventions have been carried out in UK hospitals but little or none 
studies of pharmacists evaluating CF discharge prescriptions have been 
published.  
Drug therapy related risk factors. 
Patients admitted to IV therapy stop their nebulized antibiotics and in 
most of the cases patients are expected to restart them after the IV 
course. However, when the patient is due to be discharged, the 
information regarding restarting treatment with the nebulised antibiotics 
and prophylactic antibiotics (if they were on them prior to admission) can 
be missed, with the possibly of creating confusion to parents, especially 
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when the weight of the pharmacological treatment resides primarily in 
one member of the family: for instance if the main career is not present 
during discharge talks, if there is any pharmacological information given 
verbally that is not reflected in the prescription, this information might 
not be communicated. 
Moreover, unfortunately there are not many different child friendly drugs 
in the market and very often pharmacists must find information for 
unlicensed use. Crushing and dispersing tablets is common practice when 
administering in children and palatability is not particularly pleasant in 
most of the cases. This often put parents under stress as they have certain 
knowledge of the disease and understandably expect quick solutions, as 
the multidisciplinary CF team is heavily involved. It is also a challenge for 
CF pharmacists when seeking unlicensed alternatives as not only do 
governance bodies expect any risk aspects of treatment being covered 
but in parallel commissioner bodies can be unhelpful with requests made 
to import overseas presentations that are licensed in other parts of 
Europe.  
Below paragraphs reflect a description about specific drug therapy with 
antibiotics and its duration of with a potential cause of confusion, delay 
or error affecting patient’s trust with the medical team and adherence 
(explain the need of greater information of CF disease when prescribing 
or screening a prescription): 
Generally speaking prescriptions with antibiotics in the UK must 
includethe duration of treatment. If this was missing, the prescription 
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would automatically be queried by the pharmacist, leading to extra 
waiting time for the patient if waiting in community pharmacy. Also 
patient information leaflets dispensed with antibiotics described short-
term treatment, which is not always the case in CF. 
However a CF pharmacist or doctor would not necessary request to add 
any duration antibiotics if for instance the regime prescribed 
corresponded to a prophylactic regimen (easily identifiable via dosage or 
frequency) in a CF patient or if the treatment is to cover a pathogen that 
has been isolated, as patients can be on a course of antibiotics with 
treatment doses for 18 months, for instance in Non Mycobacterium 
Tuberculosis (NMT). 
Hence one of the recommendations adding value to antibiotics prescribed 
for CF patients could be adding information like “long term antibiotic 
therapy” or “until further notice” or even stating the time “for 18 months, 
started on… or to finish/review by…”.  
Information added to the label of antibiotics for CF prophylaxis would 
allow a faster clinical screening for GPs prescribing in primary care, 
community pharmacies as well as parents being able to identify which is 
the antibiotic drug amongst the others in a cupboard. 
From a CF perspective, it is accepted that doses and length of antibiotics 
may differ from standard dosing guidelines. Furthermore prescriptions for 
CF should have clear instructions as this would help adherence (by adding 
consistency with the instructions given to the careers/patient). 
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Prescriptions in primary care for antibiotics in CF children might be 
considered to contain prescribing errors when using standard electronic 
prescribing for age/weight and potentially community pharmacist can 
hold prescriptions due to what it might be thought “a prescribing error”. 
However, in reality this prescribing might have been written intentionally 
as this dosage might be necessary and safe for a child with CF.  
However and less importantly the drug therapy prescribed is a crucial 
factor in paediatric CF patients. Considering that not many paediatric 
friendly formulations are available, there is a risk of error if the 
prescription does not specify the formulation or the strength desired as 
often patient’s administration are based with the volume. Another risk is 
the non-adherence if the child dislikes its flavour and all these factors 
need to be taken into consideration too in order to help with adherence. 
Health care system risk factors. 
Pharmacists, as well as doctors, are also involved in an in-depth learning 
curve when starting their career in hospital. Junior or foundation 
pharmacists are the ones on call and dealing with general queries. 
Sometimes they are required to cover specialty wards with little training 
provided.  
Diseases like CF in the paediatric population and the polytherapy children 
have, can be a challenge for a junior trainee, either doctor or pharmacist. 
Prescribing on a busy ward, with lack of supervision plus other factors 
affecting prescribing are cause of prescribing mistakes135.  
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Furthermore, the current system in the UK comprise a large variety of 
prescriptions. Inexperienced staff may cause incomplete medicines 
reconciliation despite best efforts to prescribe correctly, with the worry 
of omissions or wrong presentation/pharmaceutical affecting dosage and 
adherence. 
While most authorities agree that the use of drugs outside the terms of 
their licence is a necessary part of paediatric practice, instances of more 
unconventional prescribing, and worries about potentially unnecessarily 
restrictive policies, are part of safety medicines incidents reports. Also, 
professionals often feel frustrated of the lack of paediatric friendly 
formulations in the UK market as well as cost pressures and 
documentation required (when they are available) to import them from 
European countries 
The quality of a prescription for CF patients, is held to a different 
standards to that of a normal prescription. There are other factors that 
contribute to compliance problems in CF included patients receiving 
conflicting information145. It is clear that the paediatric population with 
CF is more vulnerable to medication errors. 
The professionals involved in prescribing are junior doctors (ward 
prescribing, discharge summaries); senior doctors (named registrar in the 
UK); Consultants (clinic letters); CF independent prescribing pharmacist 
(clinic letters and homecare prescribing); GPs (acute and repeat 
prescriptions); Community pharmacist (prescriptions and over the 
counter products); ward pharmacist and junior pharmacist (for on call 
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queries). Specialist nurses often deal with the prescribing and should also 
be asked as well about what they consider quality in prescribing. 
Educating the patient to better understand how the drug will help is also 
essential in adherence. But also community pharmacists and primary care 
doctors could benefit with some CF training or a hospital visit with 
specialist team if they have to deal with CF children in their clinics.  
Specialist nurses, Consultants, junior doctors, dieticians and hospital 
pharmacist agree that better communication between the hospital, GP 
and local pharmacist would help patients to obtain medication in the 
community more efficiently.  
Table 1.12 summarises the main patient, drug therapy and health system 
related risk factors associated within medication errors in children with 
CF. 
 
Table 1.12.  Main risk factors to drug errors in children with CF. 
Patient- related risk factors. 
 Lack of understanding of parents/teenage/child leading to failure to 
adhere to treatment. 
 Complex administration dispositives (nebulisers). 
 Need to individualised therapy (per body weight, body surface, indication 
or PK monitoring). 
 Lack of diverse palatability of the drugs. 
 Lack of child friendly preparations. 
 Pharmaceutical forms not always adequate for gastrostomy use. 
 Multiple hospital admissions with swapping nebulised antibiotic for 
intravenous. 
 School time clashing with administration time. 
 Conflicting information from media, other professionals, leaflets, etc. 
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Drug-therapy related risk factors  
 Polypharmacy. 
 Pathologies associated to CF with multiple specialties input in drug 
therapy.  
 Routes of administration, as often CF children end up with gastrostomies 
in situ. 
 Complex pharmacotherapy regime (alternating days, months, etc). 
Health care system risk factors  
 Multiple doctors involved in the prescribing process of medication. 
 Multiple types of prescriptions leading to complicated gain of real drug 
history. 
 Rotational junior staff in University Hospitals. 
 Lack of knowledge of junior prescribers.  
 Lack of knowledge of junior pharmacist. 
 Continuous rotation of junior staff. 
 
Hence it is important that experienced CF pharmacists deal with 
prescriptions for CF. It would be advisable that community pharmacist 
with CF patients as regular customers get specific education of the 
disease and its pharmacology in order to engage with patients/parents to 
help adherence as well as implement medicines optimisation.  
Therefore, in CF prescriptions for children the following factors could also 
be considered as a quality aspect: essential medication not being omitted, 
allergies being confirmed, weight of the patient present in the 
prescription and fast communication with primary care (doctors and 
community pharmacists). 
All professionals would agree that the aim of quality in CF prescriptions 
are: safety, effectivity, efficacy, cost management, patient’s education to 
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reinforce and provide consistency to improve adherence.  The quality 
standards to be set up in the CF prescribing environment would provide 
greater in-depth information if they were analysed per groups of 
professionals dealing with CF patients, which is a field to explore. 
The Royal London Hospital for Children is a referral centre for paediatric 
CF spending a great time educating staff, parents and children. The centre 
work with a multidisciplinary team with a focus on patient’s best interest. 
Currently there is dedicated consultant pharmacist who is developing 
guidelines and clinical information as well as being heavily involved with 
the education of parents/patients/staff in which the quality of the CF 
prescribing service improves and can project towards excellence.  
Table 1.13 describes strategical and preventive actions that can mitigate 
risks factors described in Table 1. 12. 
Table 1.13. Strategical and preventive actions. 
 Specific designated staff liaising with prescriptions for homecare, drug chart, clinic 
letter medication list and discharge prescriptions. 
 Clear pathway of education for rotational junior staff in University Hospitals for CF. 
 Other specialty consultants treating pathologies associated with CF to liaise with 
specific staff. 
 Limit prescribing and screening in junior doctors or pharmacist with no previous 
exposure to a limited number of CF patients. 
 Continuous educational workshops for parents, relatives and teachers. 
 Online skype workshops for CF adolescents to understand effects in failure to 
adhere to treatment. 
 Research into different pharmaceutical forms for paediatric population. 
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However, the RLH referral centre is getting larger with more patients and 
being a teaching hospital there are continuously new rotational junior 
staff. From a prescribing perspective, there are also external factors to 
consider when prescribing such as different prescriptions and collection 
points of medication with potentially different staff providing information 
on the current pharmacotherapy. Moreover, CF patients undergo 
multiple hospital admissions and as the children grow medication dosage 
requires adjusting; polytherapy and associated pathologies also play a 
part in prescribing as well as junior and rotational staff involved in 
patient’s care. The inspiration of this study relies on getting evidence to 
find out if there is room for improving the current discharge prescribing 
system and a depth knowledge on how pharmacy service can deliver best 
service for CF Team. 
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2.1.  Main objective 
The main objective of this study conducted in hospitalised children with 
CF receiving IV antibiotics is: 
 To improve the quality of the discharge prescription with the use of 
safety indicators in CF paediatric patients that are admitted to receive 
IV antibiotics treatment.   
In order to achieve the main objective, the study was carried over within 
two periods: a retrospective phase and a prospective phase. Each period 
had into consideration the following specific objectives: 
Retrospective phase. 
 Evaluate quantitative and qualitatively the medication errors found in 
discharge prescriptions previously validated by a pharmacist. 
 Evaluate quantitative and qualitatively the medication errors found in 
the discharge letters written after discharging the patient.  
 Identify, classify and analyse the causes of medication errors found 
more frequently.  
 Propose improvement recommendations to the prescribing 
professionals and design strategies to implement these 
recommendations in clinical practice.  
Prospective phase 
 Evaluate quantitative and qualitatively the medication errors found 
during patients’ admission. 
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 Evaluate quantitative and qualitatively the medication errors found in 
discharge prescriptions previously validated by a pharmacist. 
 Evaluate the impact of the improvement recommendations carried 
over.  
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3. Methods and Materials 
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3.1.  Design. 
Ambispective study conducted in two phases: 
 A retrospective longitudinal observational descriptive study from 
January 2013 to December 2014 (24 months).  
 A prospective longitudinal quasi-experimental study from May 
2016- December 2016 (8 months).  
 
3.2.  Study setting. 
Barts Health (BH) NHS Trust is the association of five different NHS 
University hospitals in London. BH is a tertiary Regional CF centre for 
adults and children.  The paediatric centre is based at The Royal London 
Hospital (RLH) and CF patients are looked after by the paediatric 
respiratory department until the children reach 16 years old, which is 
when the transition process to adult CF clinics occurs. 
Clinical Effectiveness Unit at Barts Health NHS Trust granted permission 
to commence a retrospective and prospective study. 
The study was registered within the Clinical Effectiveness Unit at Barts 
Health NHS Trust. The number given for this study was ID: 7080. Figure 
3.1 corresponds to the consent given for the study to take place.  
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Figure 3.1. Consent received by Clinical Effectiveness Unit to start study 
 
3.3.  Sources of information. 
Seven sources of information were used in order to analyse the 
prescription at discharge and also to conciliate medication on admission:  
1. Electronic Prescribing Records (EPR, from BT®): this document 
was used in the retrospective study. This is the document written 
by the doctor at the time of discharging the patient from the 
hospital, and the prescribing medication is validated by a 
pharmacist. This document is sent to primary care doctors and 
given to parents of patients the day of discharge. This was the 
official document in 2013 and 2014 used when discharging a 
patient admitted at the RLH. Figure 3.2 represents a print screen 
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example from the Electronic prescribing system used during the 
time of the retrospective study.  
 
 
Figure 3.2. Example of EPR©, from British Telecom (BT).  
 
2. Discharge letter (free type word version): is a comprehensive 
word document recording the admission time of the child’s 
clinical situation, microbiological antibiograms, blood tests, 
spirometer results, etc. In this document there is a medication 
section with the list of the medicines prescribed on discharge. This 
is not a prescription document and therefore pharmacists do not 
validate the section where the medicines are listed. This 
document is not the official document used for discharging the 
patient but it is extremely useful as it includes sections for 
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following up disease progress. This document is also sent to 
primary care doctors and to parents of patients as soon as 
possible after the day of discharge. This document was only 
studied in the retrospective study. Figure 3.3 is a print screen of a 
patient’s discharge letter section for medication at discharge. 
 
       Figure 3.3. Medication list example in a Discharge letter 
 
3. Electronic prescribing (CRS (Clinical Records System), from Cerner 
Millenium®): CRS contains clinical information with a prescribing 
section integrated in the same system. This document was 
installed in the place of the study during 2015 and was used to 
study the electronic prescribing in the prospective study. Figure 
3.4 represents an example of CRS from a print screen and Figure 
3.5 shows the final transcribed CRS prescription in the printable 
document version. 
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Note that the CRS system needs manual typing of the name of the drug and 
route, as well as dosage. There is no designated space for pharmaceutical form 
and this has to be entered in the space for the drug too. Furthermore, the space 
for communication has a limited number of characters and often the 
information has to be entered in different separated lines under pharmacy 
comments. This system was implemented during 2015 at the RLH and was used 
to study the prospective discharge electronic prescriptions. 
Figure 3.4. CRS® Discharge TTA* example from a print screen.  
*TTA:  To take away (medication patient needs to take home on discharge). 
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TTA:  To take away (medication patient needs to take home on discharge). 
Figure 3.5. CRS®TTA transcription to document for patient  
 
4. Summary Care Records (SCR, from NHS digital146): this is the 
information of primary care electronic prescribing. This document 
was used for the prospective study. Due to lack of permission 
there is no example of the medication listed of a patient on SCR. 
5. Patient’s own drugs (PODs): this is the physical medication the 
patient brings to hospital that is checked by pharmacy staff to 
confirm reconciliation on admission. In the UK, by law all 
medicines categorised as “Prescription Only Medicines” (POM) 
must have a label identifying the name of the patient, drug 
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dispensed and instructions on how to take these medicines. 
Figure 3.6 is an example of the labelling system used in the UK 
prescribed medicine. 
 
Note the square D and C for dispenser and checker to sign the label attached to 
drug. 
 Figure 3.6. Example of type of label used in the UK. 
 
6. Drug chart of the patient: this was used in the prospective study. 
The drug chart is the tool used in the wards to prescribe and 
record administration of medicines. It is an A4 booklet different 
number of pages with different sections for prescribing and 
recording administration. Figures 1.2-1.7 in introduction chapter 
correspond to different pages of a drug chart. 
7. Homecare prescriptions: managed in secondary care by specialist 
teams. In 2015, High cost nebulisers (HCN) commissioning 
changed and the patients on HCN needed repatriating to 
secondary care. HCN are currently commissioned by NHS-England 
whereas the previous commissioner was primary care via clinical 
commissioning groups (CCG). At the RLH this was done via 
homecare63 during 2014. The homecare prescriptions used for 
Paediatric CF patients at Barts Health have been agreed and 
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developed by the Consultant Pharmacist with the homecare 
company as a proforma to aid mitigating prescribing errors. Figure 
3.7 is an example of the prescription used at the Royal London 
Hospital. The medications included in homecare for CF children 
relate to either HCN or Ivacaftor. These prescriptions are another 
source of information that should be used to confirm drug history 
for medicines reconciliation when patient comes into hospital.  
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Figure 3.7. Homecare proforma used for CF patients on HCN. 
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In summary, the next Table (Table 3.1) shows the description of 
the purpose of the information used in each phase of the study. 
 
Table 3.1. Summary of sources of information used with main peculiarities of 
the system related with pharmacy. 
 Sources of 
information 
Purpose 
R
e
tr
o
sp
ec
ti
ve
 p
h
as
e Electronic 
Prescribing 
Record (EPR) 
Discharge electronic prescription (TTA*), given to 
parents on the same day at discharge. Sent to Primary 
care. Validated by pharmacist. 
Discharge letter 
(DL) 
Comprehensive document that includes clinic history of 
patient such as microbiology results, spirometries and 
list of drugs prescribed on discharge. 
Sent to parents’ although not necessarily same day of 
discharge. Sent to Primary care. Not validated by 
pharmacist. 
P
ro
sp
e
ct
iv
e
 p
h
as
e 
Clinical Record 
System (CRS) 
Database with discharge electronic prescriptions or 
TTA* including all sort of health related documents 
(equivalent to EPR in the retrospective study). Validated 
by pharmacist. 
Sumary Care 
Records 
Primary Care prescriptions records of acute and repeat 
prescriptions. Not validated by pharmacist. 
Patients own 
drugs (PODs) 
Physical medication of the patients, labelled. 
Used in reconciliation of medicines in hospital 
admission. Validated by community pharmacist 
Drug chart of 
the patient 
Hand written prescription used on the wards that 
records administration of medicines. Validated by ward 
pharmacist. 
Homecare 
prescriptions 
Prescriptions from specialist in secondary care 
Used in reconciliation of medicines in hospital 
admission. Validated by pharmacist. 
* TTAs (to take away, related to medication at discharge for the patient) are 
named in this study EPR for the retrospective study and CRS for the prospective 
study. TTAs are created with a section for pharmacist validation. 
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3.4.  Patients. 
At present the Respiratory Department looks after CF children of East of 
London, West and North East Essex. RLH also share-cares with Colchester 
and Queens Hospital. The Specialist Clinical Nurses for CF have a database 
of the patients that are being looked after by the department. 
The specialist nurse notified patients in the quarterly CF bulletin that a 
project would be carried out by Pharmacy department and should any 
patient not wish to be added to the project to let her know. 
3.4.1. Retrospective phase. 
All paediatric CF patients admitted to RLH to receive IV antibiotics during 
the years of 2013 and 2014 were included in this period of the study. 
A list of CF children registered in the database of 2013 and 2014 period 
was provided by the specialist nurse. 
Each hospital number was entered in the electronic prescribing system 
(EPR) in order to establish if the patient had been admitted into hospital 
during any of the two years of the retrospective stage.  
When the patient was identified in the system, this was registered in the 
database to follow the study and data started to be collected. 
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3.4.2. Prospective phase. 
The patients included in the prospective phase of the study were all CF 
patients admitted into the respiratory ward (7E ward) to receive IV 
antibiotics in the RLH from May 2016 to December 2016 (8 months).  
The Paediatric respiratory pharmacist covering 7E ward and the Pharmacy 
Technician based on the wards were informing of any new CF patients 
that were admitted. The name and the room of the child were identified 
with the daily handover list that is kept in the ward. The patient’s notes 
and drug chart were taken to do a full drug history of the patient.  
A data collection form was designed and this corresponds to the next 
Figure 3.8. Once data was collected, the non-confidential information was 
entered in an excel database. These sheets were kept locked for 
confidential information protection and will be destroyed after 
presenting the study to the team. 
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3.5.  Variables studied.  
The number of variables analysed has been high. To facilitate the 
comprehension of the study Table 3.2 summarises the variables studied 
in both retrospective and prospective phases and the main source of 
information used.  
Figure 3.9 represents in a diagram the steps of how the study was 
followed and implemented, and in bolded letters the sources used to 
detect improvement opportunities projecting towards an improved 
discharge prescription with correct medication prescribed. 
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Table 3.2. Summary of variables in each phase of the retrospective and prospective study with source of information used 
 
 
 
 
Variables studied 
Retrospective Prospective 
Discharge Admission 
(DHx Reconciliation) 
Hospital 
stay 
Discharge  
Electronic 
prescribing 
(EPR)  
Discharge 
letter (DL) 
Drug chart Primary 
care (SCR) 
Drug 
chart  
(Green pen) 
CRS 
(electronic 
discharge) 
 
 
Related to 
patient 
 
0- Hospital number ✔ ✔ ✔ ✔ ✔ ✔ 
1- Age ✔  ✔    
2- Gender ✔  ✔    
3- Number associated pathologies ✔     ✔ 
4- Type associated pathologies  ✔  ✔    
5- Parent’s English   ✔    
6- Child living with parents   ✔    
 
Related to 
hospital 
stay 
7- Reason for admission ✔ ✔ ✔    
8- Days of hospitalisation (n) ✔  ✔   ✔ 
9- Week day of admission   ✔    
10- Week day of discharge ✔     ✔ 
 
Related to 
drug 
therapy 
11- Weight ✔ ✔ ✔ ✔  ✔ 
12- Allergy documentation ✔ ✔ ✔ ✔ ✔ ✔ 
13- Same allergies in PC    ✔   
14- Type of drugs ✔ ✔   ✔ ✔ 
15- Prescribing doctor ✔ ✔    ✔ 
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16- Validating pharmacist ✔     ✔ 
17- Seniority of the pharmacist ✔     ✔ 
18- Presence of DL  ✔     
19- Date of DL  ✔     
20- N discrepancies in DL versus EPR  ✔     
21- Drugs prescribed (N) ✔ ✔ ✔ ✔ ✔ ✔ 
22- Brand name drugs (N) ✔      
23- High cost nebulisers in PC    ✔   
Related to 
Improve-
ment 
strategies  
24- Deeper MR (≥3 sources)   ✔ ✔   
25- N prompt cards effectuated   ✔    
26- Pharm intervention n and type     ✔  
27- Pharm intervention accepted     ✔  
28- N discharges drug listed      ✔ 
29- Communication needed    ✔   
30- Communication done      ✔ 
N=Number of; DHx: Drug history; MR=Medicines Reconciliation; PC= Primary Care; Px= Prescription; H= Hospital. 
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Figure 3.9. Diagram of the process of the ambispective study followed  
Retrospective 
discharge 
prescription process 
analysis
•EPR
•DL
Improvement 
opportunities 
identification
Improvement 
strategies selection
Prospective 
implementing 
strategies and 
safety actions 
Exhaustive reconciliation
Prompt chart
Interventions monitoring
Drug lisitng
Communication
Prospective 
discharge 
prescription 
process 
analysis
CRS
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   3.5.1.     Patient related variables. 
The following variables relating to patients were collected from the 
hospital number and electronic prescribing. Variables of age, gender, 
hospital number and associated pathologies were studied in the clinical 
part of the document in EPR and in the discharge letter. Socio-
demographic variables 5 and 6 were collected from information directly 
from the clinical specialist nurses. 
0. Hospital number: variable collected to study other variables kept 
in different database. Given nil number as this was used but not 
presented for any of the results. 
1. Age of the patient on the day of discharge: quantitative continue 
variable.  This variable was collected in years. 
2. The gender of the child: qualitative dichotomy variable that takes 
values boy (male)/ girl (female). 
3. Number of associated pathologies: cumulative continue variable 
that sums the number of associated pathologies of a child with CF 
presented at the time of discharge. 
4. Associated pathologies of the patient: categorical variable that 
takes into account the number and type of associated pathologies 
the child has as they are related to CF. These pathologies are well 
known within CF patients are they were categorised the following 
way: 
 Pancreatic insufficiency 
 Gastro-oesophagus reflux disease (GORD) 
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 Diabetes  
 Liver disease 
 Other (ABPA, DIOS, bronchiectasis, asthma, …) 
5. Parent’s English: Variable related to the first language of the 
parents. It is a qualitative dichotomy variable that takes values yes 
when the English language of mum/dad/carer is their first mother 
tongue or no when English is an additional language. 
6. Parental support: categorical variable that refers to the child living 
with one parent (mother or father, including foster parents) in the 
main home or with both parents (mum and dad). 
3.5.2. Hospital stay related variables. 
These variables were obtained from EPR and DL for each patient’s during 
the retrospective part or from the drug chart and electronic discharge 
prescription (CRS) in the prospective phase of the study.  
7. Reason for admission: qualitative dichotomy variable that takes 
values of elective admission or infective exacerbation (severe 
admission). These can be: 
a. Elective admission: this type of admission is for patients that 
come in to hospital either  
 to be admitted for routine intravenous (IV) treatment 
every 3 months due to their clinical condition, or 
 Pre-procedure admission: this includes patients that are 
admitted for a procedure like gastrostomy, ear/nose and 
throat surgery, bronchoscopy, etc. They are admitted few 
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days prior to procedure and discharged few days after in 
order to receive IV antibiotics 
b. Infective exacerbation: this includes different situations listed 
below:  
 Severe clinical symptoms or deteriorated lung function.  
 Mild to moderate clinical symptoms or reduced lung 
function that are not improving with oral antibiotics.  
 Eradication needed of isolated microorganism/s. 
8. Number of days the patient stayed in hospital during that 
admission:  quantitative continue variable calculated as the 
difference of days between the date of admission and the 
discharge date.  
9. Admission day of the week: categorical dichotomy variable defined 
as the type of service provided by pharmacy service during the 
week. This variable was collected in the prospective study. 
a. Monday- Friday: during these days a ward pharmacist cover is 
arranged and respiratory doctor in on duty. A pharmacist is 
ward based or reachable between 9am-5pm. 
b. Saturday-Sunday: during these days there is no pharmacist 
ward cover and the doctor on duty is not necessarily a 
respiratory doctor. The on call pharmacist is reachable but has 
not necessarily had any paediatric experience or covered any 
respiratory ward before. 
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10. Discharge day of the week: as above, this was a categorical 
dichotomy variable defined as the type of service provided by 
pharmacy service during the week. 
3.5.3. Drug therapy related variables. 
As pharmacists are integrated in the multidisciplinary team with daily 
ward rounds, continued pharmaceutical assistance during hospital stay 
was studied in the best possible way in order to provide quality of the 
discharge prescription. Hence variables were collected in three different 
steps: admission of the child, hospital stay and at discharge.  
The variables in this section 3.5.3 relate to either primary care 
prescriptions, admission medicines, hospital stay or at discharge in either 
the retrospective study or prospective or collected for both studies.  
The discharge date was estimated from the prompt card attached to the 
drug chart during the admission data collection and a note was taken in 
the diary in order to capture the information during stay and analyse the 
discharge prescription on CRS. As confirmation of the date of discharge, 
the pharmacist covering 7E ward was informing the investigator of the 
potential CF children going home on the day.  
The variables studied that relate to drug therapy were the following: 
11. Related to child’s weight being recorded (dichotomy categorical): 
i.  Yes: if the weight had been recorded. 
ii.  No: when the weight was not recorded. 
12. Related to the allergy section (dichotomy categorical): 
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i.  Yes: if the allergy section had been documented.  
ii.  No: if the allergy section had not been documented. 
13. Same allergies documented in primary care as in hospital 
(dichotomy categorical): 
i. Yes: If the allergies stated in primary care records were the 
same as in CRS. 
ii. No: if there were any allergies documented different than in 
CRS. 
14. Related to type of medication commonly used in CF in the UK: 
these variables were studied in groups of drugs that were 
considered the most common regular medication in a child with CF 
treated in the UK. They were studied during the retrospective and 
prospective studies in discharge prescriptions (also on admission 
prospectively) and were dichotomy categorical variables. 
a. Nebulised mucolytic prescribed:  
i. Yes: if at least one nebulised mucolytic was prescribed.  
ii. No: if the prescription did not have any nebulised 
mucolytic.  
b. Motility, anti-reflux, proton pump inhibitor (PPI) or any 
gastrointestinal tract drugs prescribed:  
i. Yes: if there was at least one drug prescribed for the 
gastrointestinal tract. 
ii. No: if there was no gastrointestinal medication in the 
prescription. 
c. Pancreatinin prescribed in pancreatic insufficient patients: 
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i. Yes: if any pancreatinin enzymes drugs were prescribed. 
ii. No: if the prescription had non pancreatinin enzymes. 
d. Lipophilic vitamins prescribed in pancreatic insufficient 
patients:  
i. Yes: if there were any lipophilic vitamins in the 
prescription. 
ii. No: if there were no lipophilic vitamins prescribed. 
e. Nebulised antibiotics prescribed:  
i. Yes: if at least one nebulised antibiotic was prescribed.  
ii. No: if the prescription did not have any antibiotic 
nebulised. 
f. Oral or IV antibiotics prescribed: 
i. Yes: if any oral or IV antibiotic was prescribed. 
ii. No: if no antibiotic was prescribed. 
g. Inhalers prescribed: this variable was studied as salbutamol 
inhalers were constantly seen prescribed in CF children, 
although these are not considered always indispensable in CF:  
i. Yes: if there was at least one inhaler prescribed. 
ii. No: if the prescription did not have any inhalers. 
15. Prescribing doctor for discharge electronic prescription: 
qualitative categorical variable defined as the title of the doctor 
that writes the electronic prescription for that episode. 
i. Junior doctor (equivalent to a Resident 1-3 in Spain). 
ii. Senior doctor/Registrar/Clinical Fellow (equivalent to a 
Resident of year 4-5 in Spain).  
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iii. Consultant (equivalent to the specialist doctor or medico 
adjunto in Spain). 
16. Related to the pharmacist that validated the medication 
prescribed/listed on discharge, dichotomy categorical variable: 
i. Yes: if the pharmacist had validated the medication. 
ii.  No: if the pharmacist had not validated the medication. 
17. Related to the seniority of the pharmacist validating the discharge 
prescription, dichotomy categorical variable. When junior 
pharmacists were validating the prescription or the validation was 
performed by a senior pharmacist (Band 7 who had been working 
over 6 months as a B7 within the paediatric pharmacy 
department). 
Below variables 18-19 were referred as administrative analysis of 
the DL.  
18. Related to the presence discharge letter (DL) on discharge. This 
was studied in the retrospective phase, and also was a dichotomy 
categorical variable. 
i. Yes: if the patient had DL. 
ii. No: if the patient had no DL for that admission. 
19. Date of discharge letter. This variable was calculated with the 
difference of days between the date of the DL and the date of the 
day of discharge stated in the same discharge letter. The variable 
of date of DL would give an indicator of delay of DL and it was 
studied in the retrospective study. 
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20. Number of discrepancies found in DL compared with the EPR used 
as a reference.  
21. Number of drugs prescribed (cumulative continue variable): this is 
the total number of medicines that were prescribed per patient in 
the retrospective phase in EPR and DL. In the prospective phase 
this variable was collected from four information sources: the drug 
chart on and after admission, the repeat prescription in primary 
care and the discharge prescription on CRS. 
22. Number of drugs that had been prescribed as brand name per 
patient (cumulative continue variable). This variable was studied 
in EPR as indicative of using correct brand names for CF disease. 
23. Existence of high cost nebulisers (HCN) in the repeat prescription. 
This variable looked at the presence of any of the high cost 
nebulisers that had been repatriated to secondary care during 
2014-2015 taking values of yes/no (dichotomy categorical 
variable). This variable showed a potential cost lost or misuse of 
the drug if general practitioner continued prescribing these HCN 
(ig. Bramitob®, Dornase alpha, Colistin®/Promixin®…). 
3.5.4. Improvement strategies and safety actions variables.  
The following variables were collected prospectively because they were 
defined and implemented in the best capacity level as a consequence of 
the results of the retrospective study.  
24. Medicines reconciliation: categoric variable (yes or not) that 
regarded whether the pharmacist had done a medication 
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reconciliation with the patient’s regular medication within the first 
three days of admission with a minimum of 3 sources of 
information. 
25. Number of drug charts with attached prompt chart: cumulative 
continue variable that was defined to improve the prescription 
process at discharge. The aim of the prompt card was to avoid 
common mistakes found in the retrospective study or possible 
errors identified with the new computer system used. 
26. Pharmacy interventions during the hospitalisation of the patient: 
cumulative variable that defined the number of interventions 
made by any pharmacist during the time the patient was admitted 
and up to the discharge day that were reflected in the drug chart. 
This variable was captured by checking any contributions to care 
made by using green pen on the drug chart (green pen is the colour 
used by pharmacist). For capacity reasons, verbal interventions 
during ward round or whilst pharmacist was in the ward were not 
captured. The classifications used in these contributions to care 
were:  
a. Preventive interventions (non-medication errors): 
1. Lack of signature after prescribing.  
2. Weight omitted on the drug chart.  
3. Allergies not confirmed prior to prescribing.  
4. Illegible prescription or drug monitoring plan. 
b. Corrective interventions (medication errors), classified 
depending on the pharmacotherapy recommendation: 
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1. Omit or add regular drugs to treatment. 
2. Amend dose. 
3. Amend frequency. 
4. Specify/amend length of treatment not specified. 
5. Amend pharmaceutical form. 
6. Specify/amend route of administration not 
specified. 
c. Educational interventions for the professional prescriber, 
nurse or patient/relative. These include information on 
how to administer a drug given by nasogastric (NG) route 
or percutaneous endoscopic gastrostomy (PEG) route or 
oral medication that needed dose adjustment in an off 
license use of tablets such as crushing and dispersing 
tablets information, and volume required for specific 
pharmaceutical form, timing of drug administration, 
potential side effects monitoring.  
27. Pharmacist interventions or contributions to care accepted: this 
was a dichotomy categorical variable studied per hospital 
admission of each patient finding if the intervention had been 
accepted (yes) or not (no).  
28. Number of discharge prescriptions in which the pharmacy 
technician or pharmacist had previously drug listed patient’s 
regular medication on the electronic system (cumulative continue 
variable). This task was introduced a few weeks after the 
commencing period of the prospective study in order to help in 
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different ways: getting discharge medication on time; helping 
speed up the discharge process; as well as avoiding omitted 
prescribing mistakes in the recently new electronic discharge 
system implemented (CRS). This service was not always facilitated 
as it depended on the capacity of the paediatric pharmacy 
department. 
29. Communication needed with primary care (dichotomy categorical 
variable): If there was information that would need to be 
addressed to the general practitioner to update the most recent 
medication records (referring to the information collected during 
admission in medicines reconciliation and during hospital stay if 
there were any changes of pharmacotherapy too). 
i. Yes: when either justified discrepancies had been found 
or regular medication of the patient had been amended.   
ii. No: when no changes occurred of patient’s regular 
medication so no need to emphasise anything at primary 
care level. 
30. Communication provided to primary care on discharge (when 
needed) (dichotomy categorical variable): 
i. Yes: when any amendments needed were addressed to 
the general practitioner and documented in the electronic 
prescription. 
ii. No: when all amendments needed were not addressed to 
the general practitioner and therefore not documented in 
the electronic prescription. 
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3.6. Improvement opportunities. 
Improvement opportunities (I.O) were defined as any circumstances that 
cause or could cause a medication error to reach or harm a patient due 
to lack of information or incorrect information in the prescribing 
process147.  
I.O were studied in the retrospective and prospective study.  
 In the retrospective phase the I.O were analysed in EPR as well as in 
the DL, using EPR as a reference to conciliate the information written 
in the DL. 
 In the prospective phase the I.O were analysed:  
o On admission within the first three days of admission, 
evaluating discrepancies and conciliation errors comparing 
the primary care repeat prescription and the drug chart (as 
part of the improvement and safety actions with an 
exhaustive or deeper medicines reconciliation than the 
standard one). These are presented in the results chapter as 
part of the implemented improvement strategies and safety 
actions, separated from the improvement opportunities 
section.  
o At discharge the prescriptions were reviewed after validation 
up to the next 3 days after patient’s discharge, comparing the 
prompt card and the drug chart with CRS (electronic 
prescription at discharge) system after pharmacist validation.  
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3.6.1. Improvement opportunities classification. 
The channelled actions to prevent or solve the errors found in the 
retrospective phase during the quality evaluation of the discharge 
prescriptions and also during medicines reconciliation studied 
prospectively were initially classified in two types: 
a. Non-medication errors such as lack of signature in prescribing, 
allergies not confirmed prior to prescribing, omitted weight or hand 
written prescription illegible. At discharge lack of signature was not 
considered since prescriptions were made in electronic system. 
However, all non-medications errors indicated above were analysed 
during the admission and hospital stay in the prospective study. They 
were considered first steps to provide a neat discharge prescription 
with no queries to follow whilst and after prescribing at discharge. 
b. Prescription errors:  defined as medication errors and classified in the 
next section 3.7. 
 
3.7. Medication errors. 
Medication errors (ME) were defined as any preventable incident that 
could cause harm to a patient for inappropriate use of the drugs due to 
incorrect/unclear prescription, during hospital stay or at home148.  
Methods. 
158 
 
3.7.1. Classification. 
The type of ME errors followed the next classification when any of the 
following parameters (6 rights) that were considered mandatory in 
paediatric prescriptions had any unintentional mistake: 
1. Drug. 
2. Dose.  
3. Frequency.  
4. Duration. 
5. Pharmaceutical form.  
6. Route of administration.  
And all above factors were studied for any of the following subtypes:  
 Committed errors: defined as an actual mistake in the prescription 
due to lapse, lack of knowledge, lack of procedures, unawareness of 
procedures or guidelines, training need, technological causes, etc. 
 Omitted errors or missing errors: defined as any omission of essential 
information included in Table 3.3 on EPR or the discharge letter. 
The following Table 3.3 describes the definition of type and subtype of 
the medication errors. 
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Table 3.3. Definition of the type and subtype classification of the medication/prescribing errors   
 Committed: incorrect information in the actual 
prescription 
Omitted: lack of completion of the prescription 
Drug When the drug prescribed was either: 
 Wrong  for the indication needed; 
 Continued when should have been stopped;  
 Interactions/absorption problems affecting 
efficacy or causing potential medication related 
problems (itraconazol and proton pump 
inhibitors prescribed together, for instance).  
 When the name of the drug was missing in the list 
of medication in EPR but was listed in the list of 
medication in the discharge letter or viceversa; 
 When the drug that the patient was regularly on 
had been missed during admission/discharge. 
Examples: nebulised mucolytics/antibiotics, 
insulin, voriconazole, etc 
 When there was evidence that rescue antibiotics 
should be easily accessible to patients in primary 
care and these were not listed on the repeat 
prescription. Examples: Co-amoxiclav, 
Ciprofloxacin … 
Dose  When the dose was prescribed in volume or 
wrong units (excluded AquADEKs®, Sytron® and 
Lactulose). 
 When either higher than or less than 20% of the 
dose for age/weight was prescribed.  
This was checked with age/weight of the child and CF 
dosing guidelines used locally or British National 
Formulary (BNF) for children in the medication listed. 
 Dose or units missing in the prescription. 
 Dose stating “take as directed” (excluded 
pancreatinin enzyme preparations and 
creams/ointments or medication that was not 
related to CF or any associated pathology) 
Frequency  Any frequency higher than or less than 20% of 
what would be expected for that age/weight 
from the references used were considered 
mistakes. 
 Incomplete frequency or omitted in the 
prescription (saying “when required” with no 
maximum number of times per day). 
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Duration When the duration prescribed for a drug was 
incorrect and evidence to show that this was wrong 
was found. 
Considered for: 
 Antibiotics;   
 Steroids; 
 Alternating nebulised treatments; 
 New medication prescribed (if there was any 
review date to prompt doctors to check this in the 
following visit/admission). 
Pharma-
ceutical 
form* 
 Wrong pharmaceutical form prescribed; 
 Better preparation for adherence was available 
with minimal cost implications;  
 Less expensive pharmaceutical form available in 
the market;  
 Inconsistent pharmaceutical forms in the same 
prescription for other drugs; 
 Evidence that patient already taking tablets but 
liquid preparations were being issued (exception 
itraconazole liquid). 
 When more than one presentation was licensed in 
the market (referring mainly to liquid 
preparations) if the pharmaceutical form was not 
present in the prescription it was considered and 
improvement opportunity. 
 The type of nebuliser/inhaler/insulin prescribed 
was missing. 
 
Route of 
administra
tion* 
 Wrong; 
 Inconsistent with other medicines that would 
normally be administered in the same route. 
 Missing in the drug. 
*Note that Pharmaceutical form and Route of Administration were mandatory factors for prescribing whilst using EPR© system, 
whilst CRS© system would allow prescribing without this information. 
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3.7.2. Identification. 
Medication errors (ME) in the retrospective phase of the study were 
identified by observing EPR and then comparing the discharge letter (DL) 
with EPR in each patient’s discharge. The doses and frequencies were 
calculated according to CF guidelines and latest weight/age found either 
on EPR or DL. 
The DL contained a medication section which was not validated by the 
pharmacist. This section was compared to the EPR that is normally 
validated by the pharmacist prior to discharge, considering EPR was the 
latest new medication regimen the patient was prescribed on the actual 
day of discharge.  
Medication errors in the prospective phase of the study were detected 
the same way as in point 3.6 for I.O: 
 On admission: during drug history medicines reconciliation with 
primary care prescription, drug chart and patient’s own 
medication. 
 At discharge: after pharmacist validation with CRS compared with 
drug chart and information written on the prompt chart. 
The evaluation of medicines reconciliation is explained in section 3.8. 
During hospital stay no ME were analysed but the types of interventions 
that were done by pharmacist on the ward with the green pen on the drug 
chart as part of the improvement strategies and safety actions 
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implemented after the retrospective study (see variables number 26 and 
27).  
3.7.3. Causes. 
Although most errors may have multiple causes, the main cause 
contributing to the error was selected. The classification was categorised 
by the investigator when reviewing the errors, and the main 
circumstances in which the error occurred were evaluated depending on: 
the type of error, the member of staff involved, the moment and the 
time/day, the type of prescribing system used. This classification was 
made purely subjectively, however the investigator was in all cases the 
same person evaluating the cause of error in both parts of this study: 
retrospective and prospective. The causes of the prescription errors were 
classified in the following Table 3.4.  
Table 3.4. Main causes of ME and some examples that can contribute to the cause. 
Cause Examples 
Technological  Computer system that does not transfer information 
properly into final document like signature, allergy or 
weight;  
 Mandatory prescribing of 6 rights not set up on 
computer system;  
 Computer system being down. 
 Lack of safety alerts on computer system (maximum 
dose, allergies when prescribed a drug that contains 
the allergenic ingredient, drug interactions...) 
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Organisational   Guidelines not easily available.  
 Overload work, shortage of staff. 
 Weekend service admissions/discharges (no 
respiratory team and minimal pharmacy service). 
 Locum healthcare professionals not knowing the 
patient/condition or the importance of updating 
records on time. 
Communication  Lack of communication between healthcare 
professionals or between patients and healthcare 
professionals. 
 Language barrier. 
Educational  Lack of knowledge of the mistake that could be 
prevented by providing training. 
 Lack of knowledge of special procedures for 
prescribing expensive/restricted drugs. 
Human  Awareness of the correct way of prescribing but 
unintentionally mistake occurred due to lapse, forget, 
distraction. 
3.7.4. Severity.  
The severity of medication errors was categorised depending on the 
potential pharmacotherapy morbidity, as per IASER© method, which is a 
scale from 1 to 5 that describes higher severity while going up the 
values149. The following Table 3.5 defines de severity scale. 
Table 3.5. Scale to evaluate the potential severity of the medication errors (IASER® 
method). 
Grade Description 
1 ME that has not caused any harm or that the harm caused was 
reversible (with no changes in vital signs) but monitoring was 
required. 
2 ME that has caused reversible harm (with no changes in vital 
signs) but modification of treatment was required. 
 
Methods. 
164 
 
3 ME that has caused reversible harm and required additional 
treatment, prolonged hospital stay. 
4 ME that has caused irreversible harm or disability. 
5 ME that caused patient’s death. 
ME: Medication error 
  
3.8. Medicines reconciliation evaluation. 
Medication reconciliation is a formal process of obtaining and verifying a 
complete and accurate list of each patient's current medicines. It is an 
essential process for patient safety, promoting safer use of medicines 
with effective communication at the interface, particularly when patients 
are admitted and discharged from hospital150. 
In the retrospective phase, DL was reconciled with EPR as this was the 
only source of information available.  
However, medicines reconciliation evaluation was studied prospectively 
during transition of patient’s care as explained in point 3.6.  
The necessary data to elaborate the drug history (or medicines 
reconciliation on admission) was obtained from a minimum of three 
sources selected from the following:  
 patient’s own medicines (PODs);  
 information from the parents;  
 primary care records (SCR);  
 previous admission’s discharge prescription;  
 latest medication list written down in clinic;  
Methods. 
165 
 
 homecare prescription when the patient was on regular high cost 
nebulisers such as Dornase alpha or nebulised antibiotics.  
The NHS number was needed to access primary care records and 
permission was granted beforehand.  
The evaluation was made depending on: 
1. Discrepancies: 
i. Yes:  
 When the information in the primary care prescription did not 
match with the final pharmacotherapy history taken.  
 When the information in the drug chart during admission 
containing patient’s regular medication (excluding nebulised 
antibiotics) did not match the pharmacotherapy history 
taken.  
ii. No:  
 When the same medication with same dose and frequency 
the patient was regularly on was prescribed in the repeat 
prescription in primary care. 
 When the same medication with same dose and frequency 
the patient was regularly on, was prescribed in the drug chart.  
2. If the discrepancies found were justified or non-justified: 
i. Justified discrepancies were those discrepancies that had 
been intentionally changed by the prescribing doctor in order 
to optimise dose or treat according to current clinical status 
of the patient, for example. 
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ii. Non justified discrepancies were considered as conciliation 
errors which were prescribing errors occurring during 
transition of care. 
If the discrepancy was justified, it was excluded as medication error. If the 
discrepancy was not justified, it was included as reconciliation error. 
3. Number of medication errors during reconciliation found per patient. 
4. Classification (type and subtypes), cause and severity of the 
medication errors during reconciliation corresponds to the same one 
listed in Section 3.7.1. 
 
3.9. Safety actions and improvement strategies. 
From the results obtained in the retrospective phase the following 
improvement measures for the quality of the prescribing at discharge 
were implemented for evaluation in the prospective study. 
3.9.1. Print screen of the validated discharge prescription. 
In order to help minimise medication errors in the DL as well as 
discrepancies between DL and the electronic prescription -commonly 
named TTA (to take away)-, it was agreed that the DL would contain the 
same information as the electronic prescription. Therefore, the 
prescription section in the discharge prescription in CRS (normally 
validated) would be print screened and this information would be pasted 
in the word document of the DL. In this case DL would not need to be 
followed up prospectively, since it would have the same information as in 
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CRS. But also there would be consistency in information given to patients 
and primary care doctors for the same episode. 
3.9.2. In depth medicines reconciliation on admission. 
Drug history reconciliation was carried out within the first 24 hours as per 
standard policy of reconciliation, however an exhaustive or deeper drug 
history using a minimum of three sources of information was performed 
during the first 72 hours of the patient’s admission. Out of these three 
sources of information one of them had to be primary care repeat 
prescription (if consent was granted) and another one had to be 
homecare prescription (if patient was on HCN at home). Any 
discrepancies were followed up during hospital stay to avoid 
discrepancies at discharge. 
3.9.3. Prompt card. 
The following agreed prompt card was attached to the drug chart after 
reconciling the medication on admission with the aim of prompting 
prescribers of common mistakes found in the retrospective phase (as well 
as with the new discharge computer system being used at discharge, CRS) 
and improve clarity of complex drug-therapies being stopped/restarted. 
The card was added for each patient included in the prospective phase, 
which were all CF patients admitted to 7E Respiratory ward. The prompt 
card consisted of an A6 paper form containing the following information 
(Figure 3.10): 
1.  Estimated day of discharge. 
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2.  Adding route of administration in CRS. 
3.  Adding dose in CRS. 
4.  Adding frequency in CRS. 
5.  Adding pharmaceutical form in CRS. 
6.  Prompting if the patient was regularly on nebulised antibiotics.  
7.  Prompting that patient usually takes prophylactic therapy with 
certain antibiotic. 
8.  Confirmation that junior doctor confirms with Consultant the restart 
of the regular nebulised and prophylactic antibiotics (points 6 and 7). 
  
Figure 3.10. Example of the prompt card designed and attached to patient’s 
drug chart. *TTA: discharge electronic prescription, commonly named TTA for 
to take away medication from the hospital at discharge.  
 
The prompt card was presented to the colleagues working in the 
respiratory ward and training was given to junior doctors and pharmacy 
colleagues covering respiratory ward. 
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3.9.4. Follow up of patients during hospital stay to identify the 
contributions to care made by pharmacist. 
A closer follow up with monitoring of written pharmaceutical 
interventions suggested by the ward pharmacist during hospital stay. The 
written interventions were collected towards the end of the hospital stay 
by looking at the green pen interventions made on the drug chart by 
pharmacist and there were classified following the same classification as 
variable 26. 
The verbal contributions were not captured as there was no capacity to 
organise this consistently due to the different pharmacists involved in the 
respiratory ward at the time of the prospective phase.  
3.9.5. Drug listing pharmacy staff with conciliation at discharge. 
The service of a drug listing pharmacy staff in some of the prescriptions 
was offered depending on the capacity of the pharmacy service. A 
member of the pharmacy paediatric team was either drug listing in CRS 
the regular medication of the children or reconciling the discharge 
prescription with the drug chart, prior to pharmacist validation. This way, 
the physical medication of the patient (newly started or medicines 
brought from home during that hospitalitzation) was checked in order to 
ensure that there would not be delays obtaining the medication required 
at discharge. The goal of this was to facilitate patient’s discharge but 
indirectly this also helped to improve the quality of the prescriptions in 
CRS.  
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3.9.6. Communication with primary care. 
Any communication needed with primary care prescribers was written in 
the prompt card (and the most relevant one was communicated to the CF 
consultant pharmacist) to make sure this was available to be captured at 
discharge. The discharge prescription was then checked for the type of 
communication provided, whether just conciliating errors picked up in 
primary care had been communicated or drug changes during hospital 
stay were documented or both.  
 
3.10. Quality indicators. 
The indicators were defined in order to evaluate the quality of the 
discharge prescription in the retrospective phase as well as evaluating the 
impact of the improvement actions taken to reduce medication error in 
discharge prescription during the prospective phase of the study. 
Therefore, the quality indicators defined in this study were designed to 
make sure that: 
 The most physiological organs affected in CF were receiving 
treatment, as per current practice in the Department.  
 Correct prescribing of these drugs was optimised for 
age/weight. 
 Pharmacotherapy was individualised per patient, in an effective 
and safely manner. 
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 Clarity of starting/stopping/restarting or review of the 
medication was provided.  
 Communication with primary care doctors at discharge was 
achieved for patients to be able to get the right medicines in 
community. 
3.10.1 Assessment of the quality of the prescription.  
In this study the quality of discharge prescription in children with CF was 
evaluated taking into account the aspects indicated in the following 
common points 1 to 11 (for EPR, DL and CRS).  
Table 3.6 summarises the definition and the way of calculating the quality 
indicators related to points 1 to 11, with the standard values, 
corresponding to the indicators of the quality of discharge prescription 
in children with CF. 
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Table 3.6. Definition of the quality indicators of the discharge prescription, how to calculate them, standard value for both parts of the 
study in which the indicators were applied. 
Quality Indicator; 
Qi (description) 
Definition Standard 
value (%) 
Retros-
pective 
Pros-
pective 
Qi 1 (identity) Number of prescriptions with correct name and DOB* 
documented divided by the total number of prescriptions and 
multiplied by 100. 
100 ✔ ✔ 
Qi 2 (weight) Number of prescriptions with weight documented divided by the 
total number of prescriptions and multiplied by 100. 
80 ✔ ✔ 
Qi 3 (allergy) Number of prescriptions with allergies documented divided by the 
total number of prescriptions and multiplied by 100. 
80 ✔ ✔ 
Qi 4 (vitamins in 
pancreatic 
insufficient 
children) 
Number of prescriptions that contained lipophilic vitamins 
prescribed divided by the total number of prescriptions and 
multiplied by 100 (Pancreatic sufficient patients were not included 
in this quality indicator). 
80 ✔ ✔ 
Qi 5 (Creon®) Number of prescriptions that contained Creon® or another 
pancreatinin enzyme prescribed divided by the total number of 
prescriptions and multiplied by 100. (Pancreatic sufficient patients 
were not included in this quality indicator). 
80 ✔ ✔ 
Qi 6 (drug) Number of prescriptions identified with correct drugs and no 
interactions between two or more drugs (ig. fluconazole and 
itraconazol, two macrolides) divided by the number of 
prescriptions and multiplied by 100. 
90 ✔ ✔ 
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Qi 7 (dose) Number of prescriptions with correct dose divided by the total 
number of prescriptions and multiplied by 100. 
90 ✔ ✔ 
Qi 8 (frequency) Number of prescriptions with correct frequency divided by the 
total number of prescriptions and multiplied by 100. 
90 ✔ ✔ 
Qi 9 
(pharmaceutical 
form) 
Number of prescriptions with correct optimised pharmaceutical 
form divided by the total number of prescriptions and multiplied 
by 100. 
90 ✔ ✔ 
Qi 10 (route) Number of prescriptions with correct administration route divided 
by the total number of prescriptions and multiplied by 100. 
90 ✔ ✔ 
Qi 11 (duration) Number of prescriptions in which duration of certain medication 
like antibiotics or information regarding when to restart 
treatment was clear without any need of further clarification, 
divided by the total number of prescriptions and multiplied by 
100. 
90 ✔ ✔ 
*DOB: Date of birth. 
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3.10.2 Assessment of the quality of the prescription process 
To evaluate the quality of the prescription process at discharge the 
specific points Qi 12-13 (for DL) were designed and were applicable 
exclusively in the retrospective phase, in which the quality of the 
discharge prescription process was evaluated taking into account the 
following points:  
 The discharge letter was written (retrospective study). 
 The date of the discharge letter: when the discharge letter was 
dated either the same day or two days from the date of 
discharge. In case that discharge letter was not written, variables 
related to drug therapy number 20 and 21 were considered as 
missing values (retrospective study). 
The following Table 3.7 summarises the definition and the way of 
calculating the quality indicators related to quality to the prescription 
process (Qi 12 and Qi13). 
Table 3.7. Definition of the quality indicators of the prescription process at discharge 
related to DL in the retrospective study, calculation and standard value used. 
Quality Indicator: 
Qi (Description) 
Definition Standard 
value (%) 
Retros-
pective 
Qi 12 (discharge 
letter) 
Number of discharge letters written divided by 
the total of number of discharge patients and 
multiplied by 100.  
80 ✔ 
Qi 13 (date/delay 
of discharge 
letter) 
Number of episodes which discharge letter were 
dated with 2 or less than 2 days of the discharge 
date divided by the total number of discharges, 
and multiplied by 100. (Excluding the patients 
whose discharge letter was not written). 
80 ✔ 
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From the obtained values in the retrospective study it was possible to 
agree improvement strategies and these are described in the following 
section. 
3.10.3 Assessment of the improvement actions implemented. 
In order to improve global quality prescription at discharge the following 
quality indicators for the improvement actions and safety strategies 
were defined and implemented prospectively. 
The following Table 3.8 summarises the definition and the calculation 
mode of the quality indicators used to evaluate the improvement actions 
defined from results obtained in the retrospective part of this study (Qi 
14 to Qi18). 
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Table 3.8. Definition of the quality indicators of the discharge prescription related to the improvement actions implemented 
prospectively, calculation and standard values. 
Quality Indicator: Qi 
(Description) 
Definition Standard 
value (%) 
Prospective 
Qi14 (medicines 
reconciliation, variable 24) 
Number of admissions with medicines reconciliation on admission 
confirmed with a minimum of three or more sources of information 
divided by the total number of admissions and multiplied by 100. 
80 ✔ 
Qi 15 (prompt card, 
variable 25) 
Number of drug charts that had a drug chart attached to it with 
information to address for discharge divided by the total number of 
admissions/discharges and multiplied by 100. 
80 ✔ 
Qi 16 (acceptation of 
interventions, variable 27) 
Number of pharmaceutical interventions accepted after contributing 
to care divided by the total number of interventions made and 
multiplied by 100. 
80 ✔ 
Qi 17 (drug listing, variable 
28) 
Number of electronic prescriptions that had been either drug-listed or 
reviewed by pharmacy technician prior pharmacist validation divided 
by the total number of discharges and multiplied by 100. 
60  ✔ 
Qi 18 (communication 
with primary care, variable 
30) 
Number of electronic prescriptions that highlighted if changes or no 
changes had been made during hospital stay plus changes required in 
the repeat prescription divided by the total of number of discharge 
prescriptions and multiplied by 100.  
80 ✔ 
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3.10.4 Assessment of the global quality  
It was considered quality prescription in children with CF when the global 
quality and safety indicator Qi 19 was greater than 50% (quality 
standard), which overlooked the following aspects, corresponding to the 
6 rights: 
1. The correct drug/s prescribed with not known drug interactions. 
2. The correct dose for the age/weight of the patient. 
3. The correct frequency for the patient. 
4. The correct/most optimised pharmaceutical form for the patient. 
5. The correct route of administration. 
6. Duration and clear information on when to restart nebulised 
antibiotics or when to review new medication prescribed. 
The global quality was assessed through the quality indicator showed in 
Table 3.9, in which all 6 rights had to be present for each drug prescribed 
in a full discharge prescription. This indicator was measured in both parts 
of this study (from the EPR in the retrospective, and from the CRS in the 
prospective). 
Table 3.9. Definition of global quality indicator of the discharge prescription in CF 
children, calculation and standard value. 
Quality 
Indicator: Qi 
(Description) 
Definition SV 
(%) 
Retros-
pective 
Pros-
pective 
 
 𝑄𝑖19
𝐸𝑃𝑅 𝑜𝑟 𝐶𝑅𝑆
  
 
Number of prescriptions that comply with 
each of the 6 rights defined Qi6-Qi11 divided 
by the total number of prescriptions and 
multiplied by 100. 
 
50 ✔ ✔ 
SV: Standard value. 
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3.11. Data collection, data processing and 
statistical analysis.  
The information collection during the retrospective study was carried by 
the same investigator directly by observing EPR and DL and entering this 
in excel for Windows®. A data collection form was created for the 
prospective study (see Figure 3.8) and this information was entered 
prospectively in the database prepared with excel program for 
Windows®. The statistic programme used was carried out with the 
formulas from excel spreadsheet151,152,153. Statistically significant 
differences were considered when the p value was < 0.05 and when p was 
<0.001 the differences were statistically highly significant. 
3.11.1. Descriptive analysis. 
Descriptive data presentation was performed depending on the type of 
data: quantitative or categorical data. 
Quantitative data was described by statistic index based in momentous 
(mean, standard deviation and minimum/maximum) when they followed 
a normal distribution or by order based index (median and Harverage 
quartiles Q1, Q3) if they did not follow a normal distribution. Categorical 
data was shown as absolute frequencies and relatives (proportions or 
percentages) with 95% confidence interval. 
The improvement opportunities were calculated per patient, per 
admission/discharge and per 100 drugs prescribed.  
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3.11.2. Analysis between variables. 
Results were compared depending on the type of variables. Continuous 
variables and categorical variables were compared depending on the 
analysis needed for the type of variable and the way the results were 
distributed.  
Mean comparison. 
To test the assumption of normality, Kolmogorov-Smirnov test was 
applied and when normality of the variable was met, parametric tests 
were used. Student-t statistic test (when comparing two results) and 
Variance analysis (ANOVA) when more than two samples were 
compared. 
In case of Student-t test for independent samples, the calculated 
statistics for each variable were mean, standard deviation and 95% 
confidence interval.  
The statistics calculated values for each group were: mean, standard 
deviation and 95% confidence interval for the mean and ANOVA test 
of a factor was used to determine the effect of the quantitative 
variable.  
Proportions/percentages comparison. 
Chi squared (ᵪ2) was applied to compare proportions.  
Due to the mixture of variables compared in the study, the observational 
study followed either a follow up study of cohorts (when there were two 
populations: one exposed and another one not exposed), in which the 
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Relative Risk (RR) was calculated; or a case-control type of study, in which 
the Odds Ratio (OR) was calculated. In both cases the information 
provided from the analysis was to understand the magnitude of the 
differences after applying Chi squared. 
When the RR is greater than 1, informs that the proportion of the I.O 
is greater in the group of patients studied than in the control group of 
patients used as a reference. The exposed group was the validated by 
pharmacist and the not exposed group was the not validated by 
pharmacist (DL for instance). 
The OR evaluates the probability to identify cases in the control group 
in relation to the other group. The control group was EPR and the 
other group was CRS in the prospective group. Statistical significance 
for OR was considered when the unit was not included in the 95% 
confidence interval. 
3.11.3. Calculation of rates of improvement opportunities. 
Improvement opportunities (I.O) were expressed per absolute number 
and per rate using the following formulas: 
 Rate of I.O per patient: Division in which the numerator was the 
number of I.O and the denominator the number of total patients 
admitted. 
 Rate of I.O per admission/discharge: Division in which the 
numerator was the number of I.O and the denominator the total 
number of admissions/discharges. 
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 Rate of I.O per 100 drugs prescribed: Division in which the 
numerator was the number of I.O and the denominator the total 
number of drugs prescribed. This quotient was multiplied by 100 
(representing the 100 drugs prescribed). 
3.11.4. Calculation of percentages of patients, discharges and 
drugs with improvement opportunities 
 Percentage of patients with I.O: Division in which the numerator 
was the number of patients that had I.O and the denominator the 
total number of patients included in the variable studied, with the 
result multiplied by 100. 
 Percentage of episodes (discharges or admissions when 
improvement strategies and safety actions were implemented) 
with I.O: Division in which the numerator was the number of 
episodes (discharges or admissions) that had I.O and the 
denominator the total number of discharges/admissions included 
in the variable studied, with the result multiplied by 100. 
 Percentage of drugs with I.O: Division in which the numerator was 
the number of drugs that had I.O and the denominator the total 
number of drugs included in the variable studied, with the result 
multiplied by 100. 
3.11.5. Calculation of quality indicators. 
The definition and calculation of each quality indicators and the global 
quality indicator is explained in their corresponded Tables 3.6-3.9 in 
section 3.10.1. 
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4.1. Retrospective phase. 
4.1.1 Patients. 
A total of 108 paediatric CF patients were registered in the CF system 
during the years of 2013 and 2014, being 56 (52%) males and 52 (48%) 
females.  
During the retrospective phase of 24 months, the number of discharges 
(episodes) that followed the inclusion criteria was 100 which 
corresponded to 42 CF children, representing 39% of the total children 
with CF registered in the data base of the RLH (n=108).  Of these 42 
children, 16 (38%) were boys and 26 (62%) were girls, with a mean age of 
9.8 years + 4.43 (min 1, max 17). The mean of admissions per patient was 
2.43 + 2.04, with a minimum of 1 and a maximum of 8 admissions. 
There was no opposition from any of the parents to being part of the 
study. 
4.1.2. Variables.  
The studied variables are presented in two different sections describing 
patient and hospital stay variables in the first section; and drug therapy 
variables in the second section. Each section has the information that 
relates to electronic prescription (EPR) and discharge letter (DL). 
4.1.2.1. Related to patient and hospital stay variables. 
The following Table 4.1 represents the characteristics of the children 
studied together with hospital stay variables.  
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Table 4.1. Demographic variables of the number of episodes of the patients included in 
the retrospective phase (n=100). 
# Variable Results 
1 Age (mean ± SD, min-max) 10.5 + 3.9 (1-17) 
2 Gender n; % (95%CI)     male 
                                          female 
31; 31 (22.78-40.63)  
69; 69 (59.37-77.22) 
 
4 
 
 
 
 
 
 
 
 
 
3 
 
Associated pathologies n; % (95%CI) 
 Pancreatic insufficient 
 GORD 
 CF related diabetes 
 Liver disease/Gallstones 
 Other 
 
98; 98 (93-99.45)  
73; 73 (63.57-80.73) 
31; 31 (22.78-40.63) 
17; 17 (10.89-25.55) 
53; 53 (43.29-62.49) 
Number associated pathologies per patient n; % (95%CI) 
 1  
 2  
 3  
 4  
 5  
 
13; 13 (7.76-20.98)  
31; 31 (22.78-40.63) 
29; 29 (21.01-38.54) 
27; 27 (19.27-36.43) 
 0; 0 (0-3.7) 
 
6 Reason for admission n; % (95%CI) 
 Infective exacerbation 
 Elective  
 
45; 45 (35.61-54.76) 
55; 55 (45.24-64.39) 
7 Hospital stay (mean ± SD, min-max) 12.8 + 4.2 (2,22) 
10 Days of discharge n; % (95%CI) 
 Monday-Friday 
 Saturday-Sunday 
 
81; 81 (72.22-87.49) 
19; 19 (12.51-27.78) 
#: Number of variable; n: number; SD: standard deviation; 95%CI: 95% confidence 
interval; GORD: gastro oesophageal reflux disease. 
4.1.2.2. Related to drug therapy variables. 
Table 4.2 summarises the information related to drug therapy variables: 
weight, allergies and type of prescriber/validating pharmacist.  
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The DL complements the electronic prescription at discharge (EPR) and 
have a section of medicines. A total of 76% of the discharges had a DL that 
complemented EPR. 
From the total of 100 discharges, the children’s weight was documented 
in 85 (85%; 95%CI: 76.72-90.69) EPR and in 75 (98.68%; 95%CI: 93-99.45) 
DL. There were two electronic prescriptions without the weight being 
documented and without a discharge letter, this corresponds to a 13% of 
discharges with no information on the patient’s weight at all on that 
episode. 
Allergies were recorded in 98% of the electronic prescriptions, however 
only 34 (44.74%; 95%CI: 34.08-55.90) of the DL had allergy information 
documented indicating either the allergies the patient had or that there 
were no known allergies. There was no letter found corresponding to any 
allergic child whose allergies had not been documented, the key 
information in allergic children was present in DL.  
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Table 4.2. Weight, allergies documented, type of prescriber and pharmacist documented in the electronic prescription (EPR) or discharge 
letter (DL) of patients included in the retrospective phase. 
# Drug-therapy variables EPR n=100 DL n=76 P 
11 Weight documented %; (95%CI) 85.00; (76.72-90.69) 98.68; (92.92-99.77) 0.002 
12 Allergies documented %; (95%CI)                                                 98.00; (93.00-99.45) 44.74; (34.08-55.90) <0.001 
15 Prescribing doctor  
     Junior %; (95%CI) 
     Senior/clinical fellow (%) 
 
100.00; (96.30-100) 
0.00; (0-3.7) 
 
90.79; (82.19-95.47) 
9.21; (4.53-17.81) 
 
0.002 
0.002 
16 Pharmacist validation (Y/N %)  
     Junior %; (95%CI) 
     Senior %; (95%CI) 
85/15 
73.00; (63.57-80.73) 
12.00; (7.00-19.81) 
 
N/A 
 
 
#: Number of variable; n: number; N/A: not applicable; Y: yes; N: no; p: statistical value.
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On all occasions the prescriber of EPR was a Junior Doctor. Most DL were 
signed by ST2-ST3 and only 7 (9.21%; 95%CI: 4.53-17.81) by a Clinical 
Fellow/Registrar. All DL had the name of the Consultant next to the 
electronic signature of the junior/registrar signing the prescription. 
During the retrospective study, a clinical pharmacist had validated 85 
(85%; 95%CI: 76.72-90.69) electronic prescriptions at discharge and 73 of 
them (73%; 95%CI: 63.57-80.73) corresponded to validation by junior 
pharmacist. No DL were checked by any pharmacist. 
Table 4.3 summarises the number and types of drugs prescribed in EPR 
and in the medication section in the DL, as well as the number and 
percentage of drugs prescribed in EPR as brand name. 
Table 4.3. Drug-therapy variables. 
# Variables related to drug –therapy  EPR n=100 DL n=76 
 
21  
Number of drugs 1343 984 
Mean number of drugs + SD (min,max) 13.4 ± 3.9  (6,27) 12.9 ± 3.3 (7,24) 
14 Type of drugs prescribed (%) 
Nebulised mucolytics 
Anti-reflux drugs 
Pancreatinin 
Lipophilic vitamins 
Nebulised antibiotics 
Salbutamol inhaled 
Oral or IV antibiotics 
 
100 
95 
98 
97 
76 
97 
75 
 
100 
100 
100 
100 
85 
89 
70 
22 Drugs as brand name n; % (95%CI) 375; 27.92   
(25.59-30.38) 
- 
#: Number of variable; EPR: electronic prescription used at discharge in the retrospective 
phase; DL: discharge letter; n: number; SD: standard deviation. 
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No statistical diferences were found between the mean number of drugs 
prescribed in EPR and DL (p= 0.370). 
From the 1343 total drugs prescribed electronically, 375 (27.92%; 95%CI: 
25.59-30.38) were prescribed as brand names (with a mean of 3.8 + 1.73 
brand names per patient, min 1 and max 9). The most common brand 
names prescribed were Creon®, AquADEKs®, Colistin® and Promixin®.  
Table 4.4 summarises the administrative analysis conducted on the DL 
from patients included in the retrospective phase. 
Table 4.4. Analysis of the discharge letter of patients included in the retrospective phase 
and comparison with EPR of the same patients. 
# Variables of the discharge letter 
18 Discharges with DL    n; % (95%CI) 76; 76.00 (66.77-83.31) 
19 Delay of DL (days) mean + SD  (min,max) 
0-2days of delay n; % (95%CI) 
≥ 3 days delayed n; % (95%CI) 
5,6 days + 7.6 (min 0, max 37) 
35; 46.05 (35.31-57.18) 
41; 53.95 (42.82-64.69) 
20 Number of DL with discrepancies when 
compared with EPR  n; % (95%CI) 
 
75; 98.68 (92.92-99.77) 
   #: Number of variable; n: number; 95%CI: 95% confidence interval. 
4.1.3. Improvement opportunities. 
Improvement opportunities (I.O) were evaluated in EPR and DL. The DL 
was analysed in comparison with EPR and discrepancies were noted. A 
total of 533 I.O were identified, 165 (30.96%; 95%CI: 27.18-35.01) in EPR 
and 368 (69.04%; 95%CI: 64.99-72.82) in DL. The results obtained are 
shown in the next points, according to both sources of information 
evaluated (EPR and DL). 
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 EPR:  
o From 100 discharges (EPR) 81 (95%CI: 72.22-87.49) of them 
had improvement opportunities (I.O). These 81 EPR with I.O 
corresponded to 33 (78.57%; 95%CI 64.06-88.29) patients of 
the total of 42 patients included in this phase of the study.  
o In these 81 EPR with I.O a total of 165 I.O were detected, 17 
of them (10.30%; 95%CI 6.53-15.88) related to non-
medication errors I.O, whilst 148 (89.70%; 95%CI 84.12-93.47) 
corresponded to medication errors. In these 81 EPR, there 
were 1123 (83.62%; 95%CI 81.54-85.50) drugs prescribed of 
the total of 1343. 
o The percentage of drugs with I.O was 12.28% (95%CI 10.64-
14.15). 
 DL:  
o From the 100 discharges, there were 76 discharge letters and 
75 (98.68%; 95%CI 92.92-99.77) of them had non-justified 
discrepancies (or improvement opportunities) when 
comparing with EPR (conciliation errors). These 76 DL 
corresponded to 39 (92.86%; 95%CI: 80.99-97.54) patients 
and the 75 DL with I.O also corresponded to 39 patients.  
o There were 368 improvement opportunities, in which 35 
(9.51%; 95%CI: 6.92-12.94) of them corresponded to non-
medication errors and the rest 333 (90.49%; 95%CI: 87.06-
93.08) were medication errors. The total number of drugs 
prescribed in DL with I.O was 968 which corresponded to a 
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98.37% (95%CI: 97.38-99.00) of the total drugs in the DL (984 
drugs prescribed in the total DL). 
o The percentage of drugs with I.O was 37.40 % (95% CI: 34.43-
40.47). 
The above information is summarised in Figure 4.1. 
The percentage of patients with I.O, discharges with I.O and drugs with 
I.O found in EPR and DL is revealed in Table 4.5. 
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100 episodes of 
discharges
100 EPR
42 patients
1343 drugs
165 I.O
81 discharges EPR
39 patients
17 Non-
medication errors
148 Medication 
errors (ME)
76 DL
39 patients
984 drugs
368 I.O
75 discharges with DL
39 patients
35 Non-
medication errors
333 Medication 
errors (ME)
Improvement 
opportunities 
(I.O)
Figure 4.1. Diagram and characteristics of the 100 episodes included in the retrospective phase. 
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Table 4.5. Percentages of patients and discharges with improvement opportunities found 
in EPR and DL.  
 
# 
EPR n=100 DL n=76 p 
value 
Number, percentage (95%CI) of # with  I.O  
Patients  39 92.86 (80.99-97.54) 39 100 (91.03-100) 0.091 
Discharge 81 81.00 (72.22-87.49) 75 98.68 (92.92-99.77) <0.001 
N: Number; EPR: Electronic prescription report; DL: Discharge letter; I.O: improvement 
opportunities; 95%CI: 95% confidence interval. 
Statistically significant differences between I.O in the DL and EPR were 
obtained when analising the number of discharges and the total of 
number of drugs prescribed.   
The relative risk of the percentage of discharges with I.O (EPR and DL) has 
a value of 1.21(95%CI: 1.10-1.34), informing that the proportion of having 
DL with I.O is 1.21 times greater than in EPR. 
The following Table 4.6 shows the I.O studied in EPR and DL expressed as 
rates per patient, per discharge (episode) and per 100 drugs prescribed.  
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Table 4.6. Improvement opportunities expressed per patient, per discharge, and per 100 drugs prescribed. 
IMPROVEMENT OPPORTUNITIES 
 EPR DL 
  Total Non-ME ME  Total  Non-ME ME 
 n 
 (%) 
165 17  
(10.30) 
148  
(89.70) 
 368 35  
(9.5) 
333  
(90.5) 
 RATE OF IMPROVEMENT OPPORTUNITITES PER # 
# n    n    
Patient 42 3.93 0.39 3.54 39 9.46 0.9 8.56 
Discharge 100 1.65 0.17 1.49 76 4.84 0.46 4.38 
100 drugs prescribed 1343 12.28* 1.23 11.06 984 37.4* 3.6 33.85 
n: Number; EPR: Electronic prescription report; DL: Discharge letter; * Statistical Test ᵪ2 p<0.001. 
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4.1.3.1. Improvement opportunities classified by pharmacist validation. 
The I.O in EPR prescriptions at discharge previously validated or not 
validated by pharmacist are summarised in Table 4.7.  
Table 4.7. Number of I.O that were observed in EPR during the retrospective phase 
according to validation by pharmacist. 
 
 
 IMPROVEMENT OPPORTUNITITES in EPR 
n Total (n) Non-ME n (%) ME n (%) 
Total  100 165 17 (10) 148 (90) 
Validated by pharmacist 85 117 1 (0.85) 116 (99.15) 
Not validated by 
pharmacist 
15 48 16 (33.3) 32 (66.7) 
n: number; ME: medication error.  
 There were 85 (85%; 95%CI: 76.72-90.69) EPR validated by a 
pharmacist corresponding to 37 patients with a total of 1161 drugs. 
From the 85 EPR validated by a pharmacist, 69 (81.18%; 95%CI: 71.59-
88.07) of them had I.O corresponding to 30 patients with a total of 
drugs prescribed of 975 and a total of 117 (10.08%; 95%CI: 8.48-
11.94) drugs with I.O.  
 There were 15 (15%; 95%CI: 9.31-23.28) EPR not validated by a 
pharmacist which corresponded to 12 patients with a total of 182 
drugs. From these 15 EPR not validated by a pharmacist, 12 of them 
had I.O (80%; 95%CI: 54.81-92.95) corresponding to 10 patients with 
a total of 148 drugs prescribed in which there were 48 (26.37%; 
95%CI: 20.51-33.22) I.O. 
The following Table 4.8 shows the percentage of discharges with I.O and 
percentage of drugs with I.O found in EPR when prescriptions were 
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validated and were not validated by pharmacist. The results of the 
number of patients with I.O were not expressed due to limitations of the 
study, as they were a possible confounding factor. 
Table 4.8. Percentages of discharges and drugs prescribed with improvement 
opportunities found when EPR was validated and not validated by the pharmacist. 
# 
Validated by 
pharmacist 
n discharges=85 
n drugs=1161 
Not validated by 
pharmacist 
n discharges=15 
n drugs=182 
 
Relative risk 
(95%CI) 
Percentage (95%CI) of # with  I.O 
Discharge 
81.18  
(71.59-88.07) 
80.00  
(54.81-92.95) 
0.99 
(0.75-1.29) 
Total 
drugs 
prescribed 
10.08*  
(8.48-11.94) 
26.37* 
(20.51-33.22) 
2.62 
(1.94-3.52) 
n: number; I.O: improvement opportunities; EPR: electronic prescription used at 
discharge during the retrospective study; *:  ᵪ2, p<0.001. 
 
The percentage of validated and not validated by pharmacist discharges 
with I.O did not show a statistically significant difference. However, the 
percentage of I.O per total drugs prescribed showed statistically 
significant differences and the proportion of identified drugs with I.O was 
2.62 times greater in non validated prescriptions. 
Table 4.9 presents the number of I.O per episode of discharge EPR 
according to validation by pharmacist and to the type of I.O. 
And Table 4.10 represents the days of the week in which EPR were mainly 
prescribed when the patient was discharged. 
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Table 4.9. I.O detected in EPR discharge prescriptions in the retrospective phase when 
the discharge prescription was validated and was not validated by pharmacist. 
 Validated by pharmacist Non-validated by pharmacist 
n Total Non ME ME n Total Non ME ME 
85 117 1 (0.86) 116 (99.14) 15 48 16 (33.3) 32 (66.7) 
# Number and rate of # with I.O classified according to non-ME and ME  
Discharge 85 1.38 0.01 1.37 15 3.2 1.07 2.13 
100 drugs 
prescribed 
1161 10.08 0.09 9.99 182 26.37 8.78 17.59 
n: number; I.O: improvement opportunities; EPR: electronic prescription used at 
discharge during the retrospective study; ME: medication error.  
 
 
Table 4. 10. Distribution of discharges and medication errors classified by day of the week 
of the discharge and the p value of the parameters analysed. 
 Monday-Friday 
(n=81) 
Saturday-Sunday 
(n=19) 
p 
Discharge with I.O n (%) 68 (83.95) 13 (68.42) 0.122 
ME (n) 124 24  
ME per discharge 1.53 1.26 0.210 
Drugs prescribed (n) 1096 247  
ME per 100 drugs prescribed  11.31 9.72 0.471 
n: number; ME: Medication error; I.O: Improvement opportunitities; p: statistical value.   
 
Furthermore, Table 4.11 summarises the I.O of medication errors in EPR 
classified according to discharge prescription validation or not by 
pharmacist and by day of discharge: Monday-Friday/Saturday-Sunday. 
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Table 4. 11. Distribution of discharges and medication errors classified taking into account pharmacist validation and day of the week. 
 Validated discharges (n=85) Non-Validated discharges (n=15) 
 Monday-Friday 
(n=72) 
Saturday-Sunday 
(n=13) 
Monday-Friday 
(n=9) 
Saturday-Sunday 
(n=6) 
Discharge with I.O n (%) 60 (83.3) 9 (69.23) 8 (88.89) 4 (66.67) 
ME (n) 101 15 23 9 
ME per discharge 1.40 1.15 2.56 1.5 
Drugs prescribed (n) 997 164 99 83 
ME per 100 drugs prescribed  10.13 9.15 23.23 10.84 
 n: number; ME: Medication error; I.O: Improvement opportunitities.   
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Non statistically significant differences were reveled between discharges 
containing I.O validated and not validated during week days (83.3 % vs 
88.89%) and weekend (69.23% vs 66.67%). 
Differences between the proportion of ME detected at discharge during 
the week when the prescriptions had not been validated, (1.40 vs 2.56 
p=0.790) or during the weekend (1.15 vs 1.5) when the prescriptions had 
been or had not been validated (p=0.951) were not statistically significant. 
Medical errors expressed per 100 drugs prescribed when prescriptions were 
or were not validated during the week showed significant differences (10.13 
vs 23.23, p<0.001). However, when prescriptions were or were not validated 
during the weekend there were no statistically significant differences (9.15 
vs 10.84, p=0.673).  
4.1.4. Medication errors 
The following epigraphs correspond to classification and causes of the 
medication errors (ME). 
4.1.4.1. Classification of the ME. 
 The total number of ME found in EPR was 148 (116 from discharges 
validated and the rest of them from discharges not validated by the 
pharmacist) with a mean of 1.48 ME + 1.38 (min 1, max 7). This 
corresponded to 11% ME of the total medication prescribed.  
 The total number of ME found in DL were 333, in 75 (98.6%) of the 
total DL analysed (76). The mean number of ME per discharge letter 
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was 4.44 + 2.23 (min 1, max 10). This corresponds to a 33.8% of ME 
of the total medication listed in the discharge letters. 
The number, mean with standard deviation (SD) of ME and the 
percentage of types of ME detected in EPR and DL is summarised in Table 
4.12. 
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Table 4.12. Mean and standard deviation (SD) values of medication error per EPR or DL, and number and percentage (%) of medication 
errors detected in EPR and in DL classified according the type of medication error indicated in section 3.6.  
 Medication error Statistics tests 
 EPR  DL  P  RR 
(95%CI) 
Number of ME 148 333   
Mean + SD (min, max) 1.48 + 1.38 (1,7) 4.44 + 2.23 (1,10) <0.001  
n of ME per 100 drugs prescribed at discharge 11.02 33.84 <0.001  
Type of ME  n; (%) 
(95%CI) 
n; (%) 
(95%CI) 
  
Drug                          
 
38; 25.68 
 (19.32-33.27) 
23; 6.91 
 (4.65-10.15) 
<0.001 0.27 
(0.17-0.43) 
Dose                         
  
35; 23.65 
 (17.52-31.11) 
79; 23.72 
 (19.47-28.58) 
0.987 1.00  
(0.71-1.42) 
Frequency               
                      
3; 2.03 
(0.69-5.79) 
35; 10.51 
 (7.65-14.27) 
0.002 5.19 
(1.62-16.59) 
Duration                  
                    
25; 16.89 
(11.71-23.75) 
16; 4.80 
 (2.98-7.66) 
<0.001 0.28 
(0.16-0.52) 
Pharmaceutical form            
                    
44 ; 29.73 
(22.95-37.53) 
111 ; 33.33 
 (28.49-38.56) 
0.436 1.12 
(-0.50-0.16) 
Route of administration          
 
3 ; 2.03 
 (0.69-5.79) 
69 ; 20.72 
 (16.71-25.40) 
<0.001 10.22  
(3.27—31.95) 
n: Number; SD: standard deviation; ME: Medication error; p: statistical value; RR: Relative risk; 95%CI: 95 Confidence interval. 
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ME of route of administration and frequency were higher in DL than in 
EPR, with statistically significant differences; whilst ME of drug and 
duration (mainly omitted or continued drugs from the hospital stay) were 
higher in EPR than in DL, with significant differences. 
 With regard to the subtype of medication errors: 
o In EPR, from the 148 medication errors, the number of 
committed errors found were 78 (52.70%; 95%CI: 44.96-
60.58%) and these were detected in 49 (49%) EPR. The errors 
due to omitted information were 70 (47.30; 95%CI: 39.42-
55.31), and these were also found in 49 (49%) EPR.  
o In DL, from the 333 errors, 55 (16.52%; 95%CI: 12.91-20.88) of 
them were committed errors, which were found in 43 (57%) 
DL. On the other hand, 278 (83.48%; 95%CI: 79.12-87.09) 
were omission errors and were found in 72 (94.74%; 95%CI: 
87.23-97.93) DL.   
Figure 4.2 represents the percentage of the subtype of medication errors 
in EPR and DL.  
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ME: Medication error; n: number. 
Figure 4.2. Percentage of omitted and committed errors in EPR and DL. 
 
The type (6 rights) and subtype (committed or omitted) of medication 
errors are detailed below per each source of information used.  
The following Table 4.13 summarises the types and subtypes of ME found in 
EPR and DL, followed by Figure 4.3 which represents the percentage of ME 
in EPR and DL classified by the types and subtypes defined in section 3.7.1.  
 
 
 
 
 
 
 
 
 
 
 
53%47%
0%
% EPR -ME (n=148)
% Committed errors (n=78)
% Omitted errors (n=70)
17%
84%
% DL - ME (n=333)
% Committed errors (n=55)
% Omitted errors (n=278)
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Table 4.13. Percentage of medication errors committed and omitted observed in 
electronic prescription recorded (EPR) and Discharge letter (DL). 
 
Type 
and subtype of  
ME 
Percentage of medication errors 
Committed Omitted 
EPR 
n (%) 
(95%CI) 
DL 
n (%) 
(95%CI) 
EPR 
n (%) 
(95%CI) 
DL 
n (%) 
(95%CI) 
Drug 10 (12.82) 
(7.12-22.02) 
13 (23.64) 
(14.37-36.35) 
28 (40)            
(29.33-51.71) 
10 (3.60) 
(1.97-6.49) 
Dose 34 (43.59) 
(33.14-59.64) 
26 (47.27) 
(34.69-60.21) 
1 (1.43)   
(0.25-7.66) 
53 (19.06) 
(14.88-24.09) 
Frequency 3 (3.85)     
(1.32-10.71) 
4 (7.27)    
(2.86-17.26) 
0 31 (11.15) 
(7.97-15.39) 
Duration 0 1 (1.82)    
(0.32-9.61) 
25 (35.71) 
(25.50-47.41) 
15 (5.40) 
(3.30-8.71) 
Pharm form 29 (37.18)  
(27.29-48.27) 
11 (20)   
(11.55-32.36) 
15 (21.43) 
(13.44-32.39) 
100 (35.97) 
(30.56-41.77) 
Route of adm 2 (2.56)    
(0.71-8.88) 
0 1 (1.43)  
(0.25-7.66) 
69 (24.82) 
(20.11-30.22) 
 
The main committed errors in EPR corresponded to dose and 
pharmaceutical form. In DL the committed errors were also dose and drug 
followed by pharmaceutical form. Omitted errors were greater in DL than 
in EPR. In the DL the main information omitted was in pharmaceutical 
form and route of administration, whilst in EPR the main omissions found 
were in drug and duration. 
The next Figure 4.3 represents the total ME observed in EPR and in DL 
according to the types and subtypes defined in section 3.7.1.  
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ME: Medication errors; n: number. 
Figure 4.3. Percentage of subtypes of ME in EPR and EDL. 
 
4.1.4.2. Medication errors: causes. 
The most probable causes of the medication errors observed in EPR and 
DL are summarised in Table 4.14. 
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Table 4.14. Cause of Medication Errors in EPR and DL in the retrospective phase (in EPR 
and DL) with justification and estimated percentage evaluated. 
Cause Justification of the causes % 
Organizational Rotation time for CF speciality. 
Different prescriptions used and difficulties to check each 
one to confirm reconciliation. 
Lack of prioritisation and DL/EPR written up late, therefore 
screened late.  
Pharmacist validated out of hours despite weekday. 
Overload of tasks to fulfill. 
40 
Educational Junior staff in front of complex cases in short period of 
time. 
Figure of educational pharmacist for CF not totally set up 
during 2013. 
Junior pharmacist covering respiratory ward. 
30 
Technological Different systems of prescriptions.  
Lack of alert systems. 
15 
Human Forget, lapse in concentration. 5 
Communication Not applicable as not identified retrospectively - 
CF: Cystic Fibrosis 
 
4.1.5. Quality indicators. 
The following epigraphs summarise the results of the quality indicators 
described in patients and methods section 3.10.  
4.1.5.1. Quality of the prescription. 
Table 4.15 represents the difference of the quality indicators in EPR and 
DL, with the statistical tests conducted to evaluate the results.  
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Table 4.15. Quality indicators of the medication at discharge in EPR and DL. Standard 
value, ᵪ2 p value and Relative risk with 95% confidence interval (CI). 
Quality Indicator 
(Qi)  
Standard 
value 
EPR     
(n=100) 
DL            
(n= 76) 
P RR  
(95%CI) 
Qi 1 (identity) 100 100.00 100.00 N/A N/A 
Qi 2 (weight) 80 85.00 98.68 0.002 1.16 
(1.07-1.27) 
Qi 3 (allergy) 80 98.00 44.74 <0.001 0.46 
(0.36-0.59) 
Qi 4 (vitamins) 80 97.00 100.00 0.129 N/A 
Qi 5 (Creon®) 80 100.00 100.00 N/A N/A 
Qi 6 (drug) 90 70.00 69.73 0.969 0.99 
(0.82-1.21) 
Qi 7 (dose) 90 73.00 39.47 <0.001 0.54  
(0.39-0.73) 
Qi 8 (frequency) 90 97.00 63.16 
 
<0.001 0.65 
(0.55-0.78) 
Qi 9 (pharm form) 90 66.00 15.79 <0.001 0.24 
(0.14-0.41) 
Q 10 (route) 90 97.00 46.05 <0.001 0.48 
(0.37-0.61) 
Qi 11 (duration) 90 82.00 82.89 1.000 1.01 
(0.88-1.16) 
n: number; N/A: not applicable to the retrospective study.  
 
Recorded weight and duration of the treatment was recorded in DL in 
greater proportion than in EPR. The other variables were prescribed 
correctly in greater proportion in EPR.  
 
Results. 
208 
 
4.1.5.2. Quality of the prescribing process at discharge. 
Table 4.16 shows the administrative quality indicators of the discharge 
process in DL. 
Table 4.16. Quality indicators of the discharge process (administrative analysis of the DL). 
Quality Indicator (Qi)  Standard 
value  
DL             
n= 76 
Qi 12 (discharge letter) 80 76 
Qi 13 (date/delay of discharge letter) 80 46 
   n: number; DL: discharge letter. 
 
4.1.5.3. Global quality and safety of the children CF prescription. 
Table 4.17 represents the global quality of paediatric CF prescriptions 
when considered EPR and DL separately. The last column shows the global 
quality combining EPR and DL for the same episode. 
Table 4.17. Total quality indicators values for EPR and DL and Global combined EPR and 
DL quality indicator and excellence value during the retrospective phase. 
Quality 
Indicator (Qi)  
Standard 
value  
EPR    
n=100 
DL             
n= 76 
n EPR and DL with 
same correct 6R 
Qi 19 
 
50 22.00 9.21 5 
n: number; EPR: electronic prescription at discharge used in the retrospective study; DL: 
discharge letter; 6R: 6 rights (defined section 3.7.1) 
The global combined quality indicator of discharge, combining EPR and DL 
gave a value of 5, indicating the information related to medication at 
discharge in the DL reduces the global quality of the process of discharge. 
Taking into account EPR exclusively, the quality of the process does not 
achieve the standard defined: 2 of the 6 Rights variables comply with the 
90% value stated (frequency and route) although other variables of the 
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process like identity, weight, allergy and medicines to be prescribed in 
paediatrics like vitamins and Creon® achieved much higher values than 
the 90% of the standard value.  
4.1.6. Justification of the safety actions and improvement strategies 
for the prospective phase.  
According to the results obtained in the retrospective phase and with the 
agreement with the main prescribers for the prospective phase, Figure 
4.4 represents the safety actions associated with these causes, as well as 
the improvement strategies implemented in the prospective phase (also 
explained in section 3.10). 
 
 
Figure 4.4. Safety actions and improvement strategies to be applied in the prospective 
phase. 
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4.2. Prospective phase. 
4.2.1. Patients. 
During the 8 month prospective phase of the study (May-December 
2016), there were over 65 admissions of children with CF to the RLH, 58 
to the respiratory ward 7E, and 56 (97%) of them followed inclusion 
criteria. There was one case not included in the study due to failure of 
attaching the prompt card to the drug chart and medicines reconciled 
with two sources of information, so 55 (98%) admissions were included.  
These admissions corresponded to 35 different patients, 14 (40%) of 
them boys and 21 (60%) girls, with a mean age of 10.11 years + 3.89 (min 3, 
max 16). The mean admissions per patient were 1.6 + 0.8 (min 1, max 4). 
There was no opposition from any of the parents to check primary care 
repeat prescription records. 
4.2.2. Variables. 
The studied variables are presented in two different sections: those 
related to the patient and hospital stay in the first section and those 
related to the drug therapy in the second. Each section has the 
information that relates to reconciliation, primary care, interventions 
during hospital stay and discharge.  
4.2.2.1 Related to patient and hospital stay. 
Table 4.18 describes the patient demographics and hospital stay variables 
defined for this study. 
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Table 4.18 Demographic variables of the number of episodes of the patients included 
prospectively. 
# Variable Results (n=55) 
1 Age, mean ± SD, (min, max) 10.2 + 3.9 (2,16) 
2 Gender n; % (95%CI)  male 
                                       female 
19; 34.55 (23.36-47.75)  
36; 65.45 (52.25-76.64) 
4 
 
 
 
 
3 
 
Associated pathologies n; % (95%CI) 
1. Pancreatic insufficient 
2. GORD 
3. CF related diabetes 
4. Liver disease/Gallstones 
5. Other 
 
51; 92.73 (82.74-97.14)                                       
37; 67.27 (54.10-78.19 )                                        
16; 29.09 (18.77-42.14)                                       
18; 32.73 (21.81-45.90)                                               
22; 40.00 (28.12-53.19) 
Number associated pathologies per patient n; % (95%CI) 
 
 1  
 2  
 3  
 4  
 5  
 
 
7; 12.73 (6.30-24.02) 
15; 27.27 (17.28-40.23)  
 
21; 38.18 (26.52-51.39)  
12; 21.82 (12.95-34.37) 
0; 0 (0-6.53) 
5 Language of parents n; % (95%CI) 
 English as first language 
 English not first language  
              
38; 69.09 (55.97-79.72)                                                    
17; 30.91 (20.28-44.03) 
6 Children living with parents in same house n; % (95%CI) 
 With one parent 
 With two parents     
 
17; 30.91 (20.28-44.03)                                                                                                                
38; 69.09 (55.97-79.72) 
7 Reason for admission n; % (95%CI) 
 Infective exacerbation    
 Elective  
 
35; 63.64 (50.42-75.07)                         
  20; 36.36 (24.93-49.58) 
8 Hospital stay in days, mean ± SD, (min, max) 13.8 + 2.4 (6, 21) 
9 Days of admission n; % (95%CI) 
 Monday-Friday 
 Saturday-Sunday 
 
46; 83.64 (71.74-91.14)                       
9; 16.36 (8.86-28.26) 
10 Days of discharge n; % (95%CI) 
 Monday-Friday 
 Saturday-Sunday 
 
49; 89.09 (78-94.90)                                
6; 10.91 (5.10-21.83) 
#: number of variable; SD: standard deviation; n: number; 95%CI: 95% confidence 
interval. 
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4.2.2.2 Related to drug therapy. 
Table 4.19 summarises the information related to drug therapy variables: 
weight, allergies and type of prescriber/validating pharmacist.  
All drug charts had weight documented (100%) during admission. No 
weight was documented in the primary care repeat prescriptions section. 
Weight was documented in all discharge prescriptions, however when the 
computer system transcribed the information in the final document, 
weight was only present in 36 final reports, 65.5% of the total of 55 
analysed. 
There were two drug charts during drug history reconciliation on 
admission (3.6%) with the allergy section left blank but this was rectified 
during reconciliation. From 55 primary care prescriptions checked, 40 of 
them (72.73%; 95%CI: 59.77-82.72) had matched allergies of the children 
with the real most updated allergies, and in 15 (27.27%; 95%CI: 17.28-
40.23) cases the allergies documented were not accurate. These 15 
primary care prescription corresponded to 10 patients. In 50 (91%) 
discharges, CRS had allergies recorded in the final electronic prescription 
(although they were documented in all CRS prescriptions but not 
transcribed in the final report). 
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Table 4.19. Weight, allergies documented, type of prescriber and pharmacist recorded 
for patients included in the prospective study. 
# 
Variable Drug therapy variables measured in: 
 
             Reconciliation in              
Admission           PC prescription  
Discharge  
CRS 
11 Weight n (%) 55 (100) Not found 36 (65.45) 
12 Allergies (%) 53 (96.36) 40 (72.73) 50 (90.91) 
15 Prescribing n (%) 
 Junior doctor 
 Pharmacy staff     
 
55 (100%) 
 
 
N/A 
 
 
40 (72.73) 
15 (27.27) 
28 Pharmacy technician review after 
prescribing and previous 
validation n (%) 
N/A N/A 34 (61.82) 
16 Pharmacist validation (Yes) n (%) 
 Junior      
 Senior 
N/A N/A 50 (90.91)  
 
15 (30)  
35 (70) 
#: Number of variable; PC: primary care; CRS: Clinical Records System; n: number; N/A: 
not applicable.  
On 40 (72.73%; 95%CI: 59.77-82.72) occasions the prescriber of the 
discharge prescriptions were junior doctors, and 15 (27.27%; 95%CI: 
17.28-40.23) were a pharmacy member. The name of the doctor writing 
the report was not present in the final report, it was the name of the 
consultant at discharge showing in the report. 
A total of 50 (90.91%; 95%CI: 80.42-96.05) discharge prescriptions were 
validated by pharmacy: 70% (95%CI: 56.25-80.90) by a senior paediatric 
pharmacist and the remainder by junior rotational pharmacists doing the 
paediatric rotation. A total of 5 (9.09%; 95%CI: 3.95-19.58) prescriptions 
were not finalised by pharmacy or had changes to the prescription after 
having been validated. 
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Table 4.20 summarises the number, mean and type of drugs prescribed in 
admission, primary care, during hospital stay and at discharge.  
Table 4.20. Drug-therapy variables included in prospective phase in drug chart, primary 
care, hospital stay and at discharge. 
# Variable Drug chart Primary 
Care 
Hospital 
stay 
Discharge 
CRS 
21 Number of drugs 692 674 766 822 
Mean number of drugs + SD  
(min,max) 
12.6+4.08* 
(4,22) 
12.3+4.8* 
(0,23) 
13.9 + 3.3* 
(7, 22) 
14 + 4.4* 
(3,26) 
14 Type of drugs prescribed (%) 
Nebulised mucolytics 
Anti-reflux drugs 
Pancreatinin 
Lipophilic vitamins 
Nebulised antibiotics 
Salbutamol inhaled 
Oral or IV antibiotics 
N/A N/A  
100 
100 
100 
100 
0 
100 
100 
 
100 
96 
100 
100 
78 
100 
87 
#: Number of variable; PC: primary care; CRS: Clinical Records System; SD: standard 
deviation. *ANOVA test, p=0.068. 
 
All admissions had medicines reconciled within the first 3 days of 
admission and 52 of them (94.55%; 95%CI: 85.15-98.13) were reconciled 
with 4 or more sources of information checked, the rest had been 
reconciled with 3 sources of information. Fifteen different patients, 
42.86% (95%CI: 27.98-59.14) had high cost nebulisers in the repeat 
prescription despite repatriation to secondary care completed by January 
2015.  
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4.2.3. Improvement strategies implementation 
The following epigraphs relate to the strategies used through patient’s 
admission and hospital stay.  
4.2.3.1. Deeper medicines reconciliation during admission. 
During admission medicines reconciliation was performed simultaneously 
on drug chart and on SCR primary care repeat prescription. The following 
paragraphs show the obtained information: 
 There were 39 drug charts (out of 55 drug charts) with discrepancies 
and 36 (65.45%; 95%CI: 52.25-76.64) drug charts had non-justified 
discrepancies (conciliation errors) in which 473 (68.35%; 95%CI: 
64.79-71.71) drugs had been prescribed in the regular side of the drug 
chart and these corresponded to 26 patients (74.29%; 95%CI: 57.93-
85.84). A total of 97 improvement opportunities were detected, and 
3 (3.09%; 95%CI: 1.06-8.70) of them were non-medication errors 
whilst 94 (96.91%; 95%CI: 91.30-98-94) drugs of the total of medicines 
prescribed in the regular side were medication errors. 
 From the total of 55 reviewed admissions, a total of 45 primary care 
repeat prescriptions were identified with discrepancies and 39 of 
them (70.91%; 95%CI: 57.86-81.23) were non-justified in which 477 
drugs had been prescribed in the repeat prescription section (70.77%; 
95%CI: 67.23-74.08), and these corresponded to 31 (88.57%; 95%CI: 
74.05-95.46) patients. The number of improvement opportunities 
identified was 100, of which 15 (15%; 95%CI: 9.31-23.28) were non-
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medication errors and 85 (85%; 95%CI: 76.72-90.69) were medication 
errors prescribed in the repeat prescription in SCR. 
The odds ratio value of the proportions of admissions with non-justified 
discrepancies (ME or conciliation errors) detected in drug charts and in 
primary care prescriptions (out of 55 admissions) gave a value of 1.29 
(95%CI: 0.57-2.88).  
In the following Figure 4.5 is represented a diagram with the 
characteristics of the episodes included in the prospective phase, 
including the I.O and ME found during reconciliation in the drug chart and 
SCR (for primary care repeat prescription). 
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Prospective phase
Reconciliation in 
55 admissions 
35 patients
36 Drug charts with non 
justified discrepancies
94 Medication errors
26 patients
97 Improvement opportunities
39 Primary care (SCR) repeat 
prescriptions with non justified 
discrepancies
85 Medication errors
31 patients
100 Improvement 
opportunities
Figure 4.5. Diagram and characteristics of the episodes included in the prospective phase.  
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The results of the percentages of patient and admissions with 
improvement opportunities (I.O) during reconciliation in the drug chart 
and within primary care repeat prescription are summarised in Table 
4.21.  
Table 4.21. Percentage (95%CI) of patient with improvement opportunities (I.O) and 
admissions with I.O during the different phases of drug history reconciliation studied 
prospectively. 
 
# 
Drug chart n=55 Primary Care n=55 
Number, percentage (95%CI) of # with  I.O 
Patients  26 74.29 (57.93-85.84) 31 88.57 (74.05-95.46) 
Admission  36 65.45 (52.25) 39 70.91 (57.86-81.23) 
n: number; I.O: Improvement opportunities; CI95%: confidence interval 95%. 
 
4.2.3.2. Prompt card 
All 55 (100%) drug charts had the prompt chart attached to the front of 
the drug chart. All the prompt charts had information of the regular 
medication the patient was on prior to admission and that had been 
intentionally omitted for IV therapy.  
4.2.3.3. Pharmaceutical interventions 
During hospital stay, a total of 766 drugs were prescribed in the regular 
side of the drug chart, with a mean of 13.9 + 3.3 (min 7, max 22) drugs 
per drug chart. There were 136 pharmaceutical interventions, with a 
mean of 2.5 + 1.3 (min 1, max 5) per episode of admission. A total of 134 
interventions were accepted (98.53%; 95%CI: 94.80-99.60).  
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Most of the interventions were corrective followed by preventive and 
educational. Figure 4.6 represents a summary of the type of 
interventions. Figure 4.7 shows the results of the corrective interventions 
categories.  
 
Figure 4.6. Type and % of pharmaceutical interventions performed during hospital stay. 
Figure 4.7. Percentage of the corrective interventions categories. 
29%
56%
15%
% of type of pharmaceutical interventions/contributions to care 
during hospital stay captured by green pen.
Preventive  Corrective Educational
13
66
13 8 0
0
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20
30
40
50
60
70
Omit/add
drug
Amend dose Amend
frequency
Amend
pharm form
Lenght of
treatment
% Corrective interventions (N=76)
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4.2.3.4. Drug listing member of paediatric pharmacy team. 
A total of 34 (61.82%; 95%CI: 48.61-73.48) discharges had been either 
drug-listed or previously reviewed by a pharmacy technician prior to 
pharmacist validation. The total number of drugs reviewed prior to 
validation was 541. 
After pharmacy technician’s drug listing or review and pharmacist 
validation there were: 
 25 (73.53%; 95CI: 56.88-85.40) discharges with the weight present in 
the final document of discharge and all of them had information 
about allergies. 
 22 discharges (64.71% (47.91-78.51) with no discrepancies and 12 
with discrepancies (35.29%; 95%CI: 21.49-52.09) in which a total of 
19 medication errors were found, corresponding to 2.21 ME per 100 
drugs listed by a pharmacy technician. The causes of these 12 
discharges having discrepancies were mainly technological in 8 of 
them (66.67%; 95%CI; 39.96-86.19); 1 was educational and 3 were 
caused by human error. 
 24 (70.59% (95%CI: 53.83-83.17) of the drug listed discharges had 
information for the GP to update the patient’s repeat prescription. 
4.2.3.5. Communication 
Communication with primary care was needed in mostly all discharges to 
reinforce either changes or no changes. In 45 different discharges it was 
needed to amend either allergies or regular medication or both. A total 
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of 45 (81.82%; 95%CI: 69.67-89.81) of the discharge prescriptions had 
been communicated to primary care regarding changes needed to be 
amended from that admission as well as conciliation errors noted on 
admission.  
4.2.4. Improvement opportunities. 
4.2.4.1. Admission 
The results of the rates of the improvement opportunities (I.O) found 
during drug history reconciliation are presented in Table 4.22. 
Table 4.22. Improvement opportunities per patient, admission and 100 drugs prescribed 
in the drug chart and primary care repeat prescription (SCR) during medicines 
reconciliation on admission. 
I.O found during medicines reconciliation on admission 
 
Drug chart  Primary care repeat prescription 
(SCR) 
Total 
n  
Non-ME  
n(%) 
ME 
n(%)        
 Total 
n  
Non-ME  
n(%) 
ME  
n(%)       
97 3 (3.1) 94(96.9)  100 15 (15) 85 (85) 
# IMPROVEMENT OPPORTUNITITES PER # 
n Total Non-ME ME n Total Non-ME ME 
Patient 35 2.77 0.08 2.69 35 2.86 0.43 2.43 
Admission 55 1.76 0.05 1.71 55 1.81 0.27 1.54 
100 drugs prescribed 692 14.01 0.4 13.6 674 14.84 2.23 12.61 
n: Number; ME: Medication errors; #: case or condition. 
As can be seen in Table 4.22, similar rates of ME were detected on 
admission when comparing both the drug chart and primary care when 
reconciling the medication with the patient’s own drugs and confirming 
with parents when any clarification was needed. 
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The following sections present the I.O found in primary care prescription 
classified by type of admission and by socio demographic variables 
collected in the prospective phase. 
4.2.4.1.1. I.O found in primary care prescriptions classified by type of 
admission. 
Table 4.23 shows the improvement opportunities found in primary care 
prescription classified by type of admission. 
Table 4.23. Improvement opportunities found in primary care prescription classified 
depending of type of admission. 
 Infective 
exacerbation 
(n=35) 
Elective 
admission 
 (n=20) 
p Odds  
Ratio 
(95% CI) 
Repeat 
prescription  
in PC with I.O 
n  22  17    
3.34  
(0.82-13.66) 
% 62.86 85 0.085 
(95%CI) (46.34-76.83) (63.96-94.76)  
ME                                      n 47 38   
ME per PC prescription                    2.13 1.9 0.954 1.62 
(0.21-12.44) 
Drugs prescribed             n 401 291   
ME per 100 drugs 
prescribed            
11.72 13.05 0.599 1.13 
(0.72-1.79) 
n: Number; % Percentage; 95%CI: 95% confidence interval; PC: primary care repeat 
prescription; ME: medication errors. 
 
4.2.3.1.2. I.O found in primary care prescription by socio demographics of 
the patients. 
Table 4.24 shows the improvement opportunities found in primary care 
prescription classified by the socio demographic factors studied 
prospectively. Table 4.25 shows the p values after applying Chi squared. 
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Table 4.24. Social analysis of the improvement opportunities found from primary care 
during medicines reconciliation on admission. 
 English of parents as first 
language (n=55) 
Children living with  
parents (n=55) 
 Yes 
(n=38) 
No 
(n=17) 
Both parents 
(n=38) 
One parent 
(n=17) 
PC with I.O                n 
                                    %  
                           (95%CI) 
27  
71.05 
(55.24-83.00) 
12 
70.59 
(46.87-86.72) 
25 
65.79 
(49.89-78.79) 
14 
82.35 
(58.97-93.81) 
ME                              n 50 35 59 26 
ME per PC prescription    1.85 2.92 2.36 1.86 
Drugs prescribed     n 496 196 503 189 
ME per 100 drugs 
prescribed                           
10.08 17.86 11.73 13.76 
   n: Number; PC: primary care; 95%CI: 95% Confidence Interval; ME: Medication errors. 
 
       Table 4.25. Statistical analysis with ᵪ2 of the social variables indicated. 
Social variable  ᵪ2 p 
English as 1st language (yes/no) 
 % prescriptions with of I.O 
 ME per prescription 
 ME per 100 drugs prescribed 
 
0.973 
0.804 
0.005 
Children living with parents (both/one) 
 % prescriptions with of I.O 
 ME per prescription 
 ME per 100 drugs prescribed 
 
 
0.216 
0.908 
0.469 
 
The results of the medication errors found during admission in the drug 
chart and in primary care are described in section 4.2.5, together with the 
discharge information. 
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4.2.4.2. Discharge  
The discharge prescription (CRS) was evaluated and data was collected 
withing the first 72 hours of patient’s discharge, except in 5 occasions 
when the prescription was analysed a week after discharge. 
The following information resulted after evaluating discharge 
prescriptions: 
 There were 31 (56.36%; 95%CI: 43.27-68.63) discharge prescriptions 
with I.O containing 452 (54.98%; 95%CI: 51.57-58.36) drugs 
prescribed. These 31 discharges corresponded to 23 patients. A total 
of 159 non-justified discrepancies were found, of which 24 (15.09%; 
95%CI: 10.36-21.48) were non medication errors and 135 (84.01%; 
95%CI: 78.52-89.64) were medication errors.  
The percentages of patients with I.O and discharges with I.O are 
summarised in Table 4.26. 
Table 4.26. Percentage (95%CI) of patients with I.O and discharges with I.O. 
 
# 
CRS n=55 
n, percentage (95%CI) of # with  I.O 
Patients  23 65.71 (49.15-79.17) 
Discharge  31 56.36 (43.27-68.63) 
#: Case or condition; n: number; 95%CI: 95 % confidence interval; I.O: improvement 
opportunities; CRS: computer system used with discharge prescriptions during 
prospective study. 
 
Table 4.27 summarises the results of the rates of the improvement 
opportunities (I.O) found in the discharge prescriptions per patient, per 
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admission and per 100 drugs prescribed during discharge in the 
prospective phase. 
Table 4.27. Improvement opportunities (I.O) found in the discharge prescriptions 
expressed per patient, per admission and per 100 drugs prescribed during discharge in 
the prospective study. 
IMPROVEMENT OPPORTUNITIES at Discharge (CRS©) 
#  Total  Non-ME ME 
 n 
(%) 
159 24  
(15) 
135  
(85) 
  IMPROVEMENT OPPORTUNITITES PER # 
Patient 35 4.54 0.68 3.86 
Discharge 55 2.89 0.43 2.46 
100 drugs prescribed in CRS 822 19.34 2.9 16.4 
#: Case or condition; n: number; ME: Medication error; CRS: computer system used with 
discharge prescriptions during prospective study. 
 
4.2.4.3. Classification of Improvement opportunities  
In order to evaluate the relationship between I.O with pharmacist 
validation, the discharge day of the week and the socio demographic 
variables available, the classification of the I.O was performed as per the 
following sections. 
4.2.4.3.1. According to pharmacist validation. 
A total of 50 (90.91%; 95%CI: 80.42-96.05) prescriptions were validated 
by pharmacists. A total of 84 improvement opportunities were found in 
26 prescriptions that contained 383 drugs prescribed and corresponded 
to 21 patients. 
From the 5 (9.09%; 95%CI: 3.95-19.58) prescriptions not validated by 
pharmacists, there were 75 improvement opportunities detected and 
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they were in 5 prescriptions in which 69 drugs were prescribed. This 
corresponded to 5 patients. 
Table 4.28 summarises the number and percentage of the total 
improvement opportunities (non ME and ME) detected in the discharge 
prescription when the prescription at discharge was or was not validated 
by pharmacist.  
Table 4.28. Improvement opportunities detected in discharge prescriptions (CRS) 
classified by pharmacist validation or not validation.  
 IMPROVEMENT OPPORTUNITITES 
 n Total 
n 
Non ME 
n (%) 
ME 
n (%) 
Total   159 24 (15) 135 (85) 
Validated by pharmacist 50 84 18 (21.4) 66 (78.6) 
Not validated by pharmacist 5 75 6 (8) 69 (92) 
n: Number; ME: Medication error. 
Note that the number of not validated prescriptions is kept as orientate information, to 
follow the same pattern as in the retrospective study (despite being as small number). 
 
Table 4.29 summarises the percentage of discharges with I.O in validated 
and non-validated prescriptions and percentage of drugs prescribed with 
I.O in validated and non-validated discharges. 
Table 4.29. Discharges and drugs prescribed with improvement opportunities found in 
validated and non-validated discharge prescriptions prospectively. 
 
# 
Validated (n=50) 
Drugs prescribed 753 
Non Validated (n=5) 
Drugs prescribed 69 
p 
 Percentage (95%CI) of # with  I.O  
n  n   
Discharge  26 52 (38.51-65.20) 5 100 (56.55-100)  0.041 
Drugs prescribed 66 9.76 (6.95-11.00) 69 100 (94.73-100) <0.001 
#: case or condition; I.O: improvement opportunities; n: number; 95%CI: 95% confidence 
interval. 
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Improvement opportunities were more frequent in non validated 
discharges (p<0.05).  
4.2.4.3.2. According to the discharge day of the week. 
Table 4.30 represents the discharges, discharges with I.O, drugs 
prescribed and ME expressed per discharge and per 100 drugs prescribed 
according to the discharge day of the week. 
Moreover, Table 4.31 shows the information from the previous Table 4.30 
according to whether pharmacist validation was or was not performed, 
although the number of children in each category was small when 
stratifying the groups. 
 
Table 4.30. Distribution of discharges and medication errors classified by day of the week 
of the discharge.  
 Monday-Friday 
(n=49) 
Saturday-Sunday 
(n=6) 
p 
Discharge with I.O       n (%) 28 (57.14) 3 (50) 0.742 
ME                                   n 110 25  
ME per discharge        3.92 8.33 0.622 
Drugs prescribed          n 737 85  
ME per 100 drugs prescribed  14.93 29.41 <0.001 
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Table 4.31. Improvement opportunities detected classified according to pharmacist validation and day of the week. 
 Validated discharges (n=50) Non-Validated discharges (n=5) 
Monday-Friday Saturday-Sunday Monday-Friday Saturday-Sunday 
Discharge                       n 46 4 3 2 
Discharge with I.O      n; % 
                       (95%CI) 
25; 54.35 
 (40.18-67.85) 
1; 25 
 (4.56-69.94) 
3; 100 
(43.85-100) 
2; 100 
(34.24-100) 
ME                                   n 59 7 51 18 
ME per discharge   1.28 1.75 17 9 
Drugs prescribed          n 698 55 39 30 
ME per 100 drugs prescribed              8.45 12.73 130.8 60 
n: number; I.O: improvement opportunities; 95%CI: 95% confidence interval; ME: medication error. 
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No statistically significant differences were found between discharges 
containing I.O validated and not validated during week days (54.35% vs 
100%) and weekend (25% vs 100%). 
Due to the limited sample statistically significant differences were not 
found between the rate of ME detected at discharge during the week 
(1.28 vs 17, p=0.078) or during the weekend (1.75 vs 9, p=0.702) when the 
prescriptions had been or had not been validated by pharmacist. 
Statistically significant differences were found in the ME expressed per 100 
drugs prescribed when prescriptions were or were not validated during the 
week (8.45 vs 130.8, p<0.001) or during the weekend (12.73 vs 60, p<0.001).  
4.2.4.3.3. According to the social factors. 
Table 4.32 summarises the discharges, discharges with IO, drugs prescribed 
and ME expressed per discharge and per 100 drugs prescribed according to 
socio demographic information of admitted patients.  
Table 4.32. Socio-demographic analysis of the I.O found at discharge. 
 English as first language of 
parents (n=55) 
Children living with  
parents (n=55) 
Yes 
(n=38) 
No 
(n=17) 
Both parents 
(n=38) 
One parent 
(n=17) 
Discharge with I.O n; %  
                            (95%CI) 
21; 55.26 
(39.71-69.85) 
10; 58.82 
(36.01-78.39) 
21; 55.26 
(39.71-69.85) 
10; 58.82 
(36.01-78.39) 
ME                                 n 87  48  95 40 
ME per discharge        4.14 4.8 4.52 4 
Drugs prescribed        n 579 243 598 224 
ME per 100 drugs 
prescribed                      
15.03 19.75 15.89 17.86 
n: number; I.O: improvement opportunities; 95%CI: 95% confidence interval; ME: 
medication error. 
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Statistical analysis indicates that medication errors at discharge are 
not associated with the socio demographics factors assessed 
(language p=0.096 and parents together p=0.498).  
The proportion of ME per discharge did not show statistically 
significant differences (language p=0.912 and parents together 
p=0.931). 
The proportions of the ME per 100 drugs prescribed at discharge did 
not show statistically significant differences with regards to the 
language of the parents or if the children lived with one or both 
parents, p=0.666 and p=0.857 respectively. 
4.2.5. Medication errors detected during reconciliation (on 
admission) and at discharge. 
The next epigraphs show the information relating to ME. In order to ease 
visualisation of the results ME are presented together on admission and 
at discharge. 
4.2.5.1. Medication errors classified by type and subtype. 
To facilitate the results of the medication errors, firstly they are presented 
by the subtype of committed/omitted errors, and then together with type 
and subtype. The results presented are the ones found during 
reconciliation on admission analysing the drug chart and primary care 
prescription as well as at discharge analysing CRS discharge prescription. 
Regarding subtype of medication errors, the percentage of 
omitted/committed errors during medicines reconciliation on admission 
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in the drug chart and in primary care and at discharge in CRS are shown 
in Figure 4.8. The types and subtypes of medication errors are 
summarised in Table 4.33. 
 
 
Figure 4.8. Percentage of omitted or committed errors detected in the prospective phase 
during admission, in primary care and at discharge. 
% ME-Drug chart (n=94)
% Committed errors (n=34) % Omitted errors (n=60)
% ME-Primary care (n=85)
% Committed errors (n=60) % Omitted errors (n=25)
% ME-Discharge (n=135)
% Committed errors (n=19) % Omitted errors (n=116)
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 Medicines reconciliation on the drug chart during admission and 
within SCR primary care repeat prescription had the following 
findings: 
o The total number of medication errors in the drug chart 
detected was 94, of which 34 (36.17%; 95%CI: 27.18-46.25) 
corresponded to committed errors, whilst 60 (63.83%; 95%CI: 
53.75-72.82) were omitted drugs. These corresponded to 36 
(65.45%; 95%CI: 52.25-76.64) prescriptions and to 26 
(74.29%; 95%CI: 57.93-85.84) patients. 
o The total number of medication errors found in primary care 
was 85, of which 60 (70.59%; 95%CI: 60.18-79.21) were 
committed errors and 25 (29.41%; 95%CI: 20.79-39.82) 
omitted. These corresponded to 39 (70.91%; 95%CI: 57.86-
81.23) prescriptions and 31 (88.57%; 95%CI: 74.05-95.46) 
patients. 
 At discharge, there were 135 medication errors identified, of which 
19 (14.07%; 95%CI: 9.20-20.94) were committed errors and 116 
(85.93%; 95%CI: 79.06-90.80) were due to omitted information, in 
which the most common ommission was the route of administration. 
These medication errors were found in 31 (56.36%; 95%CI: 43.27-
68.63) discharges that corresponded to 23 patients.  
The following Figure 4.9 summarises information listed above. 
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Figure 4.9. Number of medication errors (ME) found in each source of information and 
indicating the subtype of the ME. Drug history encompasses reconciliation on admission 
in drug chart and primary care prescription. 
 
The next Figure 4.10 represents the types and subtypes of medication 
errors detected in each phase studied prospectively. 
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Figure 4.10. Types and subtypes of medication errors detected in each phase 
studied prospectively. 
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Below Table 4.33 summarises the types and subtypes of the conciliation 
errors found during medicines reconciliation within the drug chart on 
admission and in SCR repeat prescription in primary care, as well as at 
discharge in CRS prescription.  
Table 4.33. Medication errors per category and subtype in different phases of the 
prospective stage.  
 Admission Discharge 
 
Total n 
Drug chart 
94 
Primary care 
85 
CRS 
135 
Committed n / Omitted n 34/60 60/25 19/116 
Committed  
 
Drug                     n; % 
(95%CI) 
9; 26.47 
14.60-43.12 
30; 50  
37.74-62.26 
0; 0 
0-16.82 
Dose                    n; % 
(95%CI) 
16; 47.06 
31.45-63.26 
11; 18.33 
10.56-29.92 
3; 15.79 
5.52-37.57 
Frequency            n; % 
(95%CI) 
6; 17.65 
8.35-33.51 
4; 6.67 
2.67-15.93 
8; 42.11 
23.14-63.72 
Duration               n; % 
(95%CI) 
0; 0 
0-10.15 
0; 0 
0-6.02 
0; 0 
0-16.82 
Pharm form         n; % 
(95%CI) 
3; 8.82 
3.05-22.96 
15; 25 
15.78-37.23 
4; 21.05 
8.51-43.33 
Route                   n; % 
(95%CI) 
0; 0 
0-10.15 
0; 0 
0-6.02 
4; 21.05 
8.51-43.33 
Omitted Drug                      n; % 
(95%CI) 
52; 86.67 
75.83-93.09 
19; 76 
56.57-88.50  
5; 4.31 
1.85-9.69  
Dose                      n; % 
(95%CI) 
4; 6.67 
2.67-15.93 
6; 24 
11.50-43.43 
1; 0.86 
0.15-4.72 
Frequency            n; % 
(95%CI) 
0; 0 
0-6.02 
0; 0 
0-13.32 
0; 0 
0-3.2 
Duration               n; % 
(95%CI) 
0; 0 
0-6.02 
0; 0 
0-13.32 
2; 1.72 
0.47-6.07 
Pharm form         n; % 
(95%CI) 
4; 6.67 
2.67-15.93 
0; 0 
0-13.32 
27; 23.28 
16.52-31.75 
Route                   n; % 
(95%CI) 
0; 0 
0-6.02 
0; 0 
0-13.32 
81; 69.83 
60.95-77.43 
PC: Primary care; n: Number; CRS: system used for discharge prescriptions during the 
prospective phase; 95%CI: 95% confidence interval. 
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4.2.5.2. Causes of medication errors. 
Table 4.34 summarises the five main causes of medication errors during 
admission and at discharge. 
Table 4.34. Causes of medication errors detected prospectively classified according to the 
evaluation time. 
 Admission Discharge 
Causes of medication errors 
 
Drug chart 
n= 94 (%) 
CRS 
n=135 
Technological                                  n; % 
(95%CI) 
0; 0 
(0-3.93) 
121; 89.63 
(83.34-93.72) 
Organizational                                n; % 
(95%CI) 
37; 39.36 
(30.09-49.47) 
6; 4.44 
(2.05-9.36) 
Educational                                     n; % 
                        (95%CI) 
30; 31.91 
(23.36-42.89) 
2; 1.48 
(0.41-5.24) 
Communication                             n; % 
                               (95%CI) 
23; 24.47 
(16.89-34.05) 
0; 0 
(0-2.77) 
Human                                             n; % 
                (95%CI) 
4; 4.26 
(1.67-10.44) 
6; 4.44 
(2.05-9.36) 
n= number of total errors analysed. Note that in primary care the errors had to be 
analysed per prescription due to the lack of knowledge of each surgery, general 
practitioner, etc and the results are not presented. 
The primary cause of error on admission was organisational followed by 
educational whilst at discharge the main cause was technological (nearly 
90% of the cause of errors at discharge in the electronic prescription used 
were technological). 
4.2.5.3. Severity. 
The following Table 4.35 shows the severity of the medication errors on 
admission and at discharge. 
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Table 4.35. Percentage of ME on admission and at discharge according to the severity. 
Severity scale Admission Discharge 
Potential severity 
 1  
 2  
 3 or above  
 
78            
22               
0 
 
93                 
7                   
0 
4.2.6. Quality indicators. 
Tables 4.36-4.38 show the results defined by the quality indicators 
described in section 3.10 and whether the Qi value is in line with the 
compliance standard.  
4.2.6.1. Quality of the prescription. 
Table 4.36. Quality indicators of the CRS prescription at discharge. Prospective phase 
Quality Indicator (Qi)  Standard value  CRS n=55 
Qi 1 (identity) 100 100.00 
Qi 2 (weight) 80 65.45 
Qi 3 (allergy) 80 90.91 
Qi 4 (vitamins in P.I.) 80 100 
Qi 5 (P.E.) 80 100 
Qi 6 (drug) 90 90.91  
Qi 7 (dose) 90 92.73 
Qi 8 (frequency) 90 85.45 
Qi 9 (pharmaceutical form) 90 74.55 
Qi 10 (route) 90 69.09 
Qi 11(duration) 90 98.18 
n: number; CRS: computer system where the discharge prescription was being written 
during the prospective phase; P.I.: pancreatic insufficient; P.E: pancreatic enzymes. 
Results. 
238 
 
4.2.6.2. Quality of the improvement strategies and safety actions. 
The evaluation of the quality indicators defined to implement 
improvement opportunities and safety actions to improve the quality at 
discharge is summarised in Table 4.37. 
Table 4.37. Quality indicators studied to implement safety actions 
Safety actions strategies variables studied 
Quality Indicator (Qi)  Standard 
value 
 CRS n=55  
Qi 14 (medicines reconciliation) 80 94.55 
Qi 15 (prompt card) 80 100 
Qi 16 (acceptation of interventions) 80 98.53 
Qi 17 (drug listing technician) 60 61.82 
Qi 18 (communication with primary care) 80 81.82 
n: number; CRS: computer system where the discharge prescription was being written 
during the prospective phase. 
4.2.6.3. Global quality of the paediatric CF prescription. 
Table 4.38. Global and standard quality indicators. 
Global and standard indicators. Prospective study 
Quality Indicator (Qi)  Standard value CRS n=55 
Qi 19 global  50 41.82 
N: number; CRS: computer system where the discharge prescription was being written 
during the prospective phase. 
 
The Global quality indicator showed a result of 41.82% of the quality of 
the prescription at discharge in the prospective phase, around 8 points 
below the minimal standad value described.  
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The variables that did achieve the standard value were identity (Qi 1), 
allergy (Qi 3), vitamins (Qi 4), pancreatic enzymes (Qi 5), drug (Qi 6), dose 
(Qi 7), duration (Qi 11), medicines reconciliation (Qi 14), acceptation of 
interventions (Qi 16), and communication (Qi 18). The indicators that did 
not achieve standard values set in methodology were weight (Qi 2), 
frequency (Qi 8), pharmaceutical form (Qi 9) and route of administration 
(Qi 10), which coincide with the majority of the omitted information 
found with a technological cause of the computer system CRS.  
 
4.3. Improvement analysis in discharge 
prescriptions. 
In order to analyse the quality improvement of the discharge prescription 
achieved and taking into account confounding factors within the 
prospective study versus the retrospective study, the main characteristics 
of the variables in each episodes were evaluated.  
Table 4.39 summarises the continuous variables for both studies between 
the two population mean difference and 95%CI. 
 Table 4.39 Continues variables of the patient and hospital stay comparison with p value. 
Variable Retrospective Prospective p 
Age (mean ± SD (min-max) 10.5 + 3.9 (1-17) 10.2 + 3.9 (2-16) 0.647 
Hospital stay (mean ± SD, min-
max) 
12.8 + 4.2 (2-22) 13.8 + 2.4 (6-21) 0.106 
Drugs prescribed (mean ± SD, 
min-max) 
13.4 ± 3.9  (6-27) 14 + 4.4 (3-26) 0.383 
SD: standard deviation. 
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The following Table 4.40 summarises the categorical variables 
comparison for both studies with the statistical analysis. 
        Table 4.40. Categorical variables comparison with p value. 
Variable Retrospective Prospective P 
Gender                            male n (%)   
female n (%)   
31 (31.00) 
69 (69.00) 
19 (34.55)  
36 (65.45) 
0.652 
0.652 
 
Associated pathologies         n (%)  
 Pancreatic insufficient 
 GORD 
 CF related diabetes 
 Liver disease/Gallstones 
 Other 
 
 
 
 
 
98 (98.00)  
73 (73.00)  
31 (31.00)  
17 (17.00)  
53 (53.00)  
 
 
 
 
 
 
 
51 (92.73)  
37 (67.27) 
16  (29.09) 
18 (32.73) 
22 (40.00)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.105 
0.454 
0.805 
0.026  
0.122 
Reason for admission            n (%) 
 Infective exacerbation 
 Elective  
 
 
 
 
 
 
 
 
45(45.00) 
55 (55.00) 
 
 
 
 
 
 
 
 
35 (63.64)                          
20 (36.36) 
 
 
 
 
 
 
 
0.027
0.027 
Days of discharge                   n (%) 
 Monday-Friday 
 Saturday-Sunday 
 
81 (81.00) 
19 (19.00) 
 
49 (89.09)                                
6(10.91) 
 
 
 
 
0.192 
0.192 
       n: number; GORD: gastroesophageal reflux disease.  
 
From all above categorical variables, elective reason of admission and 
liver disease as associated pathology are the variables showing statistical 
significance.  
The proportion boys/girls for both parts of the study showed statistically 
significant differences with p<0.001 in the retrospective study and 
p=0.030 in the prospective phase. 
The number of associated pathologies is shown in the next Figure 4.11 
and did not show statistically significant differences (p>0.05) between 
both studies and the distribution of frequencies. 
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Figure 4.11. Distribution of number of pathologies associated frequencies for both 
studies. 
 
 
The following Table 4.41 summarises the comparison of the numerical 
variables for the proportions of patients with I.O, discharges with I.O and 
total drugs prescribed with I.O in EPR and CRS, relative risk, estimate 95% 
confidence interval and p value. Table 4.42 represents the compared 
rates of I.O per patient, discharge and 100 drugs prescribed between the 
retro and the prospective phase. 
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Table 4.41. P values of the percentages of patients and relative risk of the patients, 
discharges and drugs prescribed with improvement opportunities in EPR and CRS. 
# EPR CRS p RR  (95%CI) 
Percentage (95%CI) of # with  I.O 
Patients  92.86 
(80.99-97.54) 
65.71  
(49.15-79.17) 
0.003 0.71  
(0.55-0.92) 
Discharge 81.00  
(72.22-87.49) 
56.36  
(43.27-68.63) 
0.001 0.69 
(0.54-0.89) 
Drugs 
prescribed 
12.28  
(10.64-14.15) 
19.34  
(20.17-28.51) 
<0.001 1.57 
(1.29-1.92) 
EPR: Electronic prescription retrospective; CRS: electronic prescription prospective; I.O: 
improvement opportunities; RR: Relative risk; 95%CI: 95% confidence interval. 
 
The number of patients and discharges with I.O were statistically 
significantly lower in the electronic prescription system used in the 
prospective phase (CRS) compared with the one used in the retrospective 
phase (EPR). However, when analyzing the I.O per 100 drugs prescribed 
there were more I.O in CRS system, a statistically significant difference. 
 
Table 4.42. Comparison of improvement opportunities expressed per patient, per 
discharge, and per 100 drugs prescribed. 
IMPROVEMENT OPPORTUNITIES 
 EPR CRS  
 Total 
(n) 
No ME 
n (%) 
ME 
n (%) 
Total 
(n) 
No ME 
n (%) 
ME 
n (%) 
 
p 
 165 17 (10) 148 (90) 159 24 (15) 135 (85) 
 RATE OF IMPROVEMENT OPPORTUNITITES PER # 
#        
Patient 3.93 0.39 3.54 4.54 0.68 3.86 0.895 
Discharge 1.65 0.17 1.49 2.89 0.43 2.46 0.607 
100 drugs 
prescribed 
12.28 1.23 11.06 19.34 2.9 16.4 <0.001 
n: Number; EPR: Electronic prescription report; DL: Discharge letter 
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Below Table 4.43 represents the comparison of percentages of discharge 
prescriptions and drugs prescribed that had been validated by pharmacist 
and had improvement opportunities. 
Table 4.43. Comparison of percentages of discharges with I.O in both parts of this study 
(retrospective, EPR, and prospective, CRS) when the discharges had been validated by 
pharmacist. 
Discharge prescriptions with I.O after pharmacist validation 
 
EPR CRS  
P 
 # 
Validated  
N discharges=85 
Validated  
N discharges=50 
Percentage (95%CI) of # with  I.O  
Discharge 81.18 (71.59-88.07) 52.00 (38.51-65.20) <0.001 
There were fewer significantly I.O in discharge prescriptions validated by 
the pharmacist in the CRS system than in EPR.  
The next Table 4.44 represents the comparison between medication 
errors and their type of errors observed in both parts of this study 
(retrospective, EPR, and prospective, CRS).  
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Table 4.44. Comparison of mean number of ME and type of ME in both phases. 
Medication error EPR N=148 CRS N=135 P  
Mean + SD (min, max) 1.48 + 1.38 (1,7) 4.35 + 5.27  (1,22) <0.001 
Type of ME     
Drug                         N ; % 
                            (95%CI) 
38 ; 25.68 
 (19.32-33.27) 
5 ; 3.70 
(1.59-8.38) 
<0.001 
Dose                        N ; % 
                            (95%CI) 
35 ; 23.65 
 (17.52-31.11) 
4 ; 2.96             
(1.16-7.37) 
<0.001 
Frequency              N ; % 
          (95%CI) 
3 ; 2.03 
 (0.69-5.79) 
8 ; 5.93           
(3.03-11.26) 
0.091 
Duration                 N ; % 
             (95%CI) 
25 ; 16.89 
 (11.71-23.75) 
2 ; 1.48                
(0.4-5.24) 
<0.001 
Pharm form           N ; % 
                   (95%CI) 
44 ; 29.73 
 (22.95-37.53) 
31 ; 22.96       
(16.68-30.75) 
0.198 
Route of adm         N ; % 
                      (95%CI) 
3 ; 2.03 
 (0.69-5.79) 
85 ; 62.96        
(54.56-70.64) 
<0.001 
There were statistically significant differences in the types of errors in 4 
of the 6 rights defined. The main subtype of errors is shown below. 
Table 4.45 compares the subtype of errors committed/omitted found, 
with statistical results showing that both subtype of errors were inversely 
significantly different. 
Table 4.45. Comparison of the subtype of errors in both studies and statistical results. 
 EPR (N=148) CRS (N=135) p 
Committed N ; %  
(95%CI) 
78 ; 52.70 
(44.69-60.58) 
19 ; 14.07 
(9.2-20.94) 
<0.001 
Omitted         N ; %  
                 (95%CI) 
70 ; 47.30 
(39.42-55.31) 
116 ; 85.93 
(79.06-90.8) 
<0.001 
There were statistically significant differences with both subtypes of 
errors in the prospective study, with a 6.8 greater probability of finding 
omitted medication errors in the discharge prescription with CRS than 
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when the discharge was written in EPR (Odds ratio: 6.80; 95%CI: 3.79-
12.18). In contrast, the probability of committed errors to be found in the 
prospective study were 0.15 times fewer in the prospective study (Odds 
ratio 0.15; 95%CI: 0.08-0.26).  
And finally Figure 4.12 represents the quality indicators used in the 
discharge episodes (EPR and CRS) in both phases of the study.
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Figure 4.12. Comparison of quality indicators results obtained during the study. Qi: Quality indicator; *: p<0.05; **: p<0.001 
 
 
100
85
98 97 100
70 73
97
66
97
82
22
100
65.45
90.91
100 100
90.91 92.73
85.45
74.55
69.09
98.18
41.82
0
20
40
60
80
100
120
0
20
40
60
80
100
120
Qi 1 Qi 2* Qi 3* Qi 4 Qi 5 Qi 6* Qi 7* Qi 8* Qi 9 Qi 10** Qi 11* Qi 19*
Quality indicator's values in both phases of the study.
Retrospective EPR Prospective CRS
 247 
 
 
 
 
 
 
 
 
5. Discussion 
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The quality program described could be considered as a monitoring 
program of the detected medication errors and other improvement 
opportunities at discharge as well as a study following the effects of a 
stronger/deeper integration of the pharmacy team in patient’s care. The 
study allowed evaluation of the global quality of the discharge 
prescription process retrospectively and the quality of the discharge 
prescription after pharmacist validation prospectively. 
The pleasure of this study was seeing the improvement and benefit in the 
CF department; these findings helping to achieve a better quality and 
safety of the discharge prescribing in CF children, with the most updated 
drug history at discharge, despite the limitations of the methodology in 
this study carried over in tertiary care practice. The standard practice 
changed slightly the prospective study’s development, hence the study is 
a quasi experimental study.   
There were clinical benefits in regards to the identification and 
prevention of medication errors in children with CF admitted at Barts 
Health NHS Trust. The study shows different origins of medication errors 
in different type of prescriptions/medication list: drug chart, primary care 
repeat prescriptions, and discharge electronic prescription in two 
different systems as well as a blank word document without existence of 
mandatory fields to be filled in.  
Considering that the patient is at the end of the chain of the prescribing 
process, when information is not consistent this leads to confusion 
amongst parents (or GPs) and a potential reduction in adherence to 
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pharmacological treatment or even incorrect administration of the 
medication, but also a potential loss of trust of the patient in the 
prescribers due to queries that need to be solved a posteriori. 
Medication errors can occur at any stage: prescribing, transcribing, 
dispensing, drug-administration, with particular risk with the paediatric 
population due to lack of appropriate paediatric formulation. The 
inconsistency of the medication errors contained in all analysed 
prescriptions reflects a possible lack of proactive communication 
between primary and secondary/tertiary care with a potential impact on 
the patient, in concordance with Wong et al’ s investigations regarding 
communication between health professionals and inadequate clinical 
practice154.  
Due to the complexity of the prescribing system (or the lack of a unique 
prescribing system), and the necessity to structure the best medicines 
optimisation in these high frequency patients coming to hospital for a 
long stay, it is of special importance to note that the use of unlicensed 
medication, off label preparations, high cost drugs or medication not 
approved in certain formularies can lead to confusion, prescribing 
mistakes and delays of treatment. This could also lead to a patient 
unaware of being a victim of medication errors. All due to lack of simpler 
prescribing systems that may have been mainly designed by no clinical 
experts with a compromised commissioning vision.  
As pharmacists are integrated in the multidisciplinary team the evaluation 
of the medication errors was done after the discharge prescriptions had 
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been validated by a pharmacist in most of the cases, noting that these 
errors had not been spotted by the pharmacist validating the 
prescription. When the patient had left the hospital, with no pharmacist 
validating the prescriptions, the errors made belonged to junior doctors.  
In the prospective phase studied, the improvement strategies were 
implemented and the figure of the technician was added a posteriori as 
the drug listing role taking was helping the structure of the discharge 
process. Primary care repeat prescriptions were analysed and the errors 
found belonged to the GP looking after the patient. It was not possible to 
analyse the cause of these errors (primary care) although it is likely to be 
a combination of organisational and educational factors of certain 
formulations mainly used in CF. 
In both phases of the study, the discharge prescriptions were analysed 
after the final pharmacist validation. The electronic prescriptions 
investigated in the retrospective phase of the study (EPR) were the 
control group to evaluate the quality of the process at discharge, as well 
as to typify the errors and their causes. The discharge letters containing 
the medication list of the medicines at discharge do not use any 
prescribing system but are a blank word document. Hence this type of 
prescribing gives an idea of medication errors when no prescribing 
fields/guidelines are easily visualised. In the prospective phase, the 
medication errors were also detected in the primary care repeat 
prescription and on the drug chart when patients were admitted. 
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However, the structure of the multidisciplinary CF team is to be 
applauded, especially the clinical nurse specialists who respond to broad 
enquiries, solving them and filtering them to the most relevant 
department when necessary, in which an agreed decision is usually taken 
by the Consultant. The results of the validation by pharmacist in the 
discharge prescriptions show reflects the established pharmacy members 
of the paediatric CF team as the team gains greater experience with this 
complex disease and individuals. This allows stronger pillars in the CF 
structure. 
 
5.1. Variables studied.  
5.1.1. Patients and hospital stay variables. 
All included patients in the study followed inclusive criteria and there 
were no differences of the population between both studies. The 
retrospective study was considered as a control group. The number of 
patients being admitted increased as time passed which correlates with 
the fact that there were 131 patients registered under Barts Health in the 
paediatric CF database of 2016, in comparison to the number of CF 
children in 2013-2014, which was 108 (an increase of 21.3%). This was 
reflected in a higher number of admissions during the prospective study, 
despite that the covered period did not include the full winter period in 
the prospective time. This could be related to the CF service being more 
solid after the major refurbishment of the RLH that finished beginning of 
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2012. Furthermore, in the last past years the diagnostic technique has 
become more normalised in different countries and an increasing number 
of CF patients moving from abroad to the catchment area was noticed.  
The mean age of the admissions was similar in both parts of this study. 
Considering that a large proportion of the children included in the 
retrospective phase were also admitted during the prospective phase 
electively the age of admissions could have been higher, but in fact the 
mean age and standard deviation remained very similar in both studies 
therefore pre-adolescent age was the mean admission age in CF children.  
Regarding the gender of admissions, during the study it was noted that 
girls were admitted to hospital more frequently than boys without clinical 
evidence explaining this fact in CF children. Although the sample might 
not represent the actual CF population gender ratio, this was discussed 
with experts whose belief is that girls prior to and during puberty might 
have a depletion of the immune system causing more girls to be admitted 
to hospital than boys.  Boys normally reach puberty after girls, and boys 
generally tend to be more physically active than girls. Very little literature 
has been found to support a general immune system evidence between 
boys and girls but one study investigated sex-based effects of 
immunological changes in well trained swimmers and the effect of a 
maximal incremental swimming task on immunity was shown to be 
gender dependent and more noticeable in men155. Therefore, boys might 
have stronger immune systems during these years or simply the 
difference of physically active time or they might have adhered to 
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treatment for a longer period. Another study evaluated the sex 
discordance in asthma and wheeze prevalence but no conclusive or 
relevant information that could relate to this study was found156. There is 
evidence that during puberty (a difficult time for teenagers) there is a 
potential decrease of adherence in pharmacological treatment157,158. No 
statistically significant differences were found when comparing both 
phases with the number of admissions per gender, however in each phase 
of the study there were significant differences in girls admitted to hospital 
in greater frequency than boys. Further studies would be required to 
explain why girls were admitted more frequently than boys or whether 
this occurs in other hospitals or simply that there were a few very sick 
girls during the time of the study in Barts Health. 
All children had at least one pathology associated to CF and the most 
common was pancreatic insufficiency. The hospitalised children in the 
prospective study had liver disease with significant greater frequency 
compared with the retrospective study (Table 4.40). Although this could 
be a random cause and shows that both populations in the studies were 
not homogeneous (only in this aspect), the results of this study should not 
be affected by this factor. According to the CF Trust website159 CF can 
cause the blockage of small ducts in the liver, leading to liver disease. 
Although this only happens in about eight per cent of people with cystic 
fibrosis and can sometimes be managed by drugs, it is a serious health risk 
and could require a liver transplant. Possible explanations could relate to 
liver disease being a natural fact of CF, or to drug induced liver problems 
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due to the number of drugs patients are exposed to from a young age; 
but it could simply also be that the department had agreed to share 
patients with other hospitals that specialise in liver problems. Therefore, 
further studies are required to understand what could cause a greater 
frequency of liver disease during the prospective phase or whether this is 
a random finding, but especially monitor if this might not, potentially, be 
the beginning of increased cases of liver disease in the studied population.  
In regards to the reason for admission, the prospective phase of the study 
showed more hospital admissions due to exacerbations than in the 
retrospective, and there were significant differences (Table 4.40). As 
patients were treated the same way, by the same group of professionals 
and also similar practice such as request microbiology results to adequate 
best individualised treatment, the only explanation to these findings is 
random ( due to the periods compared 8 months versus 24 months).  
UK planned days of hospital stay in admissions for elective IV antibiotic 
therapy in CF patients are normally 14 days, unless the planned admission 
is for a pre-procedure when the child comes into hospital 3 or 4 days 
before the procedure and normally these patients are discharged within 
the first week after procedure. Elective patients’ main hospital stay shows 
two days difference with exacerbations and this indicates that some of 
the patients are repatriated to their local hospitals to finish the IV 
treatment or if the parents are trained to give intravenous medications, 
the patient might go home after multidisciplinary discussion. However, if 
the admissions are due to an exacerbation, the number of days in hospital 
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tends to be higher than 14 days. There were no significant statistically 
differences regarding the mean number of days a patient was hospitalised 
in both studies (Table 4.39).  
Regarding the discharge days of the week, elective admissions mostly 
occurred during week time as the discharge day matches a week day for 
14 days of hospitalisation. The results show similar numbers in both parts 
of the study in admissions during the week and at weekends. In the 
prospective study, there were fewer discharges during the weekend 
(10.91%) when compared with the retrospective study (19%) although 
they were no significant differences (Table 4.40). This lower number of 
discharges during the weekend indicates that the service tries to avoid 
discharging at that time of the week as there is not a full respiratory, 
physiotherapy, dietician and pharmacy service.  
5.1.2. Drug-therapy related variables. 
Regarding the patient’s weight in discharge prescriptions, in the 
retrospective phase this was consistently recorded and this information 
was found in the multidisciplinary section in EPR, mainly entered by the 
validating pharmacist. When the weight information was missing in EPR, 
this information was found in the DL. Only 2 discharges had no records of 
most recent weight in either EPR or the discharge letter. However, during 
the prospective phase it was noticed that when the electronic 
prescription was automatically transferred to the final form, the 
information of the weight was missing, despite being present in the 
original CRS prescription designated space for the weight. This was a 
Discussion 
256 
 
technological cause which meant that doctors missing the induction 
pharmacy talk could be unaware of this fault in the system, unless they 
are alerted to it. Furthermore, the prompt card had not factored the 
weight in the points to remember. Although the multidisciplinary team 
communicates well there are constantly new staff (doctors and 
pharmacists) that might not be aware of this problem. The results of the 
proportions of weight documented in the prospective phase of the study 
showed statistical significance when comparing with the proportions of 
documented weight in retrospective phase (Figure 4.12, Qi2*, p=0.005) 
in favour to the retrospective study documenting the weight in higher 
proportion of prescriptions. During the evaluation of the improvement 
strategies, weight on admission was recorded in all cases and this was 
documented on the drug chart. The access to primary care prescription 
via SCR had no records of the weight of the patient but this does not mean 
that GPs do not have access to this information, as it might be recorded 
in another section not accessible in SCR. 
The paediatric department has a great culture of allergies being checked 
and documenting them in the appropriate places, and this was shown 
retrospectively on EPR and although not all allergy status were 
documented in the DL, all children who had allergies had been 
documented in the DL. However, during the prospective phase at 
discharge another problem was noticed with CRS: when allergies were 
not entered in a specific way in CRS, this information was not transcribed 
in the final document, unless this information was typed in another free 
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type section (usually by pharmacy staff), with significant differences 
(Figure 4.12, Qi 3*, p=0.043). However, when performing medicines 
reconciliation in a deeper perspective, it was noticed that primary care 
prescriptions had not updated the most recent allergies in all the children. 
Although this could be considered a problem, the likelihood of a mistake 
to occur would be low since the allergies of these CF children were mainly 
for intravenous presentations, which are rarely dispensed in community. 
However, due to the risk of real allergies and prescribing, further studies 
might be relevant for investigation in primary care and hospital for other 
population with medication allergies that refer to oral drugs taken and 
that are frequently prescribed in primary care too. 
Considering that any concurrent use of 5 or more drugs is polytherapy 
and concurrent use of 10 or more drugs is excessive polytherapy160, 
excessive polytherapy would be the accepted way in which the majority 
of CF children are treated in the United Kingdom and in other developed 
countries, regarding the number and type of drugs. The common drugs 
seen prescribed for CF children were consistently written up by the junior 
doctors in both studies, and these drugs were analysed in groups. Brown 
and Bussell confirm that the treatment of chronic illnesses includes long 
term use of pharmacotherapy but also note that approximately 50% of 
patients do not take their medication as prescribed161. Although this 
study does not review patient’s adherence, a potential risk of adherence 
was observed when statistic p value was not too far from being 
statistically significant between the mean number of drugs prescribed in 
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different stages of patient’s care, including primary care and at discharge 
with CRS (p=0.068, Table 4.20). A possible justification found by the 
investigator is that some patients were regularly admitted to hospital for 
IV therapy and they might just have kept receiving the medication at 
discharge and patients did not have the necessity to add this to the repeat 
prescription. Another posible justification was that high cost nebulised 
medication was taken into account at discharge but these drugs are 
dispensed via homecare and not through primary care. Although a 
percentage of patients still had high cost nebulisers in their repeat 
prescription, this was also taken into account, therefore the possibility of 
counting more number of medication in one or another prescription 
should be disregarded for such statistical analysis.  
Pancreatic insufficient children must take pancreatinin enzymes and 
lipophilic vitamins to ensure that fat-soluble nutrients/vitamins are 
absorbed in the gastrointestinal tract and do not compromise growth. All 
the children that came to hospital and were discharged home with any 
pancreatinin enzyme were pancreatic insufficient; the percentage of 
children who did not have pancreatinin prescribed at discharge 
corresponded to children who were pancreatic sufficient. The advice on 
how to take the pancreatinin enzymes was written mainly by pharmacists 
indicating to take them with meals. Information on taking them also with 
lipophilic vitamins was not consistent in the majority of the electronic 
prescriptions. However, this was not studied in detail as this area belongs 
to a dietician who has a closely monitors the patients. The role of the 
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dietician in the multidisciplinary team within the CF department is of high 
importance and children/parents have regular meetings with the 
dietician from the early diagnosis moments to make sure they understand 
how to take the pancreatinin enzymes and when to increase or decrease 
the daily number of doses, helping children and parents to find signs of 
steatorrhea or potential Distal Intestinal Obstruction Syndrome (DIOS) 
amongst other educational advice and nutritional input. 
Anti-reflux drugs, prokinetics and proton pump inhibitors are part of daily 
routine medication in CF prescriptions in the UK. Around 95% of the 
discharge prescriptions (in both parts of the study) contained at least one 
drug used for the gastrointestinal tract. This high number indicates either 
over prescribing or the fact that CF children need support with drugs to 
palliate symptomatology caused by associated pathologies like gastro-
oesophagus reflux disease (GORD). It is, however, noted that not all 
patients had in their records GORD as associated pathology, only around 
70% in both parts of the study which can indicate that doctors are treating 
for reflux but not documenting or considering GORD as an associated 
pathology.  
Nebulised mucolytics are necessary for the majority of children with CF, 
although it could be thought that small children might not use nebulitic 
mucolytic nebulised due to the difficulty for them to adhere and induce 
cough. However, the fact that all patients had nebulised mucolytics 
written in the prescription shows that the unwell children coming to the 
hospital are the ones who need to take the drug. Dornase alpha was 
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correctly prescribed following EU recommendations in children from a 
certain age and this drug was only not seen in any prescription in small 
children (less than 6 years old) in the retrospective phase. The prospective 
phase showed few children under 6 years old on Dornase alpha and this 
was justified in some cases due to a greater need of improving mucociliar 
clearance. The mucolytic prescribed in all prescriptions was hypertonic 
saline, followed by Dornase alpha (combined) and fewer patients had the 
additional mucolytic N-acetylcysteine, an intravenous pharmaceutical 
form for nebulise use (unlicensed). 
Beta agonists would not be expected to be in the majority part of CF 
prescriptions as the disease does not require the beta receptors 
stimulation. However, as the prescriptions analysed belonged to unwell 
children, this drug (mostly Salbutamol as main beta agonist) is prescribed 
to avoid any possible bronchoconstriction that hypertonic saline could 
cause, as well as making sure that after its intake and following 
physiotherapy, the nebulised antibiotics will penetrate in the lungs in the 
best possible way. Also, hypertonic saline might cause 
bronchoconstriction, hence Salbutamol would help reversing any 
bronchocontruction if this was to occur. 
The drugs prescribed as brand names were the expected brand names as 
per the CF drug guidelines. Hence this information was not considered 
necessary to be followed up prospectively. 
High cost nebulisers (HCN) were repatriated to secondary care by the end 
of the UK financial year in 2015 as these drugs are considered as Hospital 
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only drugs/prescriptions and are commissioned by NHS England. This 
means that HCN should not appear in primary care repeat prescriptions.   
Notwithstanding, a total of 16 prescriptions from 15 different patients, 
(42.85%) had high cost nebulisers in the repeat prescription despite 
repatriation to secondary care completed by March 2015, indicating an 
opportunity to improve primary care prescribing process too. It was 
imperative to communicate these findings with the general practitioner 
directly. 
Discharge letters complemented the electronic prescribing in EPR, 
however in few cases were ready to be given on the same day of 
discharge. Generally, parents take home the electronic prescription the 
same day their child is being discharged, together with the new and 
regular medication. The discharge letters are used as a guide for parents 
and other future prescribers and they provide more information hence 
each letter takes longer to finish and as a consequence they are normally 
posted to their home after the day of discharge. Not all discharge letters 
were written within the first two days after discharge. As discharge letters 
were written in a free field not specified for prescriptions and not 
validated by a pharmacist the results showed a higher opportunity of 
error.  
The study shows that the discharge prescribing is taken mostly by junior 
doctors in both studies. The validation by a pharmacist in the prospective 
study shows an increase in the seniority of pharmacists validating the 
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discharge prescriptions (TTAs), reflecting the favourable results of 
medication errors captured by the investigator. 
5.1.3. Confounding factors. 
A confounding variable is a variable other than the independent variable 
that may affect the dependent variable. As per the type of the study 
conducted, selection bias, information bias, and confounding were 
considered to be present to some degree162. However, the retrospective 
data was collected by the same person and the analysis was also 
performed by the same observer all the time for each patient and each 
admission. Potential confounding variables were identified at the design 
of the prospective study to ensure that valid information was collected in 
order to avoid erroneous conclusions about the relationship between the 
independent and dependent variables. The unique different act to add in 
the prospective part was the prompt card, as the other strategies 
proposed were already existent in a normal ward pharmacist’s day. 
Nevertheless, a closer monitoring was to occur as well as a deeper 
medicines reconciliation during admission in order to help better 
communication between tertiary and primary care.  
However, the collected results of all variables and the analysis of the 
discharge electronic prescriptions (CRS) were done by the same person in 
all cases, hence confounding factors would be minimal for this study.  
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5.2. Improvement opportunities. 
The improvement opportunities looked at the improvement needed 
within the pharmacy department at discharge. The I.O were studied to 
help understand pharmacist validation errors not picked up after 
validating the TTA. However, indirectly medication errors from the 
prescribers were captured retrospectively in the non-validated EPR 
prescriptions and from all the DL (although the DL are not per se a formal 
prescription but a white word document with the list of the medication 
written on it, which could provide information on number of ME by free 
typing without using a non standard prescribing system). 
EPR showed 2.2 times of less I.O than DL (Figure 4.1). The trend of the I.O 
in EPR was slowly changing as the prescriptions were studied towards the 
end of the 2014 in the retrospective phase, likely due to the pharmacist 
being more exposed to the respiratory ward at that time, and gaining 
greater seniority. Nevertheless the definition of the retrospective part of 
the study did not break up the time of data collection. 
The percentage of drugs prescribed with I.O were significantly less in 
validated prescriptions (p<0.001, Table 4.8), meaning that the greater the 
participation of the pharmacist in clinical scenarios the lesser the risk to 
patients. 
Although the discharge letter is extremely comprehensive and useful, 
omitted information in the discharge letters was found in higher 
proportion than in EPR. As a consequence the opportunities of error 
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found in the discharge letters were twice greater than the electronic 
prescribing. During the retrospective investigation it was also noticed 
information in some drugs copied and pasted from previous discharge 
letters and, as a consequence, repeated errors as well as not listing the 
most updated number of medicines the patients were taking. Another 
cause for the errors found in DL could be that some junior doctors typed 
the DL after patient’s discharge and it was likely that there was no drug 
chart against which to compare the medicines taken during hospital stay 
but also there was no pharmacist input in validating this information in 
DL.  
The causes of medication errors were estimated during the retrospective 
part of the study and the investigator estimated that the greatest causes 
were, first, the organization of the NHS system and second, educational. 
Rotational staff stay in the specialist area for 6 months, doctors and 
rotational junior pharmacists. Doctors move hospitals nationally with 
different electronic prescribing systems and drug charts lay out. This 
means they must get used to the process of the prescribing system fast. 
Therefore, however intense the educative input from the respiratory 
department is given in CF prescribing, and considering that the essence 
of prescribing should be the same in any country, still there might be 
some confusion on the process of prescribing, being then a cause of error. 
Furthermore, listing the medication in a word document as it was the case 
for the DL, is a cause of the organizational system since there is no way of 
prompting to add key information in the prescription like the 6 rights. 
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Also, junior pharmacists are required to have multiple skills that need are 
applied to paediatric prescriptions even when the juniors have had 
limited or nil exposure to paediatrics or the juniors rotating in paediatrics 
have limited clinical exposure with CF children. Furthermore, the 
prescribing by junior doctors is not always supervised by consultants but 
a pharmacist on the wards and pharmacist that validated the majority of 
the prescriptions during the retrospective phase of the study were junior 
pharmacists within a rotational post too.  
During the prospective stage, I.O were investigated in different steps 
looking from different angles of the patient’s prescribing care. The initial 
aim was to get a completed drug history on admission and monitor any 
changes in order to communicate this to primary care at discharge, with 
an updated accurate prescription at discharge. Therefore primary care 
prescriptions I.O and the drug chart on admission were studied together, 
and parent/patient interviews were carried out unobtrusively until a 
complete and accurate drug history was confirmed. The methods did not 
include any specific sort of interview of the parents, hence this was not 
accounted in any specific way for this study and when the investigator felt 
that the patient could benefit from some education in order to optimise 
treatment, this was provided in situ or referred to the CF consultant 
pharmacist. Further studies would be required to follow the trend of a 
patient’s understanding of their disease and adherence to treatment. 
Regarding primary care, the number of I.O found in the repeat 
prescriptions were similar to the ones on the drug chart on admission but 
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there were more patients with I.O in primary care repeat prescriptions 
than in the drug chart on admission, however the origins of the 
medication errors were different (Figure 4.5). This indicates a possible 
lack of time in primary care surgeries to adapt continuous new treatments 
or changing treatment/doses in patients that come to hospital frequently.  
When the I.O were studied per type of admission, there were no 
statistical differences, although the elective admissions had greater 
percentage of primary care repeat prescriptions with I.O in comparison 
with infective exacerbations (p=0.085, Table 4.23). 
In the UK, children with CF from more disadvantaged areas have worse 
growth and lung function compared with children from more affluent 
areas163.  In general, the East London population experience higher than 
average levels of deprivation with some boroughs ranking 7th most 
deprived in London and 22nd nationally164. Basic social aspects that could 
directly affect patients with medication errors of administration or even 
understanding of the necessity of good adherence to treatment were 
studied. In primary care prescriptions, there were no significant statistical 
differences between the groups of children whose parents spoke English 
as a first language or did; nor between children living with both parents 
or with one parent (and likely to spend the weekends or holidays in 
another house, with the all the medication transported with them). 
Despite the number of primary care prescriptions with I.O found in the 
group of parents with English language as their first language did no show 
statistical differences, the rate of ME per 100 drugs prescribed were more 
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frequent when parents did not speak English as their first language 
(p=0.005, Table 4.25). In regards to the other social aspect studied, the 
number of primary care prescriptions and I.O and the rate of ME per 100 
drugs prescribed did not show any significant differences with children 
living with one or both parents. 
The same two social aspects studied at discharge did not show any 
significant differences within the same variables mentioned (Table 4.32). 
Further studies are required to understand if any of the above social 
aspects studied can compromise or aid a better adherence to drug 
treatment and therefore reduce the numbers of admissions as well as 
helping to control associated pathologies in a more effective manner.   
The prospective phase had the advantage of having the figure of a 
pharmacy technician present in the paediatric wards helping the 
pharmacist to focus on clinical needs. The technician had great 
knowledge of the computer system and as the technician was ward 
based, it was easier to identify particular needs for patients (such as 
especial pharmaceutical forms stock requirements), making the 
prescribing and validating process smoother. The technician took a role 
of drug listing with an aim to facilitate the discharge process which helped 
pharmacists validating the prescriptions by entering the data needed 
that, as a default, the system was not transcribing to the final document, 
such as weight, allergies. The service to drug list was only provided when 
capacity allowed this and despite there being no significant differences, 
there was a reduction of the percentage of non-validated prescriptions in 
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the prospective study (from 15% prescriptions not validated to 9.09% of 
non validated prescriptions in the prospective study, Tables 4.8 and 4.30), 
likely due to the pharmacy techinician role with prescriptions being listed 
in a timely manner prior to patient’s discharge. 
In regards validated/non-validated prescriptions by pharmacist, the 
number of ME found in validated prescriptions was higher retrospectively 
(Table 4.7) and this could only be due to suggestions not accepted at the 
time of correcting the prescription or real errors not picked up by the 
junior pharmacist, mostly dose errors of nebulised colistimethatate. The 
contrary occurred prospectively (Table 4.28).  
I.O after pharmacist validation were found more frequently in the 
electronic prescriptions in the retrospective part of the study than in the 
prospective stage (p<0.001 Table 4.45). This could be related to the 
strategies implemented but also that there was an increased number of 
discharge prescriptions validated by senior pharmacists being exposed to 
CF cases.  
In the retrospective period of the study, the pharmacist validation of the 
discharge prescriptions did not increase the probability of identifying 
episodes of I.O and there were no significant difference (p=0.915, Table 
4.8), but there were in the prospective study (p=0.041, Table 4.31). 
However, when taking as a reference the total number of drugs 
prescribed, the validated prescription had significantly lesser number of 
I.O in both phases of the study (p<0.001, Table 4.8 and 4.29). This means 
that the participation of a clinical pharmacist is of relative importance, 
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since the reduction of medical errors is significant when the prescriptions 
are validated.  
Furthermore, the prospective part showed significant differences when 
the prescriptions were validated/not validated: when comparing the 
proportion of discharges with I.O and with the percentage of drugs that 
had I.O (p=0.041 and p<0.001 respectively, Table 4.29). These results 
show greater contribution to safety within the prospective stage. There 
were no similar publications found to compare these findings. 
Nevertheless, it is important to mention that the non-validated samples 
were small and these numbers calculated might not be fully 
representative to real scenarios but certainly orientate. In fact the 
subdivided variable of validated/not validated during the week and the 
weekend provides orientate information and statistical analysis was not 
applied due to the lack of homogeneity of the sample.  
5.3. Medication errors. 
No information was found published regarding medication errors at 
discharge in paediatric CF patients, hence the expected rate of 
medication errors was based on studies for paediatrics but most of the 
literature searched did not contemplate discharge prescriptions or 
polytherapy. Overall, between 5 to 27% of all paediatric medication 
prescriptions resulted in a medication error165,166,167. Kaushal et al 
reflected that paediatric inpatients may have three times more 
medication errors than adult inpatients, and these errors are frequently 
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harmful. In their publication relating to children, 1% of all medication 
errors carry signiﬁcant potential for harm, with 0.24% of errors causing 
actual harm166166 and stated that children are at high risk for these errors. 
Few studies identify the reason that children are at high risk for error is 
due in part to the need for weight-based dosing168,169,170. However, the 
findings in the present dissertation barely correlate with the literature as 
in the retrospective phase dosing errors were third on the list after 
pharmaceutical form and drug errors (table 4.43). In fact, the results in 
this research show that mostly pharmaceutical form is the consistent 
medication error in both phases of the study. Therefore formulations or 
pharmaceutical forms should also be considered in definitions of 
medication errors. Different reasons to justify this would mainly 
correspond to either change of therapeutic effects on pharmacokinetics 
in patients when using different formulations, or previous agreement 
between professionals and the patients to help adherence as well as the 
limited paediatric formulations, in which doses might be prescribed in 
volumes (or parents/carers might get used to the volumes) but different 
strengths might also be available, as well as when unlicensed use is often 
prescribed.  
In a prospective study of 5 months, Huynh et al. evaluated the 
discrepancies of medicines reconciliation in children at the time of 
hospital admission finding that 45% of the children had at least one 
unintentional medication discrepancy. No single source of information 
provided all the relevant details of a patient's medication history. 
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Parents/carers provided the most accurate details of a patient's 
medication history in 81% of cases. It is not surprising that children 
admitted to hospitals across England are at risk of harm from unintended 
medication discrepancies at the transition of care from the community to 
hospital171.  
Therefore CF children, normally on excessive polytherapy, are vulnerable 
to potential transitional care medication errors, specially due to their low 
thresold to hospital admission as per CF disease or associated 
pathologies. In the present study, during medicines reconciliation when 
there were discrepancies these were evaluated (justified or not justified) 
and medication errors were studied prospectively in order to have 
accurate information for the following transitional care of the discharge 
prescription, which could be used reliably as a future reference for the 
following admission. The most common errors on admission were 
omitted and continued drugs of medicines not needed due to the new 
circumstances of the admitted patient, followed by committed dose 
errors. These errors were corrected in the hospital and when there were 
community errors in the primary care repeat prescription, they were 
communicated to primary care. To have a completed accurate 
reconciliation recorded 4 sources of information were needed in most of 
the cases, the 4th one being the parents in most of the cases.  
Discharge ME found in the retrospective phase were due to incorrect 
frequency, duration and route being significantly more frequent in EPR 
than in DL, whilst errors in dose and pharmaceutical form in the DL had 
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similar percentages in EPR and in DL. In fact, some of the DL took into 
account regular nebulised antibiotics that had been omitted during 
discharge prescription, which was linked to the lower errors in duration 
in the DL which was better explained. Furthermore, there were significant 
differences in duration errors that supported the presence of DL. DL also 
gave greater clarity to the parents over when the children would need to 
restart or stop certain treatments (Table 4.12).  
The main ME in EPR were due to committed errors whilst DL mainly had 
omitted prescribing of the 6 rights, (Table 4.13). This is due to the fact 
that no computer system was used in DL that would issue a prompt to 
follow the essential information needed when prescribing.  
However, the prospective phase of the study showed a significantly 
greater rate of medication errors compared with the retrospective study 
(Tables 4.41, 4.42). After analysing the classification and the cause of 
error, the prospective study showed that drug, dosing and duration errors 
were significantly less frequent (Table 4.44) and there was also significant 
reduction in the subtype of errors committed versus omitted information, 
being the percentages containing less committed errors in the 
prospective study (p<0.001, Table 4.45). These findings are relevant 
because if the literature found relating to ME was based on discharge 
prescriptions, it would contradict some of the evidence which states that 
incorrect dosing is the most commonly reported error, including 
computation errors of dosage and dosing interval172,166.  
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The advantage of the prospective study was that the committed errors of 
dose and frequency found were discussed with the prescribers to confirm 
error and discuss any potential impact and action were taken to rectify 
them by contacting the parents directly and making sure that the error 
would not reach the administration stage (as an example, that 
Azithromycin would not be given three times a day but three times a 
week, which would be quite unlikely as this was part of their regular 
medication and parents were well aware of their children’s treatment). 
The paediatric pharmacy team is known to the CF department and this 
close relationship permits closer communication and understanding of CF 
drug therapy needs which is reflected in the way the discharge 
prescriptions were handled in the latest study. In fact the presence of a 
pharmacy technician to help on the wards and at discharge was extremely 
valuable for ensuring accuracy of usual patient’s pharmaceutical forms 
were written down in the discharge prescription as well as getting the 
discharge medication in an optimised timely manner.  
Pharmacist validation of the electronic prescription at discharge showed 
an inverse proportion of seniority validation during the prospective study: 
while in the retrospective study 73% of the validations were by junior 
pharmacist and couple of years later during the prospective study 70% of 
the validated prescriptions were screened by a senior pharmacist. The 
rates of ME were not lower prospectively but certainly the type of the ME 
committed was lower prospectively and this is to be attributed to either 
the improvement strategies or to the seniority but certainly the 
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combination of both had an effect when analysing the results of the 
prescriptions in the prospective study.  
The effect of when the prescriptions had been written, whether during 
the week or during the weekend, was studied. During the weekend, the 
main prescribers were general paediatricians that had not necessarily 
previously worked with CF children and the pharmacy service is also 
reduced, with no guarantee of a senior paediatric pharmacist covering the 
service. The retrospective study showed no significant differences of 
validated prescriptions during the week or at weekends, although only a 
small number of discharges were done during the weekend (n=13, Table 
4.11), the findings in the non-validated prescriptions during the week and 
at weekends are small and significantly higher during the week. However, 
in the prospective study the number of ME detected per 100 prescribed 
drugs were significantly more frequent in children discharged during the 
weekend (p<0.001, Table 4.30). Again, the influence of the days of the 
week when the prescription is written with pharmacist validation provide 
illustrative information as the sample numbers are too small to conclude 
anything relevant, especially in the prospective study. The non-validated 
prescriptions during the weekend prospectively would have skipped both, 
the technician and the senior pharmacist, and either due to the 
methodology definition of error or due to the computer system not 
prompting to write the pharmaceutical form or lacking of a unique field 
for route, the prescribers omitted this information at discharge. 
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Fortunately the likelihood of causing actual harm with the types of errors 
found prospectively was minimal since the majority of them were omitted 
errors at discharge and corresponded to route and pharmaceutical form 
where patients are used to taking the same medication and are aware of 
the formulation they prefer. Although it is noticeable that Barts Health 
has implemented most of the hospital wide system actions and guidelines 
recommended by the American Academy of Pediatrics Policy Statement 
published by the Committee on Drugs and on Hospital Care, it is certainly 
a challenge to reduce the ME with a computer system that has not been 
designed for paediatrics and when alert systems are not fully exploited 
for best use173. 
The causes of the ME were mainly technological of the computer system, 
in fact the odds ratio taking the retrospective study (EPR system) as a 
reference indicates that it is 82 times of more probable to err in the route 
of administration when using CRS system in the prospective phase of the 
study. When prescribing, drug listing or validating, it was difficult to 
maintain the same standard of the 6 rights for each single line prescribed, 
especially for route of administration and pharmaceutical forms, which 
are not mandatory fields to be completed when prescribing. Educational 
and human error causes were addressed constructively by the 
investigator with the individuals prescribing, drug listing and validating for 
future knowledge and reflection. As previously noted, the prospective 
stage was performed in a different prescribing system which has an 
important procedural error in the prescribing process. 
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The potential severity of the errors was higher on admission than at 
discharge and since the CF department has a fluent communication 
between the team, together with the culture of sharing mistakes, the 
tendency of these prescribing errors is diminishingover the time because 
the team is gaining greater experience.  
 
5.4. Quality indicators. 
National Institute for Health and Clinical Excellence (NICE) states that the 
quality indicators are for anyone wanting to improve the quality of health 
and care services being one of the investigator’s intentions. Smeulers et 
al. reviewed literature to identify evidence base quality indicators for safe 
in hospital medication preparation and administration and although this 
present study is based on prescribing indicators, the identified quality 
indicators in this group of investigators was an excellent starting point for 
developing prescribing specific quality indicators for medication safety. 
To ensure safe medication preparation and administration, nurses are 
trained to practice the “7 rights” of medication administration: right 
patient, right drug, right dose, right time, right route, right reason and 
right documentation174. In parallel in our study, to ensure safe medication 
prescribing we identified the 6 rights defined in methodology and the 
actual committed errors or omitted. If our definition of omitted had not 
been made, the global quality results in the prospective phase would have 
over achieved the standard value set up. Or in other words, if the 
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computer system had been designed by a paediatric pharmacist working 
in Barts Health, the results would show different values.  
The standard values of the quality indicators were different depending on 
the expected quality of the investigator. The 100% value was given 
exclusively to the indicator for correct patient’s identity and this was to 
make sure that all prescriptions had the correct identity and information 
of the patient. The 90% standard values were defined for the 6 Rights: 
drug, dose, frequency, duration, pharmaceutical form and route of 
administration, permitting a 10% of error. The 80% standard values were 
given for the nearly the rest of the indicators including allergies and 
weight since the investigator believed that patients have frequent 
admissions and most of the allergies were for IV antibiotics that are not 
prescribed in community, hence discharge prescriptions were allowed a 
higher margin of error than the 6 rights. The indicator covering drug listing 
pharmacy technician was given a standard value of 60% due to the service 
being limited in capacity.  
The overall quality indicator had the lowest standard value defined as this 
indicator viewed all 6 rights correctly prescribed in each drug for each 
prescription. Considering that there was a 10% allowance of error in each 
of the 6 rights indicators defined, it was trusted that a 50% of standard 
value would correspond to a good overall quality of prescription in CF 
children.  
The quality indicators were evaluated in the first phase of the study, 
retrospectively. The results obtained, together with the change of the 
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computer system, allowed agreement with the main prescribers to design 
a prompt card and collect other ideas to implement prospectively, named 
improvement stategies.  
The strategies implemented aimed to minimise the error rate at 
discharge at the same time as having an accurate drug history at discharge 
prescribed that would be totally reliable for future reference. Hence the 
quality of the prescription would be consistent with the information. 
Since the DL were not validated by a pharmacist and in order to provide 
consistent information to parents and general practitioners as well as to 
avoid typing the medication list of the patients at discharge in the DL, it 
was agreed with junior doctors that they would make a print screen of 
the electronic TTA (to take away prescription) of the CRS prescription, and 
pass this information to the word document of the DL letter. Few random 
DL were checked at the beginning of the prospective and the doctors had 
pasted the information from CRS.  
In regards to the concept of in depth medicines reconciliation, national 
guidance from NICE, National Patient Safety Agency (NPSA), World Health 
Organization and the Royal Pharmaceutical Society of Great Britain has 
long highlighted the importance of accurate and timely medicines 
reconciliation in reducing medication errors for patients upon transfer of 
care setting. Current guidance for medicines reconciliation excludes 
children younger than 16 years old, where widespread use of off-label 
and unlicensed formulations puts this group of patients at a higher risk175. 
The policy at Barts Health states that reconciliation must be done with at 
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least 2 sources of information within the first 24 hours of admission. A 
deeper drug history medicines reconciliation was thought to be needed 
for paediatric CF patients, in order to capture all the high cost nebulisers 
and prophylactic antibiotics that were stopped during IV therapy and to 
review them with most recent sensitivities at discharge, as well as 
reinforcing medicines optimisation and help with adherence. Four 
sources of information were used in most of the reconciliations and this 
achieved the standard value stated in the methods which was three. 
Parents were often interviewed to confirm drug history and identify any 
potential drug related problems, although this was not a described or 
defined part of the methodology. In most of the cases it was felt that to 
do so would obtain full confirmation of prescribing discrepancies found 
between primary care and labels from patient own medication or 
documentation from clinics letters or past discharge prescriptions. 
The prompt card was a home-made tool used to make sure that neither 
pharmacists nor doctors would forget about the treatment that normally 
stops during admission but restarts at discharge. Although the initial 
acceptation of adding the prompt card to the drug chart had a positive 
participation from doctors filling in the aim date of discharge, as the study 
was being conducted it was noticed that this field was not filled in, likely 
due to the persons getting used to this tool and not having any impact on 
the drug chart. 
The figure of the pharmacist is acknowledged in paediatric wards due to 
the high frequency interaction and contribution to patient’s care with 
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doctors and nurses. This study could not establish an accurate way to 
count the number of interventions made per day or per patient, as the 
investigator was based in a different ward when initiating and during the 
prospective study so direct verbal contribuition to care for CF children by 
CF pharmacists were not counted. Since the green handwriting is so 
characteristic of pharmacists, the written interventions were captured. 
The most common pharmaceutical interventions were correcting or 
amending dosage (corrective); and most of these were dosing not totally 
optimised or clarifying dotted numbers that could lead to administration 
mistakes.  
The strategy of having a member of the team ward based and providing 
support to CF discharge prescriptions was initially unplanned for this 
study, however indirectly this was helping the quality of the prescription 
and it was included: drug listing pharmacy technician. The figure of the 
technician was created to make sure that CF medication was provided on 
time at discharge, amongst other tasks. The standard value of the drug 
listing quality indicator was given a lower value. This was an extra service 
given only when capacity allowed to spare the technician to drug list them 
or filter the initial prescription prior to pharmacist validation, as the aim 
was to minimise waiting time of the patient for their medication at 
discharge.  
It should be noted again that the prospective study had to be performed 
in a different prescribing system which showed an important procedural 
error in the prescribing process: routes of administration lack a unique 
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designated field in the computer system to prompt its prescribing and  
pharmaceutical form is not mentioned in the system used during the 
prospective study, hence there is no automatic prompting for prescribers 
to complete this important information when prescribing and both 
needed manually entering. Each drug must be typed manually and 
spelling typographic mistakes were not taken into account as drug errors. 
The figure of the drug listing pharmacy technician was crucial 
prospectively to achieve the correct drug formulations written up and the 
route written next to the drug. 
In regards communication with primary care at discharge, on some 
occasions the communication was made over the phone directly with 
primary care surgeries whilst the patient was in hospital, and although 
the communication indicator value was achieved in the prospective 
study, it would be interesting to carry on further investigations to confirm 
that further information of treatment changes affecting primary care is 
updated in a timely manner. The investigator kept close contact with the 
consultant pharmacist informing of specific issues that required special 
contribution to the individual’s care. 
Although an overall value of 95-100% for all the safety indicators could 
have been defined for excellency, the standard values of the quality 
indicators given were after considering different criteria to achieve 
quality and safety. The 100% score in correct identity was required. 90% 
of the correct six rights was thought to be of good quality and safety for 
our paediatric population. 80% for the rest of the indicators was required, 
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in which allergies and weight were included here because the investigator 
considered that there could be room of ommitting since patients have 
other safety checks and wear distinctive identification tags when they 
have allergies for instance, plus the dynamics of the allergies in children 
with CF might vary from one admission to others and parents are well 
documented. The improvement strategies defined also had a standard 
value defined of 80% of indicator as the system was complex. A lower 
standard value indicator of 60% was given to the figure of the pharmacy 
technician as the drug listing was a service given when capacity allowed 
and was estimated that due to workload this value of 60% would be the 
minimum to contribute to quality and safety with the resources available.  
The quality indicators of the retrospective prescribing process took into 
account the administrative analysis of the DL. However, they were not 
studied prospectively since the doctors agreed that they would 
copy/paste on the final DL with a print screen of the information on CRS 
corresponding to the discharge, in order to provide consistent 
information to the parents/patients and to primary care. 
The department kept the good quality standards of identity (Qi 1), allergy 
(Qi 3), prescribing vitamins (Qi 4), and prescribing pancreatin enzymes (Qi 
5) in the prospective study. Furthermore the indicators of drug (Qi 6), 
dose (Qi 7) and duration (Qi 11) improved prospectively achieving the 
quality standard set up of 90%, being the three of them (drug, dose and 
duration) significant. Regarding frequency (Qi 8), although maintained to 
the standard value prospectively the percentage of correct frequency 
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information prescribed was significantly less than in the retrospective 
study (97 vs 85.45%, p=0.008). Pharmaceutical form (Qi 9) indicator 
showed an improvement from the retrospective phase results but did not 
achieve the standard set up (66% versus 74.55% prospectively). 
However, the indicators of weight (Qi 2) and route of administration (Qi 
10) showed lesser value in the prospective phase than the achieved value 
in the retrospective phase. As a consequence, Qi 2 and Qi 10 did not 
achieve the standard set up of 80 and 90% respectively. Furthermore, the 
indicator for weight was achieved significantly more frequently in the 
discharges of the retrospective study. The route of administration (Qi 10) 
was written up significantly more frequently in the retrospective 
discharge system (EPR) than in the prospective system (CRS) (97 vs 38%, 
p=<0.001). This was mostly due to omitted information on CRS. Both 
indicators of weight and pharmaceutical form/route were caused by the 
computer system of CRS used in the prospective study. The weight 
information, for instance, might had been present in the initial 
prescription but it could not had been translated to the final document, 
affecting negatively the quality of the prescribing process as well as the 
quality indicator for excellence at discharge.  
The overall quality indicator did not achieve the global standard value 
defined of 50%, although a significantly greater percentage result was 
obtained prospectively (p=0.010, Figure 4.12 Qi 19), indicating the team 
is going in the right direction although there is still room to improve.  
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However, having a computer system that does not prompt to input 
information for safe prescribing challenges prescribers and clinical 
pharmacists in an overloaded work enviroinment. Even so, currently NHS 
hospitals in crowded areas have times when simply creating a bed space 
in the hospital becomes a priority. As a consequence discharge 
prescriptions might be hastily written, which might put junior doctors in 
situations that they prescribe relying in the pharmacist who validates the 
prescription. It also compromises the validation in which the pharmacist 
trusts that a correct reconciliation was performed but with a likelihood of 
this not being completed when two sources of confirmation had been 
used whilst checking drug histories in CF children. Further studies should 
be carried out to ensure the overall quality standard continues to be 
moving towards the standard defined and that the CF Department is 
projecting to the deserved excellence due to their continuously daily hard 
work. 
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This PhD dissertation had as a main objective to improve the quality of 
the discharge prescription in the paediatric patients with CF that are 
admitted to receive IV therapy with antibiotics. The following conclusions 
were yielded: 
1. The indicators used to evaluate the quality of the discharge 
prescription in CF children during the retrospective phase of the study 
do not achieve the defined quality standard (50%), with greater 
quality in the electronic prescriptions (22.00%) than the quality found 
in the discharge letter (9.21%). These value differences highlight the 
importance of using a prescribing system that integrates specific 
fields designed to register specific information of the 6 essential 
parameters of the prescription (drug, dose, frequency, duration, 
pharmaceutical form and route of administration). 
2. In the retrospective phase of the study, the percentage of medication 
errors (committed and omitted) detected in the electronic 
prescription at discharge was similar. However, in the discharge 
letters, the medication errors omitted were detected in greater 
proportion. The type of medication errors found more frequently in 
the electronic prescription were due to pharmaceutical form followed 
by drug and dose, whilst in the discharge letter were due to 
pharmaceutical form too, followed by dose and route of 
administration. 
3. The contributing factors of medication errors registered in the 
retrospective phase of the study in the electronic prescribing and in 
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the discharge letter could be associated to system organisation 
factors.  
4. The improvement strategies implemented after analysing the 
medication errors and their causes in the retrospective phase of the 
study were directed to improve the organization of the prescribing 
process. In the same way as improving the medicines reconciliation 
on admission and at discharge, as well as improving the pharmacist 
role in the multidisciplinary team attending the paediatric CF patient.  
5. In the prospective phase of the study, the more frequently detected 
medication errors on admission were due to omitted drugs, followed 
by incorrect dose. However, at discharge the more frequent 
medication errors were due to route of administration omission 
followed by incorrect frequency. In this phase, the main causes 
contributing to these errors were technological.  
6. In the prospective phase of the study, after implementing the 
improvement recommendations designed, the percentage of 
discharges with improvement opportunities detected after 
pharmacist validation shows a significant increase in the quality. 
There was a reduction of 29.18% in the percentage of improvement 
opportunities detected in the validation process after patient’s 
discharge (81.18% in the retrospective phase, 52% prospective). 
7. Multidisciplinary teams that integrate clinical specialist professionals 
(doctors and nurses) and specialist in the medication use (pharmacist 
and pharmacy technicians) facilitate clinical decisions that improve 
the quality standard in the care of the paediatric patient with CF. 
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These improvements have an effect in the pharmacotherapy 
optimisation, in the grade of acceptation of pharmaceutical 
interventions during hospital stay and all these could contribute to 
improve the adherence of the patient’s pharmacotherapy. 
8. The indicators used to evaluate the quality of the prescription in 
paediatric patients with CF indicate that the implementation of safety 
actions and improvement strategies designed in this study has 
contributed to an improvement of the process (22% in the 
retrospective phase vs 41.82% in the prospective phase). 
Nevertheless, despite the significant quantified improvement 
obtained the quality standard (50%) was not achieved. This fact shows 
the need to strengthen, keep and improve the safety strategies 
initiated to achieve desired quality quotes/levels.  
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